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–1 programmed ribosome frameshifting (–1PRF) is commonly used in many viruses and 
cellular genes. The current study focuses on the –1PRF in two human viruses, human 
immunodeficiency virus type 1 (HIV-1) and Semliki Forest virus (SFV), which share the 
same slippery site (SS) sequence, but have different mRNA secondary structures. –1PRF on 
the gag-pol mRNA of HIV-1 results in the production of structural proteins of the capsid 
(Gag, 0-frame) and viral enzymes (Gag-Pol, –1-frame), and its dysregulation is detrimental 
for the structural integrity of the virion and its infectivity. In SFV –1PRF is responsible for 
the synthesis of the structural proteins 6K and TransFrame (TF), which contribute to the 
virus pathogenicity. Here we show that –1PRF in both viruses operates via two conserved 
kinetic pathways: tRNA dual-slippage during translocation under saturated translation 
conditions and single P-site tRNA slippage when the A site is vacant due to the limited 
supply of tRNAs. –1PRF is modulated by the abundance of Leu-tRNALeu that reads the rare 
UUA codon at the mRNA SS. In HIV-1 the Gag to Gag-Pol ratio is maintained by switching 
between two frameshifting mechanisms depending on the tRNALeu(UUA) availability. Leu-
tRNALeu(UUA) is rare in human cell lines derived from CD4+ T-lymphocytes – a natural target 
of HIV-1 infection. –1PRF in HIV-1 is additionally stimulated by a downstream enhancer 
sequence located within the first 12 nt after the SS. Finally, a second potential SS 
downstream of the first one is normally inefficient but can also support –1-frameshifting 
when altered by a compensatory resistance mutation in response to current anti-HIV drug 
therapy. With regard to SFV, we determined that its frameshifting site contains an extended 
stem-loop (SL) following the SS, which could act as a modulator of frameshifting under the 
limited supply of Leu-tRNALeu(UUA). The previously predicted enhancer sequence does not 
seem to play a role in –1PRF in SFV. Described different frameshifting regimes and 
stimulators allow the viruses to maintain a constant –1PRF efficiency regardless of 







1.1 Translation and reading frame maintenance 
1.1.1 Ribosome structure and function 
Translation is the fundamental process by which the nucleotide (nt) sequence of a 
messenger RNA (mRNA) is converted into the amino acid (aa) sequence of a protein. The 
key molecular player of translation is a ribosome – a large ribonucleoprotein complex that 
consists of two unequal subunits with distinct functions. The RNA core of the ribosome is 
built of ribosomal RNA (rRNA) and proteins conserved throughout all kingdoms of life, 
whereas on the periphery both RNA and protein amounts and composition vary significantly 
(Fig. 1) (Melnikov et al., 2012). Prokaryotic ribosomes are designated as 70S where S stands 
for Svedberg unit, which defines the rate of ribosome sedimentation during 
ultracentrifugation. 70S ribosomes consist of a small (SSU) or 30S subunit and a large (LSU) 
or 50S subunit. In turn, the SSU contains the 16S rRNA and 21 proteins while the LSU has 
both the 5S and the 23S rRNAs along with 31 proteins. Eukaryotic ribosomes are denoted 
80S; they are larger due to increased rRNA and protein content at the periphery of the 
ribosome (Fig. 1). 80S ribosomes are built of a 40S and a 60S subunits in analogy with 
prokaryotic ribosomes. The 40S subunit contains the 18S rRNA and 33 proteins, and the 60S 
subunit is composed of three rRNAs, the 5S, the 28S and the 5.8S rRNA, and 46 proteins. 
In addition to cytoplasmic ribosomes, eukaryotes also contain organellar ribosomes, namely 
in mitochondria and chloroplasts. In humans, such mitoribosomes consist of two subunits 
named 28S and 39S together forming a 55S particle (Bieri et al., 2018).  
 
Figure 1. Architecture of bacterial and eukaryotic ribosomes and their common structural core. 
Numbers below the structures refer to the size of ribosomes in megadaltons (MDa). Conserved rRNA 
and protein moieties are depicted in light blue and light red, respectively, while rRNA and proteins 
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specific to each domain of life are in blue and red, respectively. The figure is adapted from (Melnikov 
et al., 2012). 
1.1.2 tRNA structure and role in translation 
Apart from ribosomes, translation requires the presence of mRNAs, multiple accessory 
proteins (translation factors) and transfer RNAs (tRNAs). tRNAs are short (76-90 nt) non-
coding RNA molecules which deliver aa to the ribosome. tRNAs decode the nt sequence of 
the mRNA by pairing between the mRNA codon and the anticodon of tRNA. Codon usage 
bias defines frequencies of occurrence of synonymous codons in the genome. Synonymous 
codons are triplets of nt that encode the same aa. tRNAs “reading” synonymous codons but 
containing different anticodons are called isoacceptors. For instance, the human tRNALeu 
family comprises five isoacceptors reading six Leu codons (Breitschopf et al., 1995; Geslain 
and Pan, 2010). If the anticodon identity is the same, but the tRNA sequences outside the 
anticodon are different, the tRNAs are designated as isodecoders (Geslain and Pan, 2010; 
Goodenbour and Pan, 2006). For example, the human tRNAAla(GCU) isoacceptor has fifteen 
isodecoders. Individual isoacceptors and isodecoders show different expression levels and 
may have regulatory functions unrelated to protein synthesis (Geslain and Pan, 2010).  
The translation-adaptation hypothesis suggests that codon usage correlates with tRNA 
isoacceptor levels in the cell to provide optimal translation rates (Bulmer, 1987; Dong et al., 
1996). Indeed, in bacteria and lower eukaryotes, the abundance of tRNAs is directly 
proportional to the codon usage bias. In humans however, tRNA isoacceptors show tissue-
specific differences in their expression levels (Dittmar et al., 2006; Mahlab et al., 2012). 
That is why the correlation between the tRNA frequency and the preferred codons is 
significant only in the subset of highly expressed genes within specific tissues.  
Mature tRNAs adopt a distinctive cloverleaf-like structure, which consists of the 
following elements: acceptor stem, D (dihydrouridine) loop, anticodon loop, variable loop 
and TΨC (thymine-pseudouridine-cytosine) loop (Fig. 2). Upon synthesis, tRNAs acquire 
extensive post-transcriptional modifications which define unique properties of each tRNA 
(Bjork, 1995; Pan, 2018). On average, nuclear-encoded tRNAs bear more modifications (13 
per molecule) than mitochondrial tRNAs (3 per molecule) (Pan, 2018). Nuclear-encoded 
eukaryotic tRNAs are also more heavily modified than their prokaryotic homologues 
(Machnicka et al., 2014). One of the most heavily modified tRNAs is tRNATyr from human 
placenta which contains 17 modifications (van Tol et al., 1987). The most common 
modifications are found at positions 34 (a wobble position of the anticodon) and conserved 
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purine 37 (3’ of the anticodon) (Fig. 2) (Lorenz et al., 2017). The functions of modifications 
are to increase the ability of a tRNA to decode multiple synonymous codons, to stabilize 
codon-anticodon interactions and to prevent frameshift mutations thus to ensure proper 
codon reading and high fidelity of translation (Lorenz et al., 2017; Novoa et al., 2012; Pan, 
2018; Urbonavicius et al., 2001). Wrong tRNA modification patterns are linked to multiple 
diseases including type II diabetes, mitochondrial and neurological disorders (Bednarova et 
al., 2017; Bohnsack and Sloan, 2018; Torres et al., 2014).  
 
Figure 2. Consensus sequence of human tRNALeu(UUA) (UUA is a codon read by this Leu 
isoacceptor). The structure was derived by comparing all five human tRNALeu isoacceptors. N 
represents any nt A, U, G or C capable of base pairing with a given nt on the opposite side. U* 
indicates a posttranscriptional modification in the position 34 of the anticodon. 
A special class of enzymes called aminoacyl-tRNA (aa-tRNA) synthetases is 
responsible for addition of an aa to a tRNA in the process of aminoacylation. Aa-tRNA 
synthetases first activate the aa in an ATP-dependent manner forming aa-AMP, and then 
facilitate the transfer of the aa to either the 2'- or the 3'-OH of the last tRNA nt at the 3'-end. 
To select a correct tRNA for aminoacylation, synthetases recognize specific identity 
elements within the tRNA structure (Soll, 1990). Wrong aa are either discriminated against 
by the active center of the aa-tRNA synthetase before aminoacylation can occur or after the 
transfer to a tRNA, by hydrolysing the incorrectly charged aa-tRNA in the editing centre of 
the enzyme. The selection mechanisms together contribute to the high fidelity of 
aminoacylation, which normally ensures that the error frequency of aminoacylation is about 
10-6 (Fersht, 1977; Soll, 1990). 
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1.1.3 Stages of translation and reading frame maintenance 
The sequence of an mRNA that is translated into the sequence of a polypeptide and is 
enclosed by a start and a stop codons is called an open reading frame (ORF). Given the triplet 
nature of the genetic code, each mRNA has three potential ORFs, and it is a task of the 
ribosome to select the correct beginning of an ORF, and to maintain the frame until the 
protein is fully synthesized (Dinman, 2012).  
The start of the frame is established at the beginning of translation during the stage called 
initiation (Rodnina, 2018). Initiation mechanisms are quite different between prokaryotes 
and eukaryotes, however, both use the same start codon AUG encoding methionine (Met) 
(Fig. 3). In bacteria, many mRNAs contain a Shine-Dalgarno (SD) sequence 8-10 nt 
upstream of the initiation codon, which makes specific contacts to the anti-SD sequence in 
16S rRNA in SSU, resulting in the correct positioning of the ribosome on the start codon 
and thereby promoting initiation (Milon and Rodnina, 2012; Rodnina, 2018; Steitz and 
Jakes, 1975). During initiation in bacteria, an mRNA and an initiator tRNA, fMet-tRNAfMet, 
are recruited to the SSU with the help of initiation factors IF3, IF2-GTP, and IF1 (which 
bind to the SSU in this order) thus forming the 30S initiation complex (IC) (Milon and 
Rodnina, 2012). Upon 50S subunit joining and hydrolysis of IF2-bound GTP, initiation 
factors dissociate, and the mature 70S IC is formed which is now ready for translation (Milon 
and Rodnina, 2012). Translation initiation in bacteria entails multiple quality control 
checkpoints, which ensure selection of abundant mRNAs with weak folds, selection of 
correct start codons and monitoring of SD-aSD and AUG-fMet-tRNAfMet interactions 
(Rodnina, 2016, 2018). Prokaryotes also have mRNAs without SD (non-SD-led mRNAs) 
and even without 5’ UTR (leaderless mRNAs), which initiate via different mechanisms 
(Milon and Rodnina, 2012). Initiation of non-SD-mRNAs remains poorly understood, but 
they are known to contain an AUG start codon residing in the single-stranded region of the 
mRNA, supposedly to facilitate its recognition by the ribosome. Leaderless mRNAs contain 




Figure 3. Comparison between translation cycles in bacteria (green) and eukaryotes (red). Key 
processes and molecular players are indicated. Major similarities and differences are discussed in 
details in the text. The figure was adapted from (Melnikov et al., 2012). 
Initiation in eukaryotes is more complex and proceeds via multiple stages (Fig. 3). First, 
eukaryotic initiation factor 2 (eIF2) binds to initiator tRNA Met-tRNAi
Met thereby promoting 
the formation of a ternary complex (TC) eIF2-GTP-Met-tRNAi
Met. Next, TC together with 
eIF1, eIF1A, eIF3 and eIF5 assemble on the 40S SSU forming a so-called 43S pre-initiation 
complex (PIC). Eukaryotic mRNAs contain a 5’ cap composed of a 7-methyl guanosine and 
a 3’ poly-A tail made of several consecutive adenosine residues. The 43S PIC binds to the 
cap-proximal region of the mRNA with the help of eIF3, the poly(A)-binding protein 
(PABP), eIFs 4B, 4H (in mammals), and 4F complex. The eIF4F complex consists of eIF4E 
(cap-binding protein), eIF4G (large scaffolding protein) and eIF4A (DEAD box RNA 
helicase) proteins. Notably, PABP binds to the 3’ poly-A tail and circularizes the mRNA, 
which leads to mRNA stabilization, and thus bolsters initiation (Munroe and Jacobson, 
1990). Then, 43S PIC scans the 5’ UTR of the mRNA in 5’ to 3’ direction until it encounters 
an initiator codon AUG (Jackson et al., 2010). To facilitate the selection of a correct AUG 
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during scanning, the start codon is embedded in a consensus Kozak sequence,  
5′-GCCGCC(A/G)CCAUGG-3′ (Kozak, 1987). Upon start codon recognition the 48S IC is 
formed, which changes the conformation of the scanning complex into “closed” and causes 
displacement of eIF1, which, in turn, allows eIF5-mediated hydrolysis of eIF2-bound GTP 
and subsequent Pi release (Maag et al., 2005; Passmore et al., 2007). Next, the 60S LSU 
joins the 48S IC leading to the dissociation of eIF2-GDP along with other factors (eIF1, 
eIF3, eIF4B, eIF4F and eIF5) mediated by eIF5B. Eventually, GTP bound to eIF5B is 
hydrolyzed leading to displacement of eIF5B and eIF1A, and thereby making 80S ribosomes 
ready for elongation (Jackson et al., 2010). Some eukaryotic mRNAs lack a cap structure 
and utilize a so-called internal ribosome entry site (IRES) to initiate (Jang et al., 1990; 
Shatsky et al., 2018). This cap-independent initiation does not require the process of mRNA 
scanning and the ribosome is positioned directly on the start codon AUG (Shatsky et al., 
2018). 
Once the ribosome has established the ORF during initiation, it must maintain the frame 
throughout the next step of translation called elongation. Elongation is similar in prokaryotes 
and eukaryotes and entails three main steps: decoding, peptide bond formation and 
translocation (Rodnina, 2018) (Fig. 3). The decoding center is located in the SSU of the 
ribosome. During decoding, the sequence of codons in the mRNA is translated into the 
respective aa in the growing peptide chain. The ribosome has three centers for interactions 
with tRNAs: the A or aminoacyl site where newly selected cognate aa-tRNA is 
accommodated, the P or peptidyl site where a tRNA bearing a growing peptide chain is 
positioned, and the E or exit site where deacylated tRNA is transferred to before its 
dissociation from the ribosome. A codon positioned in the A site is recognized by aa-tRNAs 
bearing appropriate aa. In prokaryotes, aa-tRNAs are delivered to the ribosome in the TC 
with elongation factor EF-Tu-GTP (Rodnina, 2018; Rodnina et al., 1995). During decoding, 
the ribosome has to select an aa-tRNA that is cognate to the codon presented in the A site 
and reject all other aa-tRNA that do not match the codon. The fidelity of aa-tRNA selection 
is on average high with most errors occurring at the rate of 10-7–10-5 (Garofalo et al., 2019). 
The selection of the cognate aa-tRNA is achieved in several steps. Upon initial selection 
prior to GTP hydrolysis, binding of correct aa-tRNA to the ribosome is stabilized due to 
codon-anticodon recognition and the closure of the ribosome elements at the decoding site 
on the cognate codon-anticodon complex (Fischer et al., 2016; Loveland et al., 2017; 
Rodnina et al., 2017). If the incoming tRNA is correct, EF-Tu-bound GTP is hydrolyzed 
followed by EF-Tu-GDP rearrangements and Pi release, leading to the accommodation of 
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the aa-tRNA in the A site (Rodnina, 2012). After GTP hydrolysis by EF-Tu, the correct  
aa-tRNA moves to the A site on the LSU where it donates its aa to the growing nascent 
peptide chain, whereas incorrect tRNAs are rejected at a stage called proofreading (Rodnina, 
2018; Rodnina and Wintermeyer, 2001a, b). EF-Tu-GDP dissociates from the ribosome and 
is recycled by its nucleotide-exchange factor EF-Ts, which substitutes GDP with GTP thus 
allowing EF-Tu to enter a new cycle of decoding (Rodnina, 2018; Rodnina et al., 2000; 
Rodnina and Wintermeyer, 1995). In eukaryotes, decoding proceeds via the same steps 
involving EF-Tu and EF-Ts analogues called eEF1A and eEF1B, respectively (Dever and 
Green, 2012; Rodnina and Wintermeyer, 2009).  
Next, in the peptidyl transferase center of the LSU, a peptidyl-tRNA in the P site and a 
newly accommodated aa-tRNA in the A site react to form a peptide bond. The mechanism 
of peptide bond formation entails the nucleophilic attack of the amino group of the aa-tRNA 
on the carbonyl carbon of the ester bond in peptidyl-tRNA (Rodnina et al., 2006). The 
peptidyl transferase center is composed solely of RNA making the ribosome the largest 
known RNA catalyst (Rodnina, 2018; Rodnina et al., 2006). As compared to the reaction 
between model substrates in solution, the ribosome increases the rate of peptide bond 
formation by about 107-fold. This enhancement is achieved by ordering water molecules, 
correct positioning of rRNA and tRNA, and electrostatic shielding. 
In the rare cases when an erroneous aa was incorporated into the nascent peptide despite 
all the discrimination mechanisms, the ribosome is capable of retrospective editing (Zaher 
and Green, 2009). The ribosome monitors the quality of codon-intercodon interactions in the 
P site, and if the mismatch was identified, the fidelity of tRNA selection in the A site is 
significantly decreased. The drop in fidelity leads to accumulation of more mismatches, 
eventually leading to premature termination and degradation of the wrong peptide (Zaher 
and Green, 2009).  
The last step of elongation, translocation, is driven by a ribosome-activated GTPase  
EF-G (in prokaryotes) or eEF2 (in eukaryotes) at the expense of GTP hydrolysis (Rodnina 
and Wintermeyer, 2009). In the pre-translocation ribosome, immediately after peptide bond 
formation, the peptidyl-tRNA in the A site and the deacylated tRNA in the P site adopt 
classical states meaning that their anticodons and 3’ ends are positioned in A (A/A) and P 
(P/P) site, respectively. In the absence of EF-G, this complex is dynamic, and tRNAs can 
fluctuate between classical and hybrid states (Moazed and Noller, 1987). In the hybrid states 
the 3’ acceptor stems of the tRNAs in the A and P site can spontaneously move to the P 
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(A/P) and the E site (P/E), respectively. EF-G can bind to the ribosome irrespective of the 
tRNA state, but it stabilizes the hybrid state (Holtkamp et al., 2014b; Sharma et al., 2016). 
EF-G binding and subsequent GTP hydrolysis promote a conformational change in the 30S 
subunit and drive the ribosome into a so-called unlocked state. Unlocking of the decoding 
center relaxes codon-anticodon interactions and allows the tRNAs along with the mRNA to 
move through the ribosome (Rodnina et al., 1997; Savelsbergh et al., 2003). Translocation 
involves large-scale conformational changes such as the rotation of the SSU head and the 
SSU body relative to the LSU. (Belardinelli et al., 2016). Upon translocation, the peptidyl-
tRNA moves into the classical P/P state while the E-site tRNA and EF-G dissociate from the 
ribosome; the A site is now vacant and is waiting for the next round of aa-tRNA binding. 
The elongation cycle continues until the ribosome encounters a stop codon, which is 
recognized by release factors (RFs) (Fig. 3). In bacteria, RF1 and RF2 act on UAA/UAG 
and UAA/UGA stop codons, respectively (Scolnick et al., 1968). Upon stop-codon 
recognition, RF1 and RF2 facilitate the hydrolysis of an ester bond of the peptidyl-tRNA, 
this takes place in the peptidyl transferase center of the LSU. Interestingly, the mechanism 
of peptide bond hydrolysis is different from that of peptide bond formation (Kuhlenkoetter 
et al., 2011). Finally, a GTPase, RF3, displaces RF1/RF2 from the ribosome at the cost of 
GTP hydrolysis (Adio et al., 2018; Peske et al., 2014). In eukaryotes, eRF1 recognizes all 
three stop codons. eRF1 and a GTPase, eRF3, form a complex which is responsible for 
peptide-bond hydrolysis (Hellen, 2018). Notably, in eukaryotes eRF3-bound GTP is 
hydrolyzed before the peptide is released (Dever and Green, 2012; Jackson et al., 2012).  
After termination, the ribosome enters the last step of translation – recycling (Fig. 3). 
The aim of recycling is to release the mRNA and the deacylated tRNA, and to split the 
ribosomal subunits to allow their re-use in a new translation cycle. In bacteria, recycling is 
mediated by EF-G, ribosome-recycling factor (RRF) and IF3; the latter prevents  
re-association of the subunits (Peske et al., 2005; Rodnina, 2018). In eukaryotes, recycling 
is coupled to termination. NTPase ABCE1/Rli1 binds to eRF1 on the post-termination 
complex, which triggers ATP hydrolysis and subsequent splitting of 80S into 60S and 40S 
with still bound mRNA and deacylated tRNA. 40S recycling could be achieved by redundant 
pathways involving initiation factors (eIF1, eIF1A, eIF3 and eIF3j), ligatin and to a lesser 
extent ligatin homologs MCT-1 (multiple copies in T-cell lymphoma-1) and DENR (density-




Despite multiple quality control checkpoints and editing mechanisms, the error rate of 
translation remains at about 10-7–10-5 with error hotspots of up to 10-3 (Garofalo et al., 2019). 
The most severe translation error is a failure to maintain the reading frame because it leads 
to the production of wrong peptides, which could be toxic and thereby detrimental for the 
cell viability (Drummond and Wilke, 2009; Kurland, 1979). The error frequency of 
spontaneous frameshifting is about 10-9–10-5 (Hardin et al., 2007). However, in some cases 
the sequence of the synthesized protein differs from that encoded by the 0-frame ORF, which 
indicates that the mRNA is recoded compared to its initial coding sequence (Fig. 4). 
Recoding is a change of standard decoding rules after the ribosome encountered specific 
stimulatory signals embedded in the mRNA sequence or structure (Atkins and Gesteland, 
2010; Atkins et al., 2016; Gesteland et al., 1992). The main functions of recoding are to 
enlarge the genome-coding capacity and genome plasticity, and to regulate gene expression. 
Recoding events encompass stop-codon read-through, bypassing and PRF (Fig. 4) 
(Gesteland and Atkins, 1996). Normally, stop codon recognition by the ribosome leads to 
termination of protein synthesis, however, in a specific mRNA context the meaning of stop 
codons can be redefined leading to a so-called stop-codon read-through (Baranov et al., 
2002; Engelberg-Kulka and Schoulaker-Schwarz, 1988). Read-through is especially 
prevalent in Drosophila melanogaster, but is also found in several mammalian genes 
(Loughran et al., 2014). Read-through serves two main functions: to translate a C-terminal 
peptide downstream of the stop codon or to incorporate non-universal aa selenocysteine and 
pyrrolysine, which are not decoded by the standard genetic code (Baranov et al., 2002; 
Loughran et al., 2014). Bypassing (or hopping) is very well studied on the gene 60 mRNA 
of bacteriophage T4 (Chen et al., 2015; Groisman and Engelberg-Kulka, 1995; Maldonado 
and Herr, 1998; Samatova et al., 2014). Here the ribosome translates the first 46 codons of 
the mRNA until it encounters the glycine codon GGA followed by a stop codon UAG. The 
GGA codon is referred to as a “take-off” codon. Peptidyl-tRNAGly disengages from pairing 
with the GGA codon and is instead retained within the ribosome as it slides over a 50-nt 
non-coding gap sequence. Upon traversing the gap, tRNAGly re-pairs with the mRNA at 
another GGA triplet called a “landing site”, and normal decoding is resumed (Agirrezabala 




Figure 4. Programmed recoding events: read-through, bypassing and –1 frameshifting. Green and 
blue colors depict two different ORFs. Black arrows indicate the movement of the ribosomes during 
recoding. Peptides produced upon normal translation or recoding are drawn on the right. In read-
through, the yellow rectangle represents a non-universal aa incorporated at the stop codon (STOP). 
Figure from (Caliskan et al., 2015). 
1.2.1 Programmed ribosome frameshifting 
PRF allows to produce multiple proteins from the same mRNA by shifting the reading 
frame in the forward (+PRF) or backward (–PRF) direction (Fig. 4). The slippage is typically 
by one nt, although two-, four-, five- and six-nt shifts were reported (Fang et al., 2012; Jacks 
et al., 1988a; Jacks et al., 1988b; Jagger et al., 2012; Weiss et al., 1987; Wickner, 1989; Xu 
et al., 2004). PRF is a ubiquitous phenomenon occurring in species from the simplest viruses 
to higher mammals. The main functions of PRF are to increase the genome-coding capacity, 
to regulate the stoichiometric ratio between proteins, to regulate gene expression by 
influencing mRNA stability and to contribute to infectivity of pathogenic organisms (Atkins 
and Gesteland, 2010; Atkins et al., 2016; Farabaugh, 1996, 1997).  
1.2.1.1 +1 Programmed ribosome frameshifting 
+1PRF occurs in viruses, bacteria, yeast and mammalian cells (Farabaugh, 1996). The 
most well-studied example of +1PRF is found in the bacterial prfB gene encoding RF2 
(Craigen and Caskey, 1986). The mechanism of this frameshifting is a single slippage of the 
P-site tRNA caused by the translational pause due to persistently vacant A site (Farabaugh, 
1996). Here the A site contains an UGA stop codon, which is recognized by RF2. When the 
level of RF2 in the cell drops, the recognition of the UGA codon is very slow, resulting in 
spontaneous +1PRF; on the contrary, if RF2 is abundant, then fast recognition results in 
termination at the UGA codon. This process represents an autoregulatory loop to control the 
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cellular level of RF2 (Craigen and Caskey, 1986; Curran and Yarus, 1988; Donly et al., 
1990). Other examples of +1 slippages include gag3 and pol3 genes of the yeast 
retrotransposon Ty3, yeast gene est3 and the gene of mammalian ornithine decarboxylase 
antizyme (Belcourt and Farabaugh, 1990; Farabaugh et al., 1993; Matsufuji et al., 1995; 
Taliaferro and Farabaugh, 2007). 
1.2.1.2 –1 Programmed ribosome frameshifting 
–1PRF is found in all kingdoms of life including higher eukaryotes but it is especially 
prevalent in viruses and mobile genetic elements (Belcourt and Farabaugh, 1990; Clare et 
al., 1988; Dinman, 2006; Plant, 2012 ). The efficiency of –1PRF can vary in a wide range 
between 0.5% and 80% depending on the organism (Brierley, 1995; Brierley and Dos 
Ramos, 2006; Caliskan et al., 2015; Fayet and Prère, 2010; Parkin et al., 1992; Reil et al., 
1993; Tsuchihashi and Kornberg, 1990; Wilson et al., 1988). Typically, –1PRF is governed 
by two cis-acting elements – the SS and a downstream mRNA secondary structure (Caliskan 
et al., 2015; Farabaugh, 1996, 2000; Qiao et al., 2017). The SS is a repetitive heptanucleotide 
sequence of a type X1 XXY4 YYZ7, which allows the two tRNAs that read the 0-frame 
codons XXY and YYZ to re-pair to their cognate XXX and YYY codons after the slippage 
into the –1-frame (Blinkowa and Walker, 1990). The mRNA secondary structure – a SL or 
a pseudoknot – acts as a roadblock to hinder translocation and thereby promote frameshifting 
(Atkinson et al., 1997; Caliskan et al., 2014; Kim et al., 2014). The spacer between the two 
elements is crucial for the correct positioning of the ribosome, and in most cases is 
constrained to between 5 and 9 nt (Atkinson et al., 1997; Brierley, 1995; Lin et al., 2012). In 
addition, SD-like sequences in bacteria (Larsen et al., 1994), trans-acting proteins in viruses 
(Kobayashi et al., 2010; Li et al., 2014; Napthine et al., 2017; Wang et al., 2019),  
G-quadruplexes (Endoh and Sugimoto, 2013; Yu et al., 2014) and miRNAs in mammalian 
cells (Belew et al., 2014) can modulate the –1PRF efficiency. Examples of –1PRF events in 








Table 1. Examples of –1PRF in three domains of life 
Eukaryotes Bacteria Archaea 
HeT-A, Drosophila sp. 
retrotransposon for telomere 
formation (Danilevskaya et 
al., 1994) 
dnaX mRNA, γ-subunit of 
Escherichia coli (E. coli) 
DNA Pol III holoenzyme 
(Tsuchihashi and Kornberg, 
1990) 
fucA1 mRNA, α-L-fucosidase 
of thermoacidophile 
Sulfolobus solfataricus 
(Cobucci-Ponzano et al., 
2006; Cobucci-Ponzano et al., 
2012) 
Edr1 (human PEG10) mRNA, 
mammalian embryonal 
carcinoma differentiation 
regulated gene (Cardno et al., 
2015; Clark et al., 2007; 
Manktelow et al., 2005) 
cdd mRNA, cytidine 
deaminase of Bacillus subtilis 
(Mejlhede et al., 1999) 
 
Ma3 mRNA, human 
paraneoplastic antigen (Wills 
et al., 2006) 
IS1, transposition activity of 
the E. coli insertion element 
(Luthi et al., 1990) 
 
CCR5 mRNA, co-receptor for 




–1PRF is often used by bacteriophages (Mu phage, Enterobacteria phage P2) and 
viruses infecting fungi and unicellular protozoans (Giardia lamblia virus, Saccharomyces 
cerevisiae (S. cerevisiae) virus L-A); plants (Pea enation mosaic virus-1, Barley yellow 
dwarf virus (BYDV)); birds (Turkey astrovirus 1, Avian infectious bronchitis virus (IBV)) 
and mammals including humans (Human astrovirus 1, Porcine reproductive and respiratory 
syndrome virus, Human coronavirus 229E, Human SARS coronavirus, Mouse mammary 
tumor virus (MMTV), HIV-1, SFV, Middleburg virus (MIDV)) (Brierley, 1995; Plant, 
2012). In most viruses the function of frameshifting is to produce viral replicases; in 
retroviruses (e.g., HIV-1) PRF also produces a viral integrase and a protease (Jacks et al., 
1988b). However, frameshifting could also serve many non-canonical functions. In phage 
Mu –2PRF is responsible for structural proteins needed for its tail assembly (Xu et al., 2004). 
–1-frame NS1 protein of flaviviruses plays a role in viral neuroinvasiveness by regulating 
innate immune response (Melian et al., 2010). In alphaviruses (e.g., SFV) frameshifting on 
6K mRNA results in the synthesis of the structural proteins TF and 6K needed for virion 
assembly and involved in infectivity (Firth et al., 2008; Snyder et al., 2013).  
1.2.1.3 Mechanism of –1PRF 
Two main mechanisms of –1PRF were elucidated up-to-date. The first mechanism was 
revealed by rapid kinetic methods using the 1a/1b model mRNA of IBV (Fig. 5) (Caliskan 
et al., 2014; Caliskan et al., 2015). The IBV frameshifting motif consists of a SS U1 UUA4 
AAG7 encoding leucine (UUA) and lysine (AAG), and a pseudoknot positioned 6 nt 
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downstream. Here –1PRF occurs during the late stage of translocation when the confirmation 
of the ribosome resembles a chimeric hybrid state with tRNALeu in the pe/E and tRNALys in 
the ap/P states (Belardinelli et al., 2016; Caliskan et al., 2014) (Fig. 5). Lower-case letters 
are used to indicate that the tRNA is bound in a chimeric state within SSU or LSU, whereas 
upper-case letters refer to canonical A, P or E sites on either subunit. For instance, pe/E state 
means that the anticodon loop of the tRNA is bound between the P site of the SSU head and 
the E site of the SSU body, whereas the tRNA acceptor stem makes contacts to the classical 
E site of the LSU (Belardinelli et al., 2016). The downstream pseudoknot structure impedes 
the closing movement of the 30S SSU head, which, in turn, hinders the release of a 
deacylated tRNA from the E site (Caliskan et al., 2014; Chen et al., 2013; Chen et al., 2014; 
Kim et al., 2014). The presence of a strong secondary structure element leads to translational 
pausing during which EF-G may take multiple attempts to complete translocation while the 
ribosome tries to resolve the secondary structure to continue canonical decoding in 0-frame 
(Chen et al., 2014; Namy et al., 2006; Yan et al., 2015). Numerous EF-G attempts together 
with the SSU head rotation seem to destabilize the codon-anticodon interactions on the SS 
and thereby promote the simultaneous leftward slippage of tRNALeu and tRNALys. Notably, 
–1PRF appears favorable for translation because the ribosomes which shifted the frame 
complete translocation and release EF-G three times faster as compared to those remaining 
in 0-frame (Fig. 5) (Caliskan et al., 2014). Hence, –1PRF could be considered as a rescue 
mechanism to resolve a persistent translational block caused by a secondary structure, and 
resume translation at its normal rate. Translocation-dependent –1PRF seems to be 
responsible for most cases of dual backward slippages described in the literature including 
bacterial dnaX (Fig. 6 & 7, upper panel) (Caliskan et al., 2017; Chen et al., 2014; Kim et al., 





Figure 5. Kinetic model of translocation-dependent –1PRF on 1a/1b mRNA of IBV. PRE (pre-
translocation) and POST (post-translocation) refer to different conformational states of the ribosome 
prior to and after tRNA translocation, respectively. SS-bound tRNAs Leu-tRNALeu and Lys-tRNALys 
are depicted in light green and magenta, respectively. tRNAs reading the codon after the SS in  
0-frame (Phe-tRNAPhe) and –1-frame (Val-tRNAVal) are in blue and red, respectively; EF-G is in 
purple. Colored circles attached to a peptidyl-tRNA represent a growing peptide. Rates of different 
steps are given. Commitment to the –1-frame takes place during step 6. The figure is from (Caliskan 
et al., 2014). 
Translation of the dnaX mRNA produces the full-length τ protein and the shorter γ 
protein as a result of frameshifting. Both products are essential for the loading of the sliding 
clamp onto the DNA strand and formation of DNA polymerase III holoenzyme complex in 
E. coli (Larsen et al., 1994; Tsuchihashi and Brown, 1992; Tsuchihashi and Kornberg, 1990). 
The frameshifting efficiency measured in bacterial cells is about 70%-80% (Caliskan et al., 
2017; Tsuchihashi and Brown, 1992). The dnaX mRNA frameshifting site contains an 
internal SD-like sequence, SS and a downstream SL (Fig. 6). The SD-like sequence is 
located 11 nt upstream of the SS and might be involved in base pairing with the 3' end of the 
16S rRNA (Larsen et al., 1994). The SS has the sequence of A1 AAA4 AAG7 coding for two 
Lys residues (Blinkowa and Walker, 1990). The SS and the SL are separated by a 6-nt spacer, 
which is responsible for the correct positioning of the ribosome with regard to the secondary 
structure during frameshifting. Mutations or removal of any frameshifting elements greatly 




Figure 6. Structure of the frameshifting motif of the dnaX mRNA. The main elements of the dnaX 
frameshifting sequence are underlined. The loop is shown in light green, stem 1 – in orange, stem 2 
– in green. The 0- (non-frameshifting) and the –1-frame (frameshifting) peptides are given. Figure is 
from (Caliskan et al., 2015). 
Notably, –1PRF in dnaX can proceed via two alternative mechanisms, of which one is 
activated by aa-tRNA limitation (Fig. 7, lower panel) (Caliskan et al., 2017). Here the A site 
remains vacant due to the absence of the cognate aa-tRNA causing a pause in translation 
which eventually stimulates a single slippage of the P-site tRNA (Fig. 7, lower panel). Once 
the ribosome encounters a codon which could be decoded by available aa-tRNAs, normal 
translation is resumed (Caliskan et al., 2017). This frameshifting route could take place at 
any codon, and it is independent of the downstream mRNA secondary structure. In addition, 
as compared to translocation-dependent –1PRF, this so-called “hungry” frameshifting is 
very slow (Caliskan et al., 2017). This mechanism can also explain the appearance of 
peptides from multiple alternative frames (e.g., –2, +2 or –4) and accumulation of incomplete 
peptides during in vitro translation of dnaX (Fig. 7, lower panel) (Yan et al., 2015). 
 
Figure 7. Comparison between translocation-dependent (upper panel) and “hungry” (lower panel) 
pathways of –1PRF on dnaX mRNA of E. coli. SS tRNAs are in magenta and green, EF-G is in 
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purple. The two mechanisms are discussed in details in the text. The figure is from (Caliskan et al., 
2017).  
1.2.1.4 Role of cis-acting enhancer sequences in +1 and –1PRF 
Frameshifting can be stimulated by cis-acting elements following the SS, known as 
enhancers, which usually do not fold into stable mRNA secondary structures but are thought 
to make interactions with the ribosome based on sequence specificity. Enhancers are known 
to stimulate +1PRF in the gag3-pol3 gene overlap of yeast retrotransposon Ty3 and yeast 
gene est3, and could be responsible for –1PRF stimulation in SFV and BYDV (Fig. 8). 
+1PRF in Ty3 and EST3 mRNAs occurs by a mechanism which does not require 
conventional tRNA slippage but relies on particular peptidyl-tRNAs (Farabaugh et al., 1993; 
Vimaladithan and Farabaugh, 1994). For instance, in Ty3 frameshifting takes place on a 
GCG3 AGU6 U7 SS and depends on the presence of peptidyl-tRNA
Ala reading GCG codon, 
and translational pausing caused by slow decoding of a low-abundance AGU codon  
(Fig. 8A). The frameshifting product is generated without a P-site tRNA slippage by out-of-
frame binding of a tRNAVal to the GUU codon while the A site is vacant (Vimaladithan and 
Farabaugh, 1994). In Ty3 the SS is followed by a downstream 14-nt sequence, often called 
a Ty3 context or stimulator, which increases the frameshifting efficiency by almost 8-fold 
(Guarraia et al., 2007). The est3 gene contains a 27-nt enhancer after the SS providing a 
similar level of frameshifting stimulation (Fig. 8B) (Taliaferro and Farabaugh, 2007). The 
EST3 stimulator is more complex and consists of three individual domains each responsible 
for an about 2-fold increase in +1PRF. Ty3 and EST3 enhancers do not share primary 
sequence similarity; however, mutations of nt in positions 8 and 9 following the SS have 
detrimental effects on frameshifting efficiencies (Guarraia et al., 2007). The exact 
mechanism of their action remains unknown, but these stimulators seem to interact with 
rRNA or other parts of the ribosome, thereby promoting frameshifting. A potential enhancer 
was identified to mediate –1PRF in 6K mRNA of an alphavirus SFV. Similarly to Ty3 and 
EST3, in SFV the SS is followed by a 18-nt sequence, in which mutations or deletions 
significantly decrease the efficiency of –1PRF (Fig. 8C) (Chung et al., 2010). Notably, the 
potential enhancer sequence might reside within a SL structure predicted by bioinformatics 
analysis (Chung et al., 2010). 
Plant virus BYDV uses upstream and downstream enhancers to promote –1PRF in its 
RNA polymerase gene (Fig. 8D) (Barry and Miller, 2002). BYDV contains a classical 
frameshifting motif made of a slippery heptamer G1 GGU4 UUU7 followed by a bulged SL. 
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The upstream enhancer forms two SLs, deletions in which decrease the frameshifting 
efficiency by about 50%. Their probable functions are to slow down the ribosome already 
before the SS to enhance frameshifting or to act as an “insulator” to prevent misfolding of 
the downstream stimulators. The downstream stimulator is located 3 kilobases away from 
the SS, and its deletion abolishes –1PRF. This long-distance frameshifting element is 
predicted to fold into a SL structure, which could base pair with the bulge of the SL following 
the SS thereby stimulating –1PRF (Fig. 8D). Frameshifting stimulation by a long-distant 
base pairing is conserved among different BYDV isolates and is also predicted for a BYDV-
like virus, Soybean dwarf virus (Barry and Miller, 2002).  
 
Figure 8. Cis-acting stimulators of +1 frameshifting in GAG3-POL3 mRNA of S. cerevisiae 
retrotransposon Ty3 (A), S. cerevisiae mRNA EST3 (B), and –1 frameshifting in Semliki Forest 
virus (SFV) 6K mRNA (C) and Barley yellow dwarf virus (BYDV) (D). SS are highlighted light 





1.3. –1 Programmed ribosome frameshifting in human immunodeficiency virus 
HIV is the causative agent of the acquired immunodeficiency syndrome (AIDS). In 
2017, about 40 million people worldwide were infected with HIV, and about 1 million died 
from AIDS or AIDS-related illnesses. HIV belongs to the genus Lentivirus within the family 
Retroviridae. Based on the origin, genetic characteristics and differences in viral antigens, 
HIV is classified into HIV-1 and HIV-2, with HIV-1 being more common. HIV-1 is further 
subdivided into O, P, N and M groups, with the M group being predominant. Viruses within 
M group are divided into subtypes, and subtype B is the most widespread among HIV-
infected individuals. Non-human primates are infected by another retrovirus similar to HIV 
called simian immunodeficiency virus (SIV).  
The HIV virion contains the HIV genome and is built of an outer layer called envelope 
with spikes of glycoproteins (gp) and an inner core called capsid. The HIV genome is built 
of two identical single-stranded RNA molecules and contains 9 genes whose protein 
products are responsible for viral particle formation and replication (gag, pol, env, tat, rev) 
and for infectivity (nef, vif, vpr, vpu) (Turner and Summers, 1999) (Fig. 9). HIV genes can 
be subdivided into early genes (tat, rev and nef) which are expressed upon viral entry into 
the host cell and late genes (gag, pol, env, vif, vpu and vpr) transcribed before virion 
formation and virus release from the cell (Cullen, 1991). Notably, the codon usage of HIV 
early-expressed genes corresponds to that of highly expressed host genes, but the codon bias 
of the late genes is remarkably different posing the question about the mechanism of their 
efficient translation (van Weringh et al., 2011). 
 
Figure 9. Structure of HIV-1 genome. LTR stands for long non-translated repeats. Arrows indicate 
genes in which –1PRF takes place. 
HIV infects a variety of immune cells including CD4+ T-lymphocytes, macrophages and 
microglial cells. To enter the host cell, HIV envelope protein gp120 attaches to the cell 
surface receptor CD4+ and its signaling co-receptor CCR5 or CXCR4. Receptor recognition 
triggers virus-host membrane-fusion, upon which the viral capsid is released into the 
cytoplasm. Here the viral enzyme reverse transcriptase (RT) converts the HIV RNA into 
DNA, which is then transported into the nucleus of the infected cell. Inside the nucleus, 
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another viral enzyme called integrase inserts the HIV DNA into the cellular genome. After 
integration, HIV uses the cellular machinery for its DNA replication, transcription and 
protein synthesis. Newly produced proteins along with genomic RNA assemble on the cell 
surface to form new HIV virions, which are then ready to bud off from the host cell. Viral 
progeny is non-infectious at first, but upon budding an HIV protease processes viral proteins, 
which leads to mature particles that can now infect another host cell (Maartens et al., 2014). 
Frameshifting in HIV-1 takes place at two positions of the genome: in the env gene and 
in the gag-pol gene overlap (Fig. 9) (Jacks et al., 1988b; Olubajo and Taylor, 2005). The env 
gene encodes structural proteins, which together with the outer lipid membrane constitute a 
viral envelope. –1PRF in the env gene leads to the production of a truncated glutathione 
peroxidase homologue with both antioxidant and antiapoptotic activities. The frameshifting 
motif of env consists of a SS A1 AAA4 AGA7 followed by a pseudoknot. The AGA arginine 
codon is “hungry” because it is read by a rare tRNAArg isoacceptor. In infected cells arginine 
deficiency in the culture media greatly increases the frameshifting efficiency leading to 
accumulation of the glutathione peroxidase, which apparently evolved to protect HIV against 
oxidative stress in the host cell (Olubajo and Taylor, 2005).  
1.3.1 –1PRF in gag-pol gene overlap 
Two HIV-1 genes, gag and pol, encoding structural proteins and enzymes, respectively, 
overlap by 205 nt. pol does not have its own initiation codon and is positioned out-of-frame 
with regard to gag (Fig. 9) (Ratner et al., 1985; Sanchez-Pescador et al., 1985; Wain-Hobson 
et al., 1985). The SS is found at the end of the gag gene, and –1PRF over the slippery 
sequence leads to the production of a Gag-Pol fusion polyprotein, which is then processed 
into mature enzymes: RT with intrinsic RNAse H activity, protease and integrase (Jacks et 
al., 1988b). The ratio between the Gag and Gag-Pol polyproteins is crucial for virus viability. 
Changes in the ratio are detrimental for replication, particle formation and infectivity of HIV 
(Biswas et al., 2004; Karacostas et al., 1993; Park and Morrow, 1991; Shehu-Xhilaga et al., 
2001). The efficiency of gag-pol –1PRF in human cells is about 2% to 11%, as measured 
with reporter constructs containing either the frameshifting motif or a complete gap-pol 
overlap sequence using a dual-luciferase assay (Cassan et al., 1994; Grentzmann et al., 
1998a; Mathew et al., 2015; Plant and Dinman, 2006). The frameshifting efficiencies 
measured in human cells were recapitulated in different heterologous systems in vivo or  
in vitro with the help of mammalian, yeast or E. coli translation extracts, suggesting that  
–1PRF in HIV employs mechanisms evolutionary conserved through all the kingdoms of 
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life (Bidou et al., 1997; Brunelle et al., 1999; Dulude et al., 2002; Horsfield et al., 1995; 
Jacks et al., 1988b; Parkin et al., 1992; Plant and Dinman, 2006; Reil et al., 1993; Weiss et 
al., 1989; Wilson et al., 1988; Yelverton et al., 1994). 
1.3.1.1 Structure of the gag-pol frameshifting site 
The  gag-pol SS1 has the sequence of U1 UUU4 UUA7 encoding Phe and Leu in 0-frame 
(Fig. 10) (Jacks et al., 1988b). Mutations of any U to any other nt are detrimental for the 
frameshifting efficiency (Doyon et al., 1998; Girnary et al., 2007; Jacks et al., 1988b; Weiss 
et al., 1989; Wilson et al., 1988). In the majority of the HIV strains, the SS1 is followed by 
a SL element (Fig. 10), except for the O-group viruses where a pseudoknot is found in the 
same position (Baril et al., 2003b; Dulude et al., 2002; Jacks et al., 1988b). Notably, the SL1 
structures of SIV and HIV-2 have an identical geometry and differ only by single nucleotide 
polymorphism while HIV-1 contains a completely different SL1 (Marcheschi et al., 2007).  
 
Figure 10. Scheme of the gag-pol frameshifting site. The first slippery site (SS1) and the putative 
second slippery site (pSS2) are highlighted in green; the stimulatory mRNA structure element 
downstream of the SS1 is indicated as a stem-loop 1 (SL1). Aa incorporated into 0-frame and  
–1-frame peptides as well as the potential –1PRF routes and in vivo efficiencies are shown below the 
frameshifting sites. 
The SL1 of HIV-1 contains an upper and a lower stems separated by a 3-nt purine bulge 
GGA, which introduces a 60° angle between the stems (Fig. 11) (Dulude et al., 2002; Gaudin 
et al., 2005; Kang, 1998; Low et al., 2014; Staple and Butcher, 2003, 2005). The upper stem 
is highly thermostable (Tm > 90°C); it is made of 11 Watson-Crick base pairs capped with 
an ACAA tetraloop (Fig. 11). On the contrary, the lower stem, built of 8 weak base pairs, is 
unstable (Tm = 47°C). During translation, the ribosome must unwind the lower stem before 
it reaches the slippery sequence, but then is presumably stalled by a highly stable upper stem 
(Mazauric et al., 2009; Staple and Butcher, 2003, 2005). All HIV subtypes of group M 
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contain SL1 with a similar geometry despite multiple sequence variations (Baril et al., 2003a; 
Telenti et al., 2002). Sequence variability is reflected in different overall thermodynamic 
stabilities of the structures; however, the frameshifting efficiency remains unchanged 
between the subtypes (Baril et al., 2003a; Chang et al., 1999). This notion suggests that not 
the global but the local thermodynamic stability of the SL1 element influences the 
frameshifting efficiency in HIV (Garcia-Miranda et al., 2016; Mouzakis et al., 2013). 
Multiple publications reported a modulatory effect of the SL1 on –1PRF (Bidou et al., 1997; 
Cassan et al., 1994; Garcia-Miranda et al., 2016; Kollmus et al., 1994; Parkin et al., 1992). 
Other reports argue that the mRNA stimulatory element in HIV-1 is not a simple SL but a 
complex intramolecular triplex RNA structure, which could fold into different pseudoknot 
types (Dinman et al., 2002). Moreover, numerous papers suggest that the SS1 alone could 
stimulate a significant level of –1PRF while the SL1 is dispensable for frameshifting in  
HIV-1 (Brunelle et al., 1999; Honda et al., 1995; Reil et al., 1993; Wilson et al., 1988). 
Hence, the identity and the contribution of the mRNA secondary structure to –1PRF in HIV 
are still to be elucidated. 
 
Figure 11. Structure of the HIV-1 SL1. The SS1 is highlighted in light green; SL1 elements: tetraloop 
is in grey, upper stem is in blue, bulge is in magenta, lower stem is in yellow. 
1.3.1.2 Different models of –1PRF on gag-pol overlap  
–1PRF on the gag-pol SS1 gives rise to two frameshifting products, one which contains 
the 0-frame peptide Phe-Leu followed by the –1-frame aa sequence and another with a Phe 
incorporated instead of Leu, i.e., Phe-Phe followed by the –1-frame sequence. The ratio of 
the two –1PRF products is about 70% to 30% (Fig. 10) (Cardno et al., 2015; Jacks et al., 
1988b; Liao et al., 2011; Yelverton et al., 1994). The mechanism of frameshifting on the 
gag-pol mRNA is unclear and multiple models were developed to explain it. To account for 
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the two frameshifting products, Liao and co-workers proposed three potential kinetic 
pathways (Fig. 12) (Liao et al., 2011). In Pathway I, –1PRF occurs during translocation when 
the ribosome moves from its position on the AAU and UUU codons in the P and A sites to 
the UUU and UUA codons of the SS1, respectively. After the slippage, Phe incorporates in 
–1-frame; the alternative –1PRF product containing the Phe-Leu peptide cannot form. In the 
alternative pathway III, –1PRF may result from incomplete translocation over the two SS1 
codons, which will result in the Phe-Leu but not the Phe-Phe frameshifting peptide. As 
mentioned before, the mechanism that entails simultaneous slippage of two tRNAs during 
translocation represents the major frameshifting pathway in IBV 1a/1b and dnaX genes as 
well as in other studied systems (Caliskan et al., 2014; Caliskan et al., 2017; Chen et al., 
2013; Chen et al., 2014; Horsfield et al., 1995; Kim et al., 2014; Leger et al., 2007; Mathew 
et al., 2015; Mazauric et al., 2009; Yan et al., 2015). In contrast to pathways I and III, which 
lead to frameshifting during tRNA translocation, –1PRF may also occur during 
accommodation of Leu-tRNALeu into the A site (pathway II) (Liao et al., 2011), thereby 
producing the Phe-Leu –1-frame product, in agreement with previous suggestions (Brunelle 
et al., 1999; Jacks et al., 1988a; Jacks et al., 1988b). The Phe-Phe frameshifting product can 
form either through pathway I (Liao et al., 2011); or, alternatively, it could be formed by yet 
another pathway through a slippage of a single P-site peptidyl-tRNAPhe in the presence of 
the vacant A site (Fig. 12) (Brunelle et al., 1999; Cardno et al., 2015; Horsfield et al., 1995; 
Yelverton et al., 1994). The latter frameshifting mechanism can operate when the A-site  
aa-tRNA is in short supply, as described for frameshifting on dnaX mRNA (Atkinson et al., 
1997; Brunelle et al., 1999; Caliskan et al., 2017; Cardno et al., 2015; Farabaugh, 1996; 
Horsfield et al., 1995; Yelverton et al., 1994). Moreover, the HIV SS1 was reported to 
support –2PRF (Lin et al., 2012); as in those experiments the frameshifting sequence was 
placed into an unnatural context followed by an antisense oligonucleotide-binding site, the 






Figure 12. Kinetic pathways of –1PRF in HIV-1. Pathways I, II, III and IV describe alternative 
routes by which FFR and FLR frameshifting products could be formed. I, II and III correspond to 
pathways proposed by (Liao et al., 2011); IV refers to a single P-site tRNA slippage. The codon 
preceding the SS1 is in grey, SS1 codons are in green and magenta, the codon following the SS1 is 
in purple. Colored rectangles represent tRNAs. TL stands for translocation, Acc – for 
accommodation. E, P, A are ribosomal sites for interactions with tRNAs. Figure is modified from 
(Caliskan et al., 2014). 
1.3.2 Second putative frameshifting site within gag-pol overlap 
In addition to the classical frameshifting motif, the gap-pol gene was predicted to have 
a pSS2 38 nt downstream of the canonical SS1 positioned within the SL1 (Fig. 10) (Brierley 
and Dos Ramos, 2006; Doyon et al., 1998; Garcia-Miranda et al., 2016; Girnary et al., 2007; 
Knops et al., 2012). The second site has a sequence U1 UUU4 CUU7 coding for Phe and Leu 
in 0-frame; the existence of the downstream mRNA secondary structure element was not 
investigated (Fig. 10). Normally, the sequence is not slippery, but a mutation C5 to U (C5U), 
which appears as compensatory resistance mechanism upon anti-HIV therapy, may facilitate 
additional frameshifting at this normally silent site (Doyon et al., 1998; Garcia-Miranda et 
al., 2016; Girnary et al., 2007; Knops et al., 2012). The mechanism, which favors the C5U 
mutation, is well understood. Anti-HIV therapy with protease inhibitors leads to 
accumulation of mutations in the HIV protease that impair the recognition of its specific 
cleavage sites. To allow polyprotein maturation by the mutated protease, secondary 
mutations arise at the pSS2, which harbors the p1/p6 cleavage site of the Gag polyprotein 
(Bally et al., 2000; Banke et al., 2009; de Oliveira et al., 2003; Larrouy et al., 2011; Pettit et 
al., 2002). The C5U mutation changes Leu for Phe, which enhances van der Waals 
interactions between the substrate and the mutant protease, thereby increasing the protease 
activity by about 10-fold (Ozen et al., 2014). 
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1.3.3 Anti-HIV therapeutics targeting frameshifting 
Recent advances in the development of anti-retroviral therapeutics significantly 
decreased the mortality rate of HIV-infected patients and made an important impact on their 
quality of life. The most common therapy to control AIDS progression and severity is a  
so-called highly active antiretroviral therapy (HAART), which is a combination of drugs 
targeting viral proteins at different stages of the viral life cycle. However, due to the high 
mutation rate of HIV-1, virus isolates emerge that are resistant to one or multiple components 
of the HAART (Saini et al., 2012). That is why the quest for better targets and efficient 
therapeutics against HIV continues. The HIV frameshifting motif is an attractive target for 
antiviral drug design because its slippery heptamer SS1 is an invariant sequence conserved 
among HIV-1 isolates, and even between HIV-1, HIV-2 and SIV viruses (Baril et al., 2003a), 
and the frameshifting efficiency is linked to viral replication and particle formation (Biswas 
et al., 2004). Multiple attempts were made to design synthetic molecules against the 
frameshifting site of HIV-1. The first synthetic compound was 1,4-bis[N-(3-N,N-
dimethylpropyl)amidino]-benzene tetrahydrochloride known as RG501 targeting the major 
groove of the upper stem in SL1 (Hung et al., 1998). RG501 stimulated –1PRF, altered the 
Gag/Gag-Pol ratio and inhibited viral replication and particle formation. However, this 
compound displayed non-specific binding to other RNA molecules and the ribosome along 
with high cytotoxicity. Other examples of compounds targeting HIV-1 frameshifting site 
include guanidinoneomycin, idarubicin, doxorubicin, hydrazide derivatives and Arg-rich 
peptides; however, their off-target effects and cytotoxicity limit their use as therapeutics 
(Brakier-Gingras et al., 2012; Ofori et al., 2014). Miller et al. developed disulfide-containing 
peptides that bind specifically to the HIV SL1 and are not cytotoxic, however, their effects 
on the HIV life cycle were not assessed yet (Ofori et al., 2014). Modified oligonucleotides 
can also be used to target frameshifting signals. By now, no specific oligonucleotides were 
designed against HIV-1, however, an antisense-peptide oligonucleotide was used 




1.4. –1 Programmed ribosome frameshifting in alphaviruses 
The genus Alphavirus belongs to the family of Togaviridae and includes multiple 
species pathogenic to humans and livestock causing infectious arthritis, fewer, rushes and 
potentially fatal encephalitis. Alphavirus genome is a single-stranded (+)RNA, which 
contains two ORFs encoding 9 proteins. The 5’ proximal ORF codes for enzymes (NSP1-
NSP4) while the 3’ proximal ORF encodes a structural polyprotein (C-E3-E2-6K-E1), which 
is further processed by proteases to yield mature proteins (Fig. 13). A frameshifting motif is 
located within the 6K gene coding sequence, and –1PRF results in the production of another 
structural protein TF. 6K and TF are membrane proteins enriched in cysteine residues and 
acylated (Fig. 13). They have identical hydrophobic N-termini, but different C-termini: the 
6K C-terminus is a membrane segment while the C-terminus of TF is a hydrophilic 
cytoplasmic extension (Chung et al., 2010; Firth et al., 2008). 6K and TF seem important for 
envelope protein processing, membrane permeabilization, virion assembly and virus 
budding. Deletion of both proteins is not lethal for the virus, but it decreases viral load in the 
cell by 10-100-fold, and produced virions lack structural integrity and are less infectious as 
compared to wild-type (wt) (Ramsey and Mukhopadhyay, 2017). Recent data in Venezuelan 
equine encephalitis virus also suggests that TF can pass through the blood-brain barrier and 
is responsible for the neuroinvasiveness of the virus (Kendra et al., 2017).  
 
Figure 13. Genome structure of alphaviruses. Arrow indicates the gene in which –1PRF takes place. 
As described before, one prominent example of alphaviruses is SFV, which is 
pathogenic to humans but is also used as a tool in gene therapy, vaccination and cancer 
research (Firth et al., 2008). The efficiency of –1PRF in SFV measured with dual-luciferase 
reporters in human cells was reported to be about 15%. Its SS is identical to that of HIV-1 
and has a sequence of U1 UUU4 UUA7 encoding Phe and Leu in 0-frame. On the other hand, 
the presence of the mRNA secondary structure in the frameshifting motif of SFV remains 
elusive. As shown in Fig. 8C, bioinformatics analysis predicted the existence of an extended 
SL 6 nt downstream of the SS. However, mutations disturbing the SL do not seem to have a 
significant effect on the frameshifting efficiency. On the other hand, as mentioned before, 
the first 18-20 nt after the SS were shown critical to maintain the frameshifting efficiency 
and could represent a cis-acting enhancer (Chung et al., 2010).   
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1.5 Scope of the thesis 
The aim of the thesis was to study the mechanisms of PRF in viruses pathogenic to 
humans and domestic animals, such as HIV-1 and SFV, and to investigate the mechanism 
of tRNA slippage by a mutational study in the bacterial dnaX mRNA. The variety of 
proposed pathways explaining –1PRF on gag-pol mRNA of HIV-1, the lack of information 
about alternative slippage events and an unclear contribution of the pSS2 prompted us to 
dissect this frameshifting event in real time using a fully reconstituted E. coli in vitro 
translation system. The specific objectives of the study were: 
1. To unravel the kinetic mechanism governing –1PRF in HIV-1; 
2. To compare the mechanism of –1PRF in HIV-1 with that of IBV and dnaX; 
3. To identify key factors defining the ratio between the two –1PRF products containing 
the FFR and FLR motifs; 
4. To investigate alternative slippage events (e.g., –2PRF or +1PRF); 
5. To unravel the significance of the pSS2 and study the interplay between SS1 and pSS2 
using native total human tRNA. 
Upon discovering that Leu-tRNALeu(UUA) plays a role as a major modulator of –1PRF in 
HIV-1, we set out to quantify its abundance in human cell lines of different origin including 
CD4+ T-lymphocytes, which are natural reservoirs of HIV-1 infection. The analysis was 
done by tRNA-specific qRT-PCR in collaboration with Dr. Markus Hoffmann and  
Prof. Dr. Stefan Pöhlmann (Infection Biology Unit, German Primate Center, Göttingen). 
Furthermore, to bridge the gap between frameshifting data obtained in vivo in human cells 
and in vitro with bacterial components and to exclude potential artefacts arising from using 
E. coli ribosomes, we aimed to establish an in vitro reconstituted translation system with 
mammalian components and validate our key findings concerning the mechanism of 
frameshifting in HIV and its modulation by the tRNALeu(UUA) abundance (in collaboration 
with Dr. Akanksha Goyal, Department of Physical Biochemistry, Max Planck Institute for 
Biophysical Chemistry, Göttingen). 
The classical gag-pol frameshifting motif consists of the SS1 followed by the SL1. Both 
elements were studied in detail, however, their exact contribution to frameshifting in HIV-1 
remained elusive. In particular, the significance of the SL1 as a stimulator of frameshifting 
remained unclear, which prompted us to study the function of sequences downstream of the 
SS1 using sequential mutational analysis. We aimed to distinguish between the effects of 
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SL1 and potential enhancer sequence on frameshifting in HIV-1 and to discover how two 
frameshifting routes, FFR and FLR, are modulated by cis-acting elements following the SS1. 
–1PRF in SFV was studied in vivo in human cells while the mechanistic understanding 
of this process was lacking. SFV contains the same SS as HIV-1 but the stimulatory element 
of SFV remained unknown, which prompted us to examine its structure by chemical probing 
and then study its role in –1PRF. Our other goal was to understand the mechanism and 
modulation of –1PRF in SFV and to compare it to the one of HIV-1. Furthermore, we aimed 
at deciphering the significance of the potential enhancer following the SS. Chemical probing 
was carried out in collaboration with Dr. Maria M. Anokhina (Department of Cellular 
Biochemistry, Max Planck Institute for Biophysical Chemistry, Göttingen; currently 
Institute of Pathology, University Hospital of Cologne). 
–1PRF in dnaX is governed by three frameshifting elements: the SD-like sequence, the 
SS and the downstream SL. Although the contribution of each element to frameshifting was 
studied in detail, some results obtained with SS mutants are difficult to interpret, because 
there is no unifying hypothesis concerning the thermodynamic mechanism of frameshifting. 
The goal of this study was to create a library of dnaX SS mutants and correlate the 
frameshifting efficiencies with the thermodynamics of codon-anticodon interactions in 
different frames. This work was carried out in collaboration with Dr. Lars Bock and  
Prof. Dr. Helmut Grübmüller (Department of Theoretical and Computational Biophysics, 




2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Chemicals were purchased from Sigma-Aldrich (Steinheim, Germany), Roche 
Diagnostics (Mannheim, Germany), Merck (Darmstadt, Germany), Carl Roth (Karlsruhe, 
Germany) and Serva (Heidelberg, Germany), unless stated otherwise. GTP was from Jena 
Bioscience (Jena, Germany), DNA SmartLadder was from Eurogentec (Seraing, Belgium), 
GelRed was from Biotium (Fremont, USA). Kits for plasmid DNA purification, 
NucleoSpin® Gel and PCR Clean-up kits were from Macherey-Nagel (Düren, Germany), 
kits for mRNA purification (RNeasy kits) were from Qiagen (Hilden, Germany). 
Nitrocellulose and cellulose acetate filters and syringe filters were from Sartorious Biolab 
(Göttingen, Germany). DNA oligonucleotides were from Eurofins Genomics (Ebersberg, 
Germany) and from IBA (Göttingen, Germany). Synthetic mRNAs were from IBA. 
Radioactive aa were from Hartmann Analytic (Braunschweig, Germany) and PerkinElmar 
(Massachusetts, USA). Scintillation cocktails Ultima Gold™ XR and Quickzint 361 were 
purchased from PerkinElmar (Massachusetts, USA) and Zinsser analytic (Frankfurt, 
Germany), respectively. Chemical probing reagents dimethyl sulfate (DMS) and  
1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate (CMCT) were 
purchased from Sigma-Aldrich, β-ethoxy-α-ketobutyraldehyde (kethoxal, KE) was provided 




Q5 High-Fidelity DNA Polymerase  NEB (Frankfurt, Germany) 
Phusion® High-Fidelity DNA Polymerase Thermo Fisher Scientific (Finnzymes)  
Pfu DNA Polymerase    Promega (Mannheim, Germany) 
DpnI     NEB 
T4 Polynucleotide Kinase   NEB 
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T4 Quick Ligase    NEB 
T4 DNA Ligase     NEB 
Transcription enzymes 
Pyrophosphatase    Sigma-Aldrich 
T7 RNA Polymerase    made in-house 
Translation enzymes 
Pyruvate Kinase    Sigma-Aldrich 
Chemical probing and RT enzymes 
Proteinase K     NEB 
Sequenase Version 2.0 DNA Polymerase Thermo Fisher Scientific 
2.1.3 Buffers 
Table 2. Common buffers 
Buffer name Content 
General buffers and solutions 
LB medium 
10 g/l NaCl 
10 g/l tryptone 
5 g/l yeast extract 
LB agar 
10 g/l NaCl 
10 g/l tryptone 
5 g/l yeast extract 
15 g/l agar 
10X TBE 
0.89 M Tris-HCl, pH 8.3 
0.89 M boric acid 
25 mM EDTA 
10X TAE 
0.4 M Tris-HCl, pH 8.4 
0.2 M acetic acid 
10 mM EDTA 
2X RNA loading dye 
2 mM Tris-HCl, pH 7.5 
20 mM EDTA 
8 M urea 
20% glycerol 
0.05% (w/v) bromophenol blue 
0.05% (w/v) xylene cyanol 
5X DNA loading dye 
5 mM EDTA, pH 8.0 
30% glycerol 
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol 
Transcription buffer 
50 mM Tris-HCl, pH 7.5 
15 mM MgCl2 
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5 mM DTT 
2 mM spermidine 
Aminoacylation buffer 
50 mM HEPES, pH 7.5 
70 mM NH4Cl 
30 mM KCl 
20 mM MgCl2 
Translation buffers 
TAKM7 buffer 
50 mM Tris-HCl, pH 7.5 
70 mM NH4Cl 
30 mM KCl 
7 mM MgCl2 
HiFi buffer 
50 mM Tris-HCl, pH 7.5 
70 mM NH4Cl 
30 mM KCl 
3.5 mM MgCl2 
8 mM putrescine 
0.5 mM spermidine 
Eukaryotic translation buffer 
20 mM HEPES, pH 7.5 
100 mM KCl 
2.5 mM MgCl2 
0.25 mM spermidine 
1 mM ATP 
0.5 mM GTP 
Buffers for peptide separation 
HPLC buffer A 0.1% TFA 
HPLC buffer B 
0.1% TFA 
65% ACN 
HPLC buffer C 0.1% HFBA 
HPLC buffer D 
0.1% HFBA 
65% ACN 
Buffers for aa-tRNA purification  
HPLC buffer E 
20 mM ammonium acetate, pH 5.0 
10 mM magnesium acetate 
400 mM NaCl 
HPLC buffer F 
20 mM ammonium acetate, pH 5.0 
10 mM magnesium acetate 
400 mM NaCl 
15% ethanol 
Buffers for mRNA purification 
FPLC buffer A 
30 mM Bis-Tris, pH 6.0 
1 mM EDTA 
300 mM NaCl 
FPLC buffer B 
30 mM Bis-Tris, pH 6.0 
1 mM EDTA 
1.5 M NaCl 
Buffers for tRNA transcript purification  
FPLC buffer C 
30 mM Bis-Tris, pH 6.0  
5 mM MgCl2 
300 mM NaCl  
FPLC buffer D 
30 mM Bis-Tris, pH 6.0  
5 mM MgCl2 
1.5 M NaCl  
Buffers for total tRNA purification  
FPLC buffer E 
50 mM sodium acetate, pH 4.5 
10 mM MgCl2 
FPLC buffer F 
50 mM sodium acetate, pH 4.5 
10 mM MgCl2 
32 
 
1.1 M KCl  
Buffers for von Jagow Tris-Tricine SDS PAGE 
10X cathode buffer 
1 M Tris 
1 M Tricine 
1% (w/w) SDS 
pH is 8.25 without adjusting 
10X anode buffer 2 M Tris-HCl, pH 8.9 
3X gel buffer  
3 M Tris-HCl, pH 8.45 
0.3 % (w/w) SDS 
2X sample buffer 
0.1 M Tris-HCl, pH 6.8 
24% (w/v) glycerol 
2% (v/v) β-mercaptoethanol 
10% SDS 
49.5% T, 3% C mixture of 
acrylamide/bis 
48 g acrylamide 
1.5 g bis-acrylamide 
Up to 100 mL Milli-Q H2O 
49.5% T, 6% C mixture of 
acrylamide/bis 
46.5 g acrylamide 
3 g bis-acrylamide 
Up to 100 mL Milli-Q H2O 
 
2.1.4 E. coli strains 
MRE 600 (1/2 log) (UAB Fermentation Facility) 
NovaBlue (Merck (origin), prepared in house) 
2.1.5 Plasmids 
pEX-A2 (Eurofins Genomics): 2450 bp, carrying the gene for Amp resistance 
pUC18 with E. coli Trp gene (Dr. Michael Thommen): 2680 bp (without insert), carrying 
the gene for Amp resistance 
pET24a with dnaX wt insert (Dr. Neva Caliskan): 5310 bp, carrying the gene for Kan 
resistance 
pSGDLuc (Prof. John Atkins, Addgene plasmid # 87323): 5853 bp, carrying the gene 
for Amp resistance 
2.1.6 Columns 
LiChrospher 100 RP-8 (5 mm) LiChroCART 250-4 (Merck)  
LiChrospher WP 300 (5 mm) RP-18 (Merck)  
Sepharose 4B gel filtration base matrix (GE Healthcare (Chicago, USA)) 
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Phenyl Sepharose High Performance (GE Healthcare) 
DEAE Toyopearl 650M (Tosoh Bioscience (Tokyo, Japan)) 
Protino Ni-IDA 2000 Packed Columns (Macherey-Nagel) 
HiTrap Q HP column 5 ml (GE Healthcare) 
Mono Q 5/50 GL 5 50 mm (GE Healthcare) 
2.1.7 Primers 
Table 3. Primers for HIV constructs for bacterial translation system 
Primer 
name 

















































































Rev primer for long gel 
mRNAs  
HIV 97R GGTCTGCTCTGAAGAAAATTCCCTGGC 
Rev primer for short 








Rev primer, 6 nt after 









































































































































































GAAGA to ctttt  
(nt 88-93) 





Rev primer for above 
construct, full SL 
Mutated nt are in small letters in bold. 
Table 4. Primers for HIV constructs for mammalian translation system 
Primer 
name 






































Rev primer, 5 nt after the 






Rev primer for long 
mRNAs 
Mutated nt are in small letters in bold. 
Table 5. Primers for HIV in vivo studies in human cell culture 
Primer 
name 








HIV wt sequence 







HIV –1-frame control 












pSGDLuc HIV wt 






pSGDLuc HIV wt 






pSGDLuc HIV –1-frame 






pSGDLuc HIV –1-frame 







pSGDLuc HIV –1-frame 







pSGDLuc HIV –1-frame 







pSGDLuc HIV –1-frame 




























































GAGTGGTTAAGGCGTTGGACTTAA qRT-PCR, tRNALeu(UUA) 
Sequences highlighted in green are complementary to respective sequences in tRNAs. 





Table 6. Primers for SFV constructs for bacterial translation system 
Primer 
name 
Sequence (5’ to 3’) Function 
oliSFV 10 TTATACGGGAACCCCACCACG 
RT for chemical probing, 
labelled with Atto647N 












introduction of linkers 

























Reverse primer, short 




Reverse primer, short 












































Reverse primer for 















–1-frame control of 
mutated SL 
Mutated nt are in small letters in bold. 
Table 7. Primers for dnaX constructs 
Primer 
name 

































































































































































































































































































































g UUc AAa 
oliNC87F GATGTCGGCGATATAGGCGCCAG 
Forward primer for 
transcription 
oliNC90 TTCACCGGCCGCGCGC 
Reverse primer for 
transcription 
oliNC002 GCATTAGGAAGCAGCCCAGTAGT Sequencing primer 
Mutated nt are in small letters in bold. 
2.1.8 HIV dual-luciferase vectors 
Table 8. HIV dual-luciferase vectors for in vivo studies in human cell culture 










HIV insert Fwd / HIV 































HIV half SL Fwd / HIV 






HIV half SL Fwd / pLuc 






HIV half SL Fwd / pLuc 










































HIV half SL Fwd / pLuc 
180 Rev 
Start codon ATG is in bold, SS is underlined, mutated nt are in small letters in bold. 
2.1.9 mRNA sequences 
Table 9. Sequences of HIV mRNAs used in bacterial translation system  
mRNA Sequence 












































































































AUG is in bold, SS are underlined, UAG stop codon in 0-frame is in italic, and mutated nt are in small letters 
in bold. Same in Tables 10-13. 
Table 10. Long HIV mRNAs with SS1 and pSS2 variants  
SS1 pSS2 pSL2 
No stop codons in 
–2-frame 
U UUU UUA U UUU CUU +  
U UUU UUc U UUU CUU +  
U UUU cUg U UUU CUU +  
c UUc gUA U UUU CUU +  
U UUU UUA U UUU CUU + * 
U UUU UUA U UUU uUU +  
U UUU UUA U UUU uUU + * 
U UUU UUA U UUc CUg +  
U UUU UUA U UUU CUg +  
U UUU UUA U UUU CUg + * 
c UUc gUA U UUU CUU +  
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c UUc gUA U UUU CUU –  
c UUc gUA U UUU uUU +  
c UUc gUA U UUU uUU + * 
c UUc gUA U UUU uUU –  
c UUc gUA c UUU uUU + * 
c UUc gUA U UUc uUU + * 
 
Table 11. HIV mRNAs with enhancer variants 
Intrenal 
identifier 
Sequence after SS1 GGG SL1 
Wt AAG AUC UGG + 
151 cAG AUC UGG + 
169 gAG AUC UGG + 
170 uAG AUC UGG + 
152 AuG AUC UGG + 
171 AgG AUC UGG + 
172 AcG AUC UGG + 
153 AAc AUC UGG + 
173 AAa AUC UGG + 
174 AAu AUC UGG + 
154 AAG uUC UGG + 
175 AAG gUC UGG + 
176 AAG cUC UGG + 
155 AAG AaC UGG + 
156 AAG AUg UGG + 
157 AAG AUC aGG + 
158 AAG AUC UaG + 
159 AAG AUC UcG + 
160 AAG AUC UGa + 
161 AAG AUC UGg + 
148 cuc uaC UGG + 
149 cuc uag Uaa + 
177 ccu caa Uaa + 
































Table 13. Sequences of SFV mRNAs used in bacterial translation system  
mRNA Sequence 












































































Table 14. Sequence of wt dnaX mRNA  
mRNA Sequence 









2.2.1 Vector construction by polymerase chain reaction 
Insertions, deletions and nucleotide substitutions were introduced by a two-step 
polymerase chain reaction (PCR) (Mullis, 1990) in the thermocycler (peqSTAR 96 
Universal Gradient, PeqLab), as outlined in Tables 15 and 16. Forward and reverse primers 
are summarized in Tables 3-8. 
Table 15. PCR mix 
Component Final concentration 
Template DNA 50-600 ng 
dNTPs 0.2 mM 
Forward primer 0.5 µM 
Reverse primer 0.5 µM 
Q5 reaction buffer or 
Phusion HF buffer 
1X 
DMSO 3%* 
Q5 or Phusion DNA 
polymerase 
0.02 u/µl 
* DMSO was added to decrease the melting temperature (Tm) of DNA primers. 
Table 16. Two-step PCR program conditions 
Cycle step Temperature, °C Time, s Cycles 
Initial denaturation 98 60 1 
Denaturation 98 20 
5 Annealing * 30 
Extension 72 *** 
Denaturation 98 20 
25 Annealing ** 30 
Extension 72 *** 
Final extension 72 300 1 
* Annealing temperature depends on the Tm of primers. During the first 5 cycles, the annealing temperature is 
10 °C lower than Tm to achieve optimal primer binding. 
** During the next 25 cycles, the annealing temperature is increased by 5°C to assure specific primer binding. 
*** Extension time depends on the size of the vector: typically, 30 s per 1 kb (1000 bp). 
PCR products were incubated with DpnI (0.02 u/µl) for 2 hours at 37°C. DpnI treatment 
removes the template DNA because it can cleave only when its recognition site is 
methylated, which is not the case in the PCR product. Deletion mutagenesis results in linear 
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PCR products with blunt ends. To re-circularize the plasmid, the ends of the vector are 
phosphorylated with the T4 Polynucleotide kinase kit and then ligated with T4 DNA Ligase 
or the Quick Ligase kit according to the manufacturer’s recommendations. 
HIV (for both bacterial and mammalian mRNAs) and SFV inserts were cloned into the 
pEX-A2 vector as described above. HIV inserts were designed based on the HIV-1 reference 
genome (NCBI Reference Sequence: NC_001802.1) and encompassed nt 1601-1961 in 
bacterial mRNAs and 1626-1772 in mammalian mRNAs. The SFV insert was derived from 
the complete SFV genome (NCBI Reference Sequence: NC_003215.1), nt positions  
9814-9939. dnaX fragment was cloned into pET24a as described (Caliskan et al., 2017).  
2.2.1.1 Preparation of dual-luciferase vectors 
Dual-luciferase constructs were prepared by site-directed mutagenesis as described 
above using the pSGDLuc vector and primers listed in Tables 5 and 8. The HIV fragment 
(NCBI Reference Sequence: NC_001802.1, 1623-1694 nt) was inserted between Renilla 
(Rluc) and Firefly (Fluc) luciferase reporters (positions 1592-1666 in pSGDLuc). To allow 
for translation initiation, an AUG start codon was introduced before the HIV fragment. The 
insert is embedded in StopGo sequences, which allow to synthesize two proteins from a 
single ORF, rather than a fusion protein containing both reporters (Loughran et al., 2014). 
In the dual-luciferase constructs, Rluc is produced constitutively while Fluc is synthesized 
only upon –1PRF. To check the efficiency of –1-frame peptide formation, we designed a 
control vector (pLuc –1-frame control) which encodes the frameshifted sequence in frame 
and contains a mutated SS to prevent further slippages. To check background or “leaky” 
expression of Fluc, we utilized an empty pSGDLuc vector without HIV insert. The 
frameshifting efficiency was calculated according to the formula: 





where test is any construct where –1PRF takes place, control is the pLuc –1-frame control 
2.2.2 Transformation and purification of plasmid DNA 
PCR or ligation products (10-200 ng) were transformed into NovaBlue E. coli competent 
cells (50 µl). Competent cells were incubated for 30 min on ice and subsequently subjected 
to heat-shock at 42°C for 45 s. Following heat-shock, cells were kept on ice for 2 min for 
recovery and then incubated in LB medium without antibiotic with constant shaking  
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(750 rpm) for 30 min at 37°C in a thermomixer. Cells harboring the desired plasmid were 
transferred to LB agar plates containing Amp (100 μg/ml) or Kan (30 μg/ml) and grown 
overnight at 37°C. A single colony was inoculated in 2 ml of LB-medium with an appropriate 
antibiotic and grown overnight at 37°C with constant shaking (180 rpm) (New Brunswick 
Scientific Innova 4400). The cells were harvested by centrifugation for 10 min at 4,000 rpm 
and at 4°C (Eppendorf Centrifuge 5810R).  
Plasmids were purified using the Macherey-Nagel Plasmid Preparation Kit (Mini, Midi 
or Maxi scale) according to the manufacturer’s protocols. All constructs were verified by 
sequencing (Seqlab – Sequence Laboratories, Göttingen). The concentration and quality of 
the DNA preparations were checked by spectroscopic measurements at 260 nm (NanoDrop 
2000c, PeqLab) and agarose gel electrophoresis (AGE). To prepare samples for AGE, DNA 
(50-200 ng) was mixed with 5X DNA loading dye. Agarose gels (1%) were pre-stained with 
Stain G (1:50,000 dilution) and AGE was performed in 1X TAE running buffer at 100 V for 
60 min. Pictures of the gels were taken using a UV transilluminator (PeqLab).  
2.2.3 Transcription and purification of mRNAs 
mRNAs were produced by in vitro transcription with T7 RNA polymerase (Milligan et 
al., 1987; Tabor and Richardson, 1985). Short linear DNA transcription templates were 
prepared by PCR with Q5 DNA polymerase using the program described in Table 17. 
Table 17. Two-step PCR program conditions 
Cycle step Temperature,°C Time, s Cycles 
Initial denaturation 98 30 1 
Denaturation 98 10 
8 Annealing 55* 10 
Extension 72 10 
Denaturation 98 10 
25 Annealing 60* 10 
Extension 72 10 
* Primers to make transcription templates were designed with Tm ≤ 65°C. 
Transcription mix contained transcription buffer (1X), DTT (10 mM), NTPs (3 mM), 
GMP (5 mM), DNA transcription template (0.2 µM), pyrophosphatase (0.005 U/µl),  
T7 RNA polymerase (1.6 U/µl) and RNase inhibitor (0.2 U/µl). The efficiency of 
transcription was checked by the analytical transcription assay. Samples of transcription mix 
were taken over a time course of 4 h and the transcription reactions were stopped by adding 
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2X RNA loading dye. Samples were further analyzed by 7.5 M urea polyacrylamide gel 
electrophoresis (urea-PAGE) performed in 1X TBE buffer at 200 V for 1 h at the room 
temperature. Gels were fixed with acetic acid (10%) for 10 min and then stained with 
methylene blue (0.04%) in sodium acetate (2 M) solution, pH 5.0, for 20 min. Gels were 
destained with water and pictures were taken with a UV transilluminator.  
Products of preparative in vitro transcription (1-5 ml) were purified via a Mono Q 5/50 
GL anion-exchange column on an ÄKTA system (GE Amersham ÄKTA FPLC UPC-960, 
P-920, Frac-920) using FPLC buffers A and B. Fractions were analyzed by UV 
measurements at 260 nm and peak fractions were pooled and precipitated with  
0.3 M potassium acetate and 100% ethanol at -20°C overnight. The pellets were dissolved 
in Milli-Q H2O. Alternatively, mRNA transcripts were purified using the RNeasy kit 
according to the manufacturer’s recommendations. Purified mRNAs were stored at -80°C. 
The quality and purity of produced mRNAs were checked by 7.5 M urea-PAGE as described 
above. mRNA concentrations were determined from spectroscopic measurements at 260 nm 
using a spectrophotometer (Perkin Elmer LAMBDA Bio+ Spectrophotometer, Terra 
Universal). To estimate the yield, the molecular weight of the mRNAs was calculated by the 
formula below: 
Molecular weight, g/mol = (An × 329.21) + (Un × 306.2) + (Cn × 305.2) + (Gn ×345.2) + 159 
where An, Un, Cn, and Gn are the number of each respective nt within the polynucleotide. 
Addition of 159.0 g/mole to the molecular weight takes into account the 5' triphosphate. 
2.2.3.1 Design of HIV-1 mRNAs for bacterial and mammalian systems 
Control mRNAs used to establish saturating concentrations of ternary complexes and to 
determine the rate of Arg-tRNAArg incorporation in 0-frame were made by chemical 
synthesis and contained an E. coli SD sequence inserted 9 nt upstream of the start codon 
AUG. In HIV model mRNAs a SD sequence was inserted 6 nt upstream of the start codon 
AUG. In the short mRNAs used in the codon walk experiments, AUG was introduced 8 nt 
upstream of the SS1. In the mRNAs used to study +1 and –2 frameshifting, the GGG codon 
(Gly) following the SS1 was mutated to UGG (Trp) to distinguish between –1-, –2- and  
+1-frameshifting products (Mathew et al., 2015). The nearest natural AUG in the gag mRNA 
was used as a start codon in the long mRNAs to study gag-pol translation products by PAGE. 
The stop codon UAG was introduced in the 0-frame 156 nt downstream of the AUG and  
120 nt after the SS1 to allow the separation between the 0-frame (52 aa) and –1-frame  
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(120 aa) products. 0-, –1- and –2-frame control mRNAs contained respective sequences 
cloned in-frame with SS1 and pSS2 being mutated to prevent slippages. All mRNA 
sequences are listed in Tables 9-11. 
Mammalian HIV-1 mRNAs were made with the native 5’ UTR from rabbit β-globin 
mRNA containing a Kozak sequence with an embedded AUGG site to allow efficient 
initiation (Table 12). Here the AUG was placed 8 nt upstream of the SS1, and the next codon 
CAG (Gln) was mutated to GUA (Val) to improve initiation and facilitate product separation 
by high-performance liquid chromatography (HPLC).  
2.2.3.3 Design of SFV mRNAs 
In short SFV mRNAs for HPLC analysis the SD was introduced 8 nt before the start 
codon AUG (Table 13). In turn, AUG was placed 8 nt before the SS. The second codon after 
AUG, CUU (Leu), was mutated to AAG (Lys) to improve translation efficiency with E. coli 
purified tRNAs. In long SFV mRNAs used for analysis by PAGE the SD was put 6 nt before 
the AUG, which had the same position with regard to the SS as in short mRNAs (Table 13). 
Here the CUU codon remained unchanged because translation was carried out with native 
human total tRNA. The UAG stop codon was introduced into 0-frame 51 nt downstream of 
the AUG to distinguish between 0-frame (17 aa) and –1-frame (32 aa) products. 
2.2.3.4 Design of dnaX mRNAs 
dnaX wt mRNA contained a variant of the original dnaX frameshifting site modified as 
described previously (Caliskan et al., 2017) (Table 14). All mRNA mutants had the same 
length as wt and contained the native SL structure, but differed in the SS sequence, as shown 
in Tables 7, 23 and 27.  
2.2.4 tRNA preparation 
2.2.4.1 Aminoacylation and purification of individual tRNAs from E. coli 
Individual tRNAs were prepared from E. coli total tRNA (Roche) and aminoacylated 
with the respective aa as described below. For preparative aminoacylation, 50-100 μM total 
tRNA, 1% (v/v) aa-tRNA synthetase or 5% (v/v) S100 extract (contains a mixture of 
synthetases), 3 mM ATP, 2 mM DTT, 50-80 μM radioactive-labeled aa or 1 mM cold aa 
were incubated for 60 min at 37°C in aminoacylation buffer. The aminoacylation efficiency 
was controlled in an aliquot of the reaction mixture by trichloracetic acid precipitation, 
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filtration through a nitrocellulose filter, and scintillation counting with Quickszint 361 
cocktail using a Tri-Carb 3110 TR instrument (Perkin Elmer). Potassium acetate (pH 4.5) 
was added to the samples to a final concentration of 0.3 M. The reaction mixture was 
phenolized to remove proteins. The aa-tRNA was precipitated from the aqueous phase with 
2.5 volumes of cold ethanol, and the pellet of aa-tRNA was dissolved in 0.1 M sodium 
acetate (pH 4.5). 
fMet-tRNAfMet, BODIPY-Met-tRNAfMet, Phe-tRNAPhe and Gln-tRNAGln were made as 
described (Holtkamp et al., 2014a; Kothe et al., 2006; Rodnina et al., 1994) and provided by 
the laboratory facility. Gln-, Ala- and Asn-tRNA mixture, Arg-tRNAArg, Gly-tRNAGly,  
Val-tRNAVal, Ser-tRNASer, Thr-tRNAThr were prepared from E. coli total tRNA by 
aminoacylation with the respective aa and subsequent affinity chromatography of the EF-
Tu-GTP-aa-tRNA TCs on a Protino Ni-IDA 2000 Packed Columns in TAKM7 buffer. 
Purification was followed by phenolization and ethanol precipitation of the aa-tRNA. 
tRNALeu(UUA), elongator tRNAMet, tRNATyr, tRNAIle, tRNALys, tRNAAla, tRNAGlu and a 
mixture of isoacceptors tRNALeu(CUN) were prepared by consecutive chromatographies on 
Sepharose 4B, Phenyl Sepharose and DEAE Toyopearl columns. Upon aminoacylation, 
these tRNAs were additionally purified by reversed-phase HPLC (RP-HPLC) on a WP-300 
RP-18 column using HPLC buffers E and F. tRNATrp was prepared by T7 RNA polymerase 
transcription from pUC18 plasmid carrying the E. coli trp gene using the conditions outlined 
in Tables 18 and 19. The tRNA transcript was purified by Mono Q 5/50 GL column (see 
2.2.3) using FPLC buffers C and D. Upon purification, tRNATrp was aminoacylated as 
described above. 
Table 18. PCR mix 
Component Final concentration 
Template DNA 400 ng 
dNTPs 0.2 mM 
Forward primer 0.5 µM 
Reverse primer 0.5 µM 
Pfu reaction buffer 1X 
MgSO4 2 mM 





Table 19. PCR program conditions 
Cycle step Temperature, °C Time, s Cycles 
Initial denaturation 95 60 1 
Denaturation 95 30 
25 Annealing 60 30 
Extension 72 30 
Final extension 72 300 1 
 
2.2.4.2 Purification of total tRNA from HeLa cell extracts 
Total human aa-tRNA was prepared from cell extracts obtained from S10 HeLa cells 
(Fermentation facility of Max Planck Institute for Biophysical Chemistry, Göttingen). The 
cytoplasmic fraction of the cell lysate was phenolized and aa-tRNA was purified by anion-
exchange chromatography on a HiTrap Q HP column using FPLC buffers E and F. 
Purification was performed at acidic pH 4.5-5 to avoid deacylation of endogenous aa-tRNA. 
To prepare tRNA mixes aminoacylated with aa of interest, total tRNA was deacylated by 
incubation in 0.5 M Tris-HCl, pH 9 at 37°C for 3 hours. Upon tRNA recovery, 
aminoacylation was carried out as described for E. coli tRNAs but using 5% (v/v) S30 
aminoacylation extract from yeast S. cerevisiae (provided by Dr. Namit Ranjan, Department 
of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry, Göttingen). 
Concentrations of tRNAs were determined spectrophotometrically at 260 nm and, where 
applicable, by radioactivity measurements with Ultima Gold™ XR scintillation cocktail. 
2.2.5 Initiation complex formation 
70S ribosomes from E. coli MRE 600 and initiation factors (IF1, IF2, IF3) were prepared 
as described (Rodnina and Wintermeyer, 1995) and provided by the laboratory facility. 70S 
ICs were prepared by incubating 70S (1 μM) with mRNA (3-10 µM), initiation factors IF1, 
IF2, and IF3 (1.5 µM each), initiator f[3H]Met-tRNAfMet or BODIPY-Met-tRNAfMet (2 µM), 
DTT (1 mM) and GTP (1 mM) in TAKM7 buffer for 30 min at 37°C. To monitor 70S IC 
formation, samples (10 pmol) were taken over a time course of 45 min and filtered through 
a nitrocellulose filter on a vacuum unit. Filters were dissolved in Quickzint 361 scintillation 
cocktail and radioactivity was counted in the scintillation counter. The efficiency of 70S IC 
formation was estimated as follows: 
Efficiency of 70S IC formation [%] =  
Radioactivity [ H3 ] measured (dpm) × 100%








ICs were purified by ultracentrifugation through a 1.1 M sucrose cushion in TAKM7 
buffer. Centrifugation was performed in a TLS-55 swing-out rotor in an ultracentrifuge 
(Beckman Optima XP) at 55,000 rpm at 4°C for 2 h. Pellets were dissolved in HiFi buffer. 
The concentration of the ribosomes was determined from the absorbance measurements at 
260 nm assuming 23 pmol of 70S ribosomes per A260 unit. The radioactivity was measured 
by liquid scintillation counting with Ultima Gold™ XR cocktail to calculate the efficiency 
of 70S initiation. 
2.2.6 In vitro translation of HIV mRNAs 
2.2.6.1 HIV codon walk assay 
Elongation factors EF-Tu and EF-G were prepared as described (Cunha et al., 2013; 
Doerfel et al., 2013; Savelsbergh et al., 2003). To form EF-Tu-GTP-aa-tRNA TCs, EF-Tu 
(25-30 µM, or 3-fold excess over aa-tRNA) was incubated with GTP (1 mM), 
phosphoenolpyruvate (PEP) (3 mM), and pyruvate kinase (PK) (0.1 mg/ml) in TAKM7 
buffer with DTT (1 mM) for 15 min at 37°C. Then aa-tRNAs were added and incubated for 
1 min at 37°C. The concentrations of aa-tRNA were optimized to ensure the maximum 
binding at their respective codon: 1.6 µM each for Gln-tRNAGln, Ala-tRNAAla,  
Asn-tRNAAsn, Phe-tRNAPhe, and Arg-tRNAArg, 1.2 µM for Gly-tRNAGly and different 
concentrations of Leu-tRNALeu(UUA), as indicated. IC (0.16 µM) was mixed with TCs (about 
20 µM final concentration of EF-Tu), EF-G (1.6 µM), GTP (1 mM), PEP (2.4 mM) and PK 
(0.08 mg/ml) in HiFi buffer at 37°C. Incubation times were 0-10 min for time courses or  
2 min for end-point measurements.  
The stability of MQANF-tRNAPhe binding to the ribosome was tested using the 
nitrocellulose filter binding assay upon translation of HIV wt mRNA. The complexes were 
prepared by mixing IC with TC(QANF) and incubating for 30 sec to 10 min at 37°C, which 
results in the formation of MQAN, MQANF and –1-frame MQANFFR peptides.  
Gln-tRNAGln, Ala-tRNAAla, Asn-tRNAAsn, Phe-tRNAPhe and Arg-tRNAArg were used at  
0.5 µM each (10-times over 70S). The amount of total ribosome-bound peptide was 
calculated from the f[3H]Met retained on the nitrocellulose membrane upon filtration and 
scintillation counting in Quickszint 361 cocktail. MQANF and MQANFF peptides were 
distinguished based on the [14C]Phe/f[3H]Met ratio. 
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To prepare samples for the HPLC analysis, the reactions were quenched with KOH  
(0.5 M) and hydrolyzed for 30 min at 37°C; then the samples were neutralized by the addition 
of glacial acetic acid. Translation products were separated by RP-HPLC on an RP-8 column 
using HPLC buffers A and B. Eluted fractions were mixed with Ultima Gold XR scintillation 
liquid and analyzed by scintillation counting.  
The peptide products up to MQAN were not separated from each other, while all other 
peptides could be identified by either position shift on a chromatogram or by the radioactive 
label of the respective aa. The amount of each product was determined as a ratio between 
3H-counts in the respective peak and total 3H-counts in the eluate. For samples with [3H]Gly-
tRNAGly, [14C]Arg-tRNAArg, or [14C]Leu-tRNALeu(UUA) the respective peaks were calculated 
in pmol. Where necessary, the amount of MQANFLR peptide was calculated by subtracting 
the amount of MQANFLG from that of MQANFL, in pmol. Likewise, the MQANFFR 
peptide was calculated by subtracting the amount of MQANFLR from the mixed 
MQANFLR/FFR product, in pmol. Time courses were evaluated by numerical integration 
using the KinTek Explorer software (Johnson, 2009). The frameshifting efficiency was 
calculated as a ratio between the –1-frame peptides (MQANFFR and MQANFLR) and the 
sum of –1- and all 0-frame peptides (MQANF, MQANFL, MQANFLG), multiplied by 
100%.  
2.2.6.2 End-point translation assay of –2 / +1 HIV mRNA  
Translation of –2 / +1 mRNA was carried out as described for the codon-walk assay, but 
with 0.4 µM of each Gln-tRNAGln, Ala-tRNAAla, Asn-tRNAAsn, 0.8 µM of Phe-tRNAPhe, 
0.08 µM of Leu-tRNALeu(UUA), and 0.4 µM each of Trp-tRNATrp, Met-tRNAe
Met, and  
Tyr-tRNATyr. IC (0.08 µM) was incubated with TCs (about 10 µM final concentration of 
EF-Tu), EF-G (1.6 µM), GTP (1 mM), PEP (2.4 mM) and PK (0.08 mg/ml) for 2 min in 
HiFi buffer at 37°C. The efficiency of frameshifting peptide synthesis was calculated by 
dividing the amount of the respective peptide in pmol by the sum of all peptides in translation 
excluding MQAN, multiplied by 100%. 
2.2.6.3 Arg-tRNAArg incorporation assay on HIV control mRNAs 
To form post-translocation complexes (PTCs), purified ICs (0.16 µM final) were mixed 
with Phe-tRNAPhe (1.6 µM) or Leu-tRNALeu(UUA) (0.16 µM) in the presence of EF-G  
(0.008 µM, 1/20 of the IC concentration) in HiFi buffer and incubated for 1 min at 37°C. 
PTCs were then mixed with Arg-tRNAArg (1.6 µM) and EF-G (1.6 µM) and reacted for  
55 
 
1-100 s at 37°C. Translation products were analyzed by RP-HPLC as described above. The 
position of MFR and MLR peptides was identified based on [14C]Arg counts and their 
amounts were calculated in pmol. The rate of Arg incorporation was estimated by single-
exponential fitting using the GraphPad Prism software. 
2.2.6.4 End-point translation of HIV mRNAs with enhancer variants 
Translation of HIV short mRNAs with enhancer variants was done with 0.8 µM of each 
Gln-tRNAGln, Ala-tRNAAla, Asn-tRNAAsn, Phe-tRNAPhe and Arg-tRNAArg, 0.08 µM of  
Leu-tRNALeu(UUA) and 0.6 µM of Gly-tRNAGly. IC (0.08 µM) was mixed with TCs (about 
10 µM final concentration of EF-Tu), EF-G (1.6 µM), GTP (1 mM), PEP (2.4 mM) and PK 
(0.08 mg/ml) and reacted in HiFi buffer for 2 min at 37°C. Produced peptides were separated 
using RP-HPLC and frameshifting efficiencies were determined as described in 2.2.6.1. 
2.2.6.5 Analysis of TC formation by electrophoretic mobility shift assay 
Formation of TC between E. coli EF-Tu and human native aa-tRNA (1.4 µM) was 
monitored at varying concentrations of EF-Tu (0-300 µM) using an electrophoretic mobility 
shift assay. TC formation was analyzed by native gel-electrophoresis using 5% (w/v) PAGE 
supplemented with DTT (125 µM) and GTP (10 µM). The gels were run at 4°C at 150V  
(76 mA) for 4-6 h in electrophoresis buffer (50 mM Tris-HCl, pH 7.5, 10 mM magnesium 
acetate, 75 mM ammonium acetate, 1 mM EDTA, 10 µM GTP), stained with Gel Red 
(Biotium) and scanned using a UV transilluminator (Amersham™ imager 600). Band 
intensities were evaluated using the MultiGauge software. 
2.2.6.6 Translation of long HIV and B-crystallin mRNAs using human tRNAs and 
analysis of translation products 
ICs programmed with HIV mRNA constructs prepared with BODIPY-Met-tRNAfMet 
(0.08 µM) were incubated with EF-Tu (80 µM), total aa-tRNA from HeLa cells (3–10 µM), 
EF-G (1.6 µM) and RF1 (0.8 µM), GTP (1 mM), PEP (2.4 mM) and PK (0.08 mg/ml) in 
HiFi buffer at 37°C as indicated or for 30 min for single-point measurements. RF1 was 
prepared as described (Florin et al., 2017) and provided by Prajwal Karki (Department of 
Physical Biochemistry, Max Planck Institute for Biophysical Chemistry, Göttingen). In case 
of B-crystallin mRNAs, translation was carried out using IC (0.02 µM), EF-Tu (45 µM), 
total aa-tRNA from HeLa (10 µM), EF-G (1 µM), GTP (0.8 mM), PEP (1.4 mM) and PK 
(0.05 mg/ml) for 30 min in HiFi buffer at 37°C.  
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To prepare the samples for PAGE, the reactions were stopped with NaOH (0.4 M) and 
hydrolyzed as described for the HPLC sample preparation. HEPES (0.2 M, pH 5) was added 
to neutralize the reactions. Finally, the samples were mixed with equal volumes of  
2X sample buffer and separated by Tris-Tricine gel electrophoresis (Schagger and von 
Jagow, 1987). Tris-Tricine gels were prepared as outlined in Table 20. 
Table 20. Composition of separating, spacer and stacking gels* 
 Stacking gel (1 cm) Spacer gel (1 cm) Separating gel 
 4% T, 3% C 10% T, 3% C 16.5% T, 6% C 
49.5% T, 3% C mixture of 
acrylamide/bis** 
0.5 ml 0.6 ml – 
49.5% T, 6% C mixture of 
acrylamide/bis 
– – 2 ml 
3X gel buffer 2 ml 1 ml 2 ml 
Milli-Q H2O to a final 
volume of 
6 ml (add 3.5 ml) 3 ml (add 1.4 ml) 6 ml (add 2 ml) 
TEMED 20 µl 10 µl 10 µl 
APS (10%) 30 µl 25 µl 25 µl 
* Gel dimensions were 10 cm x 10 cm x 0.8 mm 
** T stands for the total percentage concentration of both monomers (acrylamide/bis). C refers to the 
percentage concentration of the crosslinker (bis) relative to the total concentration T (Hjerten, 1962). 
The gels were run in PerfectBlue™ Vertical Double Gel Systems (Peqlab) using  
1X cathode buffer in the inner chamber and 1X anode buffer in the outer chamber. The 
electrophoresis was performed at room temperature at 30V (15 mA) until the samples 
reached the separating gels and then at 150V (76 mA) until the end.  
Fluorescent peptides were visualized using a Typhoon™ FLA-9000 scanner (GE 
Healthcare Life Sciences) and the band intensities were evaluated using the MultiGauge 
software. Frameshifting efficiencies were calculated from the band intensities of the  
–1-frame product to the sum of –1- and 0-frames products as well as of translation 
intermediates appearing at 20 s of translation. The correct length of the peptides was 
confirmed using control 0-frame, –1-frame and –2-frame mRNAs. 
2.2.7 In vitro translation of SFV mRNAs 
2.2.7.1 End-point translation assay of short SFV mRNAs 
Translation and analysis of short SFV mRNAs was carried out as described for HIV 
mRNAs (2.2.6.1), but using 0.8 µM of each Ser-tRNASer and Phe-tRNAPhe and 0.25 µM of 
each Lys-tRNALys, Val-tRNAVal, Ala-tRNAAla and Thr-tRNAThr. Leu-tRNALeu(UUA) was 
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used in three different concentrations depending on the experiment: 0 µM, 0.025 µM  
(0.3x over 70S) and 0.08 µM (1x over 70S). IC (0.08 µM) was mixed with TCs  
(about 10 µM final concentration of EF-Tu), EF-G (1.6 µM), GTP (1 mM), PEP (2.4 mM) 
and PK (0.08 mg/ml) in HiFi buffer at 37°C and incubated for 2 min unless stated otherwise. 
Due to limited separation efficiency, 0-frame and –1-frame products were distinguished 
based on different radioactive labels on terminal aa as follows: [14C]Val-tRNAVal in 0-frame 
MSKSFLV and [14C]Ala-tRNAAla and [14C]Thr-tRNAThr in –1-frame peptides 
MSKSFFAT/MSKSFLAT. To identify –1-frame peptides, two labels were used 
simultaneously due to their low specific activity. Frameshifting efficiencies were calculated 
as a ratio between the –1-frame peptide (MSKSFFAT and MSKSFLAT) and the sum of  
–1- and all 0-frame peptides (MSKSF, MSKSFL, MSKSFLV), multiplied by 100%. 
Translation of long SFV mRNAs was carried out as described for B-crystallin mRNAs 
(2.2.6.6). 
2.2.8 Chemical probing of SFV mRNA secondary structure 
Chemical probing of SFV mRNA secondary structures was carried out using DMS, KE 
and CMCT as outlined in Table 21 (Hartmuth et al., 1999). 
Table 21. Scheme of chemical probing with DMS, KE and CMCT 
Modification agent DMS KE CMCT 
Reaction volume 100 µL 100 µL 100 µL 
mRNA (1 pmol) 1 µL (1 µM) 1 µL (1 µM) 1 µL (1 µM) 
Yeast total tRNA  
(10 µg/ µL)* 
1 µL 1 µL 1 µL 
IPP buffer** Fill up to 100 µL 
Reagent 0.5 µL DMS 
20 µL KE mix (2 µL 
KE + 18 µL IPP buffer) 
0.0075 g CMCT 
Incubation 
Temperature 20°C 4°C 20°C 
Time 8 min 90 min 20 min 
* yeast total tRNA was added to prevent overmodification and facilitate RNA precipitation. 
** IPP buffer: 20 mM HEPESs, pH 7.9, 150 mM NaCl, 7 mM MgCl2. 
Reactions with DMS were stopped using 2X DMS-stopper (400 mM Tris acetate,  
pH 7.5, 400 mM β-mercaptoethanol, 5 mM EDTA, 600 mM sodium acetate); reaction 
adducts of KE treatment were stabilized with 50 mM K3BO3. Upon chemical probing the 
modified mRNAs were recovered by precipitation with 3M sodium acetate (1/10 v/v) and 5 
volumes of ice-cold ethanol followed by centrifugation for 30 min at 13,000 rpm at 4°C 
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(Eppendorf Centrifuge 5415R). The RNA was re-precipitated three times to remove the 
remaining modification reagents and to improve the sample purity. After the final 
centrifugation, pellets were dissolved in Milli-Q H2O or 50 mM K3BO3 for KE-treated 
samples. Modified ICs were processed as described for mRNAs, but in addition the reactions 
were treated with 3% proteinase K and subsequently phenolized to remove proteins. 
Following mRNA recovery, a RT reaction was conducted as outlined in Table 22. 
Table 22. Outline of RT upon chemical probing 
Component Amount 
2.5 µL HY 
reaction 
Modified mRNA or untreated control mRNA 100 fmol 
10X HY buffer (0.5 M Tris-HCl, pH 8.4, 0.6 M NaCl, 0.1 M DTT) 1X 
Reverse primer oliSFV 10 labeled with Atto647N at 5' end 125 fmol 
Incubated at 96°C for 60 sec followed by 5 min at room temperature 
10X RT buffer (0.5 M Tris-HCl, pH 8.4, 0.08 M MgCl2, 0.5 M NaCl, 
0.1 M DTT) 
1X 
2.5 µL RT 
reaction dNTPs 160 µM each 
Reverse transcriptase (Sequenase Version 2.0 DNA Polymerase) 0.5 U/µL 
Incubated at 42°C for 45 min 5 µL total 
 
Sequencing lanes were prepared by adding ddNTPs (100 µM each) to the RT reaction. 
Analysis of the primer extension products was done on 9.6% (w/v) polyacrylamide/8.3 M 
urea sequencing gels with 1X TBE as running buffer (Hartmuth et al., 1999). Fluorescent 
products were visualized using a Typhoon™ Trio+ scanner (GE Healthcare Life Sciences) 
and the band intensities were evaluated using the MultiGauge and Canvas Draw software.  
2.2.9 End-point translation of dnaX mRNA variants 
Translation was carried out as described in 2.2.6 with the following changes. ICs  
(0.2 µM) were reacted with TCs (about 15-20 µM EF-Tu) and EF-G (2 µM) in TAKM7 
buffer supplemented with 1 mM GTP at 37°C for 1 min. Final concentrations of aa-tRNAs 
(per codon) were as follows: 0.4 µM for Ala-tRNAAla, Lys-tRNALys, Phe-tRNAPhe,  
Val-tRNAVal and Ile-tRNAIle; 1 µM for Glu-tRNAGlu, 1.2 µM for Gln-tRNAGln, 2 µM for 
mixture of isoacceptors Leu-tRNALeu(CUN). Formed peptides were separated by RP-HPLC 
with HPLC buffers A and B or HPLC buffers C and D (for experiments with Lys-Lys 
containing product). For all experiments, f[3H]Met was used to identify the respective 
peptide peaks; the following radioactive labels were used depending on the mRNA 
sequence: [14C]Val, [14C]Ile, [14C]Lys, [14C]Glu or [14C]Leu (Table 23, mutated nt are in 
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small letters in bold, aa sequences of the SS are underlined). The amount of each product 
was quantified as a ratio between 3H-counts in the respective peak and total 3H-counts of the 
sample. Frameshifting efficiencies were calculated as a ratio between the –1-frame peptide 
and the sum of –1- and 0-frame products multiplied by 100%¸ 
Table 23. dnaX mRNAs with slippery site mutations 
Slippery site 0-frame peptide Labeled aa in –1-frame peptide 
A AAA AAG 
fMet-Ala-Lys-Lys-Phe 
[14C]Val 
c AAA AAG 
u AAA AAG 
g AAA AAG 
A AAg AAG 
c AAg AAG 
u AAg AAG 
g AAg AAG 
A AAA AAa 
[14C]Ile 
c AAA AAa 
u AAA AAa 
g AAA AAa 
A AAg AAa 
c AAg AAa 
u AAg AAa 
g AAg AAa 
U UUU UUU 
fMet Ala-Phe-Phe-Phe [14C]Leu 
a UUU UUU 
c UUU UUU 
g UUU UUU 
U UUc UUU 
a UUc UUU 
c UUc UUU 
g UUc UUU 
U UUU UUc 
a UUU UUc 
c UUU UUc 
g UUU UUc 
U UUc UUc 
a UUc UUc 
c UUc UUc 
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g UUc UUc 
A AAA UUU 
fMet-Ala-Lys-Phe-Phe [14C]Leu 
c AAA UUU 
u AAA UUU 
g AAA UUU 
A AAg UUU 
c AAg UUU 
u AAg UUU 
g AAg UUU 
A AAA UUc 
c AAA UUc 
u AAA UUc 
g AAA UUc 
A AAg UUc 
c AAg UUc 
u AAg UUc 
g AAg UUc 
U UUU AAG 
fMet Ala-Phe-Lys-Phe 
[14C]Val 
a UUU AAG 
c UUU AAG 
g UUU AAG 
U UUc AAG 
a UUc AAG 
c UUc AAG 
g UUc AAG 
U UUU AAa 
[14C]Ile 
a UUU AAa 
c UUU AAa 
g UUU AAa 
U UUc AAa 
a UUc AAa 
c UUc AAa 
g UUc AAa 
 
2.2.10 Translation in in vitro reconstituted mammalian system  
40S and 60S ribosomal subunits from HeLa, translation initiation factors eIF1, eIF1A, 
eIF2, eIF3, eIF4A, eIF4B, eIF5, eIF5B, translation elongation factors eEF1A and eEF2 as 
well as Met-tRNAi
Met were prepared according to published protocols (Pestova and Hellen, 
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2003; Pisarev et al., 2007) and provided by Dr. Akanksha Goyal, Dr. Dmitri Burakovsky 
and the laboratory facility.  
2.2.10.1 80S Initiation complex formation 
To form 48S IC, 40S subunits (0.3 µM) were mixed with initiation factors eIF1  
(0.6 µM), eIF1A (0.6 µM), eIF2 (0.45 µM), eIF3 (0.45 µM), eIF4A (0.8 µM) and eIF4B  
(0.5 µM), Met-tRNAMet (0.9 µM) and mRNA of interest (0.75 µM) and incubated in 
eukaryotic translation buffer supplemented with RNAse inhibitor (0.5 µM) for 15 min at 
37°C. The KCl concentration in the reaction was adjusted to 90-100 mM. Next, initiation 
factors eIF5A (0.32 µM) and eIF5B (0.35 µM) were pre-activated in the eukaryotic 
translation buffer supplemented with RNAse inhibitor (0.5 µM) for 5 min at 37°C. The 
incubation was followed by the addition of the 60S subunit (0.45 µM). To form 80S IC  
(0.15 µM), 48S IC and 60S IC were reacted for 8 min at 37°C. 
2.2.10.2 Ternary complex formation and translation 
PEP (1 mM) and PK (0.1 mg/ml) were incubated in the eukaryotic translation buffer 
supplemented with RNAse inhibitor (0.5 µM) for 15 min at 37°C. Next, elongation factors 
eEF1A (10.8 µM), eEF2 (5.4 µM) and yeast Pu3 (10.8 µM, eEF1Bα analogue) were added 
to the pump and reacted for another 5 min at 37°C. Finally, total human tRNA (110-150 µM) 
aminoacylated with aa of interest was added to the mixture and incubated for 3 min at 37°C, 
leading to the formation of the TC. 
To allow for translation, 80S ICs (0.08 µM) were reacted with PEP (0.5 mM), PK  
(0.05 mg/ml), eEF1A (5.4 µM), eEF2 (2.7 µM), Pu3 (5.4 µM) and total human tRNA  
(55-75 µM) in the eukaryotic translation buffer for 4-8 min at 37°C. Translation products 
were analyzed on RP-HPLC as described in 2.2.6. –1-frame peptides were identified based 
on [3H]Arg. In the presence of Leu total translation efficiency was quantified using [14C]Leu 
and the frameshifting efficiency was calculated as a ratio between Arg-containing peptides 
and total translation products multiplied by 100%. In the absence of Leu, total translation 
efficiency was calculated using –1-frame control, which shows the maximum level of 
frameshifting peptide produced under the given conditions. Here the frameshifting efficiency 
was calculated as the ratio between Arg-containing wt peptides and –1-frame control 
peptides multiplied by 100%. 
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2.2.11 tRNA-specific qRT-PCR 
2.2.11.1 Cell lines 
Sup-T1 is derived from Non-Hodgkin's T-cell lymphoma isolated from a pleural 
effusion of an eight-year-old male and subcloned on soft agar; Jurkat is derived from human 
T-cell lymphoblast; PM1 is a derivative of HUT78, a human cutaneous T-cell lymphoma 
cell line derived from peripheral blood of a patient with Sezary syndrome; 174xCEM is a 
fusion product of human B-cell line 721.174 and a human T-cell line CEM; 293T is an 
epithelial cell line derived from human embryonic kidney cells and expressing a large T 
antigen. Information about cell lines is taken from https://aidsreagent.org/ and 
http://www.lgcstandards-atcc.org/. 
The following reagents were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: 174xCEM cells from Dr. Peter Cresswell, Sup-T1 cells 
from Dr. Dharam Ablashi, and Jurkat Clone E6-1 cells from Dr. Arthur Weiss. 293T 
(DSMZ-German Collection of Microorganisms and Cell Cultures, ACC 635) cells were 
maintained in Dulbecco’s modified Eagle medium (DMEM, Pan Biotech) supplemented 
with 10% fetal calf serum (Biochrom, FCS) and 1% of 100X concentrated 
penicillin/streptomycin (pen/strep) mix (Pan Biotech). For subculturing, cells were detached 
by resuspension in phosphate-buffered saline (PBS [293T]) or incubation with 
trypsin/EDTA solution (Pan Biotech). The human T-cell lines 174xCEM (NIH AIDS 
Reagent Program, NIH272, (Salter et al., 1985)), PM1 (Lusso et al., 1995), Sup-T1 (NIH 
AIDS Reagent Program, NIH100, (Ablashi et al., 1995)) and Jurkat (NIH AIDS Reagent 
Program, NIH177, (Weiss et al., 1984)) were maintained in Roswell Park Memorial Institute 
1640 medium (RPMI, Pan Biotech) supplemented with 10% FCS and 1% of 100X 
concentrated pen/strep mix. For subculturing, culture medium containing the suspension 
cells was centrifuged (600X g, 10 min, room temperature). Then, the supernatant was 
discarded and pelleted cells were resuspended in 10 ml RPMI medium. Further, 1 ml of this 
suspension was added to a new culture flask and filled up with 19 ml of RPMI medium. 
2.2.11.1 Quantification of tRNA levels 
Method description is provided by Dr. Markus Hoffmann. Cellular tRNA levels for 
tRNALeu(UUA), tRNALeu(CUG), tRNAVal(GUA) and tRNAVal(GUG) were quantified using a strategy 
published by (Wan Makhtar et al., 2017). Total cellular RNA was extracted using the 
RNeasy Mini Kit according to the manufacturer’s protocol. After elution the RNA content 
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was determined spectrophotometrically. To eliminate potentially co-isolated DNA from the 
samples, 0.5 µg RNA was incubated with DNase I (NEB) in a final volume of 10 µl for 30 
min at 37°C and finally heated to 65°C for 5 min to inactivate the enzyme. The primer for 
the RT entailed a tRNA-specific sequence and a stem-loop sequence (Wan Makhtar et al., 
2017). The tRNA-specific primer was the same for tRNALeu(UUA) and tRNALeu(CUG) 
(complementary to positions 47-55) and different for tRNAVal(GUA) and tRNAVal(GUG) 
(complementary to positions 62-70) (Table 5). cDNA synthesis was performed as described 
in the manufacturer’s instructions (for gene-specific primers) using the SuperScript III First-
Strand Synthesis System (ThermoFisher Scientific) and 5 µl of DNase I-digested RNA (0.25 
µg). Input RNA was removed by incubation with RNaseH. To determine the levels of the 
tRNAs, tRNALeu(UUA), tRNALeu(CUG), tRNAVal(GUA) and tRNAVal(GUG) as well as 18S rRNA 
(housekeeping gene control), quantitative PCR (qPCR) was performed employing the 
QuantiTect SYBR Green Kit (Qiagen) according to the manufacturer’s protocol on a 
Rotorgene Q device (Qiagen). The primers used for qPCR were taken from (Wan Makhtar 
et al., 2017); the forward primer for the qPCR is highly specific to each tRNA and the reverse 
primer is universal (Table 5). For each run, technical triplicates were analyzed for each 
sample and reactions containing water instead of template cDNA were used as negative 
control. Cycle conditions were chosen as follows: one cycle at 95°C for 15 min, followed by 
45 cycles consisting of 15 sec at 94°C, 30 s at 60°C and 30 s at 72°C. Finally, a linear 
temperature increase from 60 to 90°C with a ramp of 1°C per step and each step lasting 5 s 
was performed to obtain a melting curve for each reaction. In order to compare 
tRNALeu(UUA)/tRNALeu(CUG) and RNAVal(GUA)/tRNAVal(GUG) tRNA ratio between cell lines, 
cycle threshold (ct) values for each tRNA were normalized against the respective ct values 
for 18S rRNA. 
2.2.12 Statistical analysis 
To assure statistical significance of the presented data, all experiments were performed 
in multiple biological replicates (3-10). qRT-PCR experiments were done in 3 biological 
replicates with 3 technical repeats each. Error bars represent s.e.m values unless stated 




3.1 –1PRF mechanism and its modulation at the gag-pol slippery site of HIV-1 
3.1.1 In vitro reconstituted E. coli translation and peptide analysis system 
To study –1PRF in HIV-1, we established a fully reconstituted E. coli translation system 
consisting of purified 70S ribosomes, translation factors, aa-tRNAs and HIV-1 gag-pol 
model mRNAs. The wt HIV mRNA contains a native frameshifting site with the U1 UUU4 
UUA7 SS1 and the downstream SL1; in the U4C mRNA the SS1 is mutated to U1 UUC4 
UUA7. To allow for efficient translation initiation in bacterial system, we introduced a SD 
sequence (6 nt prior to the start codon AUG) and an initiator codon AUG 8 nt before the 
SS1. The presence of a SD does not interfere with the frameshifting efficiency due to the 
large distance to the SS1 (17 nt). Initiation efficiency measured with HIV-1 model mRNAs 
was 85-100%, which is a prerequisite for efficient translation. 
Translation was performed by reacting 70S ICs programmed with gag-pol mRNAs and 
TCs with desired purified aa-tRNAs in the presence of EF-G-GTP. To achieve maximum 
translation efficiency at each codon, we determined the optimal concentrations for each  
aa-tRNA using either wt HIV mRNA or short model mRNAs without frameshifting elements 
(Fig. 14A-E). The saturating amounts of TCs over 70S were used in all following 
experiments unless stated otherwise, e. g., 5-10-fold excess of TC(Gln-Ala-Asn), 10-fold 
excess of TC(Phe), 1-fold excess of TC(Leu-UUA), 5-7-fold excess of TC(Gly) and 10-fold 




Figure 14. Optimization of an in vitro translation and peptide analysis system to study –1PRF in 
HIV-1.  
(A) Titration of TC(Gln-Ala-Asn) on wt mRNA to determine saturating amounts required for 
translation. Monitored peptides are MQAN (grey circles), MQANF (purple triangles), and MQANFL 
(blue downward triangles).  
(B) Titration of TC(Phe) on model mRNA encoding fMet-Phe(UUC)-Stop.  
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(C) Titration of TC(Leu-UUA) on model mRNA encoding fMet-Leu(UUA)-Val-Stop.  
(D) Titration of TC(Gly) on model mRNA encoding fMet-Gly(GGG)-Phe-Stop.  
(E) Titration of TC(Arg) on model mRNA encoding fMet-Arg(AGG)-Val-Stop.  
(F) Separation of the wt mRNA translation products in the absence of Leu-tRNALeu(UUA) (TC(Leu-
UUA)). tRNAs used for translation are Gln, Ala, Asn, Phe, and Arg (TC(QANFR)). Peptides are 
indicated: MQAN (grey), MQANF (purple), MQANFF (orange), and MQANFFR (red outline).  
(G) Separation of the reaction products in the presence of limiting tRNALeu(UUA) (molar ratio  
0.3 TC(Leu) per ribosome). tRNAs used for translation were Gln, Ala, Asn, Phe, Leu, Gly and Arg 
(TC(QANFLGR)). Resulting peptides are MQAN (grey), MQANF (purple), MQANFL (blue 
outline), MQANFLG (green), and MQANFFR/MQANFLR (red outline).  
(H) Same as (G), but with higher excess of tRNALeu(UUA) (equimolar to ribosome).  
(I) Top panel: Translated sequence of HIV-1 model mRNA. Aa incorporated into 0- and –1-frames 
are indicated. Bottom panel: –1PRF efficiency with the wt mRNA and U4C derivative with disrupted 
SS1 measured at limiting amounts of Leu-tRNALeu(UUA) (molar ratio 0.3 TC(Leu) to 70S ribosome).  
Translation of HIV-1 mRNAs results in the stepwise incorporation of consecutive aa up 
to fMet-Gln-Ala-Asn-Phe-Leu-Gly (MQANFLG) upon 0-frame translation and up to fMet-
Gln-Ala-Asn-Phe-Leu-Arg (MQANFLR) or fMet-Gln-Ala-Asn-Phe-Phe-Arg (MQANFFR) 
in the –1-frame (Fig. 14F-I). Translation products were analyzed by RP-HPLC and 
individual peptides were assigned based on different elution positions and confirmed using 
radioactively labeled aa (Fig. 14F-H; Table 24).  





MQAN 6-7 [14C]Gln, [14C]Ala and [3H]Asn 
MQANF  11-12 [14C]Phe/f[3H]Met ratio to distinguish between 
peptides MQANFF 16-17 
MQANFL 15-16 [14C]Leu 
MQANFFR, MQANFLR 15-16 [14C]Arg 
MQANFLG 15-16 [3H]Gly 
 
Upon establishing optimal translation and peptide analysis conditions, we determined 
frameshifting efficiency on HIV wt and U4C mRNAs at limiting amounts of  
Leu-tRNALeu(UUA) (molar ratio 0.3 tRNA to 70S) (Fig. 14I). The overall frameshifting 
efficiency was determined as a ratio of –1-frame Arg incorporation relative to the sum of  
–1- and 0-frame peptides. Here the 0-frame was defined as the sum of MQANF and 
MQANFLG peptides while –1-frame corresponded to MQANFFR/FLR peptides. With the 
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wt mRNA containing a native slippery sequence, a large fraction of peptides contains Arg, 
indicating efficient –1PRF of about 40% (Fig. 14I). As expected, the SS1 mutation in U4C 
mRNA prevents efficient slippage and thereby decreases the frameshifting efficiency to less 
than 10% (Jacks et al., 1988b). 
3.1.2 Two regimes for –1PRF on the gag-pol slippery site 
Our next goal was to identify the mechanism of –1PRF on SS1. As described above,  
–1PRF can occur at the decoding step of the translation elongation cycle, when only a 
peptidyl-tRNA is bound in the P site of the ribosome while the A site is vacant (Caliskan et 
al., 2017; Yelverton et al., 1994); or during translocation, when two tRNAs together with 
the mRNA move through the ribosome (Caliskan et al., 2014; Chen et al., 2014; Kim et al., 
2014; Yan et al., 2015). If slippage occurred during decoding, the –1 frameshifting efficiency 
must depend on the competition between the 0-frame and –1-frame aa-tRNAs, Leu-tRNA 
and Phe-tRNA, for binding at the UUUA sequence in SS1. In fact, increasing the Leu-
tRNALeu(UUA) concentration lowers the –1PRF efficiency dramatically from about 50% in 
the absence to about 12% observed in the presence of saturating amounts of Leu-
tRNALeu(UUA) (Fig. 15A). In contrast, titration with a mixture of Leu-tRNA isoacceptors that 
collectively read the CUN family of Leu codons but not the UUA codon has no effect. The 
high –1PRF efficiency observed in the absence of Leu-tRNALeu(UUA) indicates that ribosomes 
can slip into the –1-frame prior to, and independent of Leu incorporation. In human cells the 
Leu codon UUA is rare (8% of Leu codons), but it is abundant in the late HIV genes 
including gag and pol. In addition, UUA is decoded by Leu-tRNALeu(UUA), which is 
underrepresented in eukaryotic cells as compared to other tRNALeu isoacceptors (Chapter 







Figure 15. Characterization of frameshifting regimes on the gag-pol SS1. 
(A) Concentration dependence of –1PRF efficiency on Leu-tRNALeu(UUA) (Leu-UUA, closed circles) 
or a mixture of tRNALeu isoacceptors reading CUN codons (Leu-CUN, open circles) monitored at 
the end of translation (2 min).  
(B) Change in the frameshifting regime with the Leu-tRNALeu(UUA) concentration. The ratio of FFR 
route (open circles) vs. FLR (closed circles) route was calculated from peptides with different 
radioactive labels (described in the text). 
(C) –1PRF efficiency in the presence of varying concentrations of Gly-tRNAGly in the presence of 
excess Arg-tRNAArg (2 µM) (green squares) or with varying concentrations of Arg-tRNAArg in the 
presence of 3 µM or 6 µM Gly-tRNAGly (red and light red squares, respectively).  
Next, we thought to determine how the –1PRF pathway changes with the Leu-
tRNALeu(UUA) concentration (Fig. 15B). To do so, we estimated the ratio of Leu, Phe and Arg 
incorporation into the –1-frame product using different radioactive labels as follows. The 
sum of FFR and FLR frameshifting products was calculated using [14C]Arg. To determine 
the amount of FLR, the wt mRNA was translated to the 0-frame peptide fMet-Gln-Ala-Asn-
Phe-Leu-Gly-Lys-Ile (MQANFLGKI). The presence of Ile allows efficient separation 
between 0-frame MQANFLGKI and –1-frame MQANFLR peptides. The FFR peptide was 
then determined by subtracting the FLR from the total Arg-containing product. In the 
absence of Leu-tRNALeu(UUA) only the FFR product is formed (Fig. 15B). Upon addition of 
Leu-tRNALeu, the amount of the FFR product decreases, whereas the FLR product becomes 
prevalent. Thus, frameshifting at the gag-pol SS can switch between two regimes and their 
prevalence depends on the concentration of the critical tRNA. As described, the ratio 
between the FLR and the FFR route measured in vivo is about 70% to 30%. Interestingly, in 
our experiments we observed this ratio at equimolar concentration of Leu-tRNALeu(UUA)  
(1 tRNA to 70S ribosome) suggesting that Leu-tRNALeu(UUA) limitation could be of crucial 
importance for frameshifting in HIV. 
69 
 
After Leu incorporation, –1 frameshifting could follow different routes: it could take 
place either during tRNALeu translocation or upon decoding of the following Gly codon. 
Again, if frameshifting took place during decoding, the 0-frame Gly-tRNAGly and –1-frame 
Arg-tRNAArg should compete for binding to the ribosome. This is, however, not observed, 
as the –1PRF efficiency is independent of Gly-tRNAGly and Arg-tRNAArg concentrations 
(Fig. 15C). This finding suggests that slippage and commitment to the new reading frame 
occur after Leu incorporation, but prior to decoding of the next codon by Gly- or Arg-tRNA. 
This is similar to the well-studied cases of –1PRF on IBV 1a/1b and dnaX mRNAs, where 
slippage occurs at a late stage of translocation of the slippery-site tRNAs, and suggests a 
similar two-tRNA frameshifting mechanism (Caliskan et al., 2014; Caliskan et al., 2017; 
Chen et al., 2013; Chen et al., 2014; Kim et al., 2014; Yan et al., 2015). 
3.1.3 –2 and +1 slippages on SS1 
Because formation of the –1-frame FFR product depends on the slippage at the “hungry” 
UUA codon, we further tested whether this also allows –2 and +1PRF. We note that normally 
such slippage events would lead to premature termination due to stop codons appearing in 
the –2 or +1 frames downstream of the frameshifting site and that such peptides are difficult 
to detect in vivo, but alternative slippage events could change the ratio between the Gag and 
Gag-Pol polyproteins. To distinguish between the products of the 0-, –1-, –2- and +1-frames, 
we designed a –2 / +1 mRNA, in which the GGG (Gly) codon following the SS1 was 
changed into a UGG (Trp) codon (Fig. 16). This mutation does not affect the –1PRF 
efficiency in vivo in human cells (Mathew et al., 2015). In addition to the aa-tRNAs needed 
for translation of the MQANFL sequence, we added purified Trp-tRNATrp (W), elongator 
Met-tRNAMet (M) and Tyr-tRNATyr (Y). The expected 0-frame peptide is now MQANFLW 
and the –1-frame peptides are MQANFFM and MQANFLM. Shifting into the +1-frame 
should yield MQANFY and into the –2-frame MQANFFY and MQANFLY. Translation 
products were identified based on their elution times on RP-HPLC and differential 
radioactive labels (Fig. 16B). The presence of a highly hydrophobic Trp residue allowed 
efficient separation of the 0-frame MQANFLW peptide eluting at 25 min from –1- and  
–2-products eluting at about 18 min. To distinguish co-eluting peaks, radioactive-labeled 




Figure 16. tRNA limitation results in –1, +1 and –2PRF. 
(A) Top panel shows the model mRNA and peptides synthesized in all frames. tRNAs for QANF 
were added to all translation reactions; in addition, Met (M), Leu (L), Trp (W) and Tyr (Y) were 
added in the “all present” sample; –M, –L, W and –M ,L ,W indicate the aa-tRNAs that were omitted 
from the respective translation reaction. Positions of peptide peaks in the HPLC analysis were 
determined using [14C]-labeled Tyr, Met, Leu or Trp. Two-tailed two-sample equal variance t-test 
was performed between marked samples; blue lines for +1 peptides and red lines for –2 peptides. 
n.s., not significant, * indicates p ≤ 0.05, *** is p ≤ 0.001. 
(B) HPLC separation of products formed upon translation of –2 / +1 mRNA. Translation was 
performed at 1-fold tRNALeu(UUA) over the 70S. Resulting peptides are MQAN (grey), MQANF 
(purple), MQANFY (dark green outline), MQANFL (blue), MQANFLM (red outline), MQANFLY 
(light green outline) and MQANFLW (magenta).  
When all required aa-tRNAs are present, the –1-frame peptides account for about 25% 
of product, consistent with the –1PRF efficiency on the native gag-pol sequence in the 
presence of equimolar amounts of Leu-tRNALeu(UUA) and 70S (Fig. 16 & 15A), whereas the 
amounts of the +1 and –2 peptides are small. When Met-tRNAMet is omitted, –2PRF 
increases more than two-fold, whereas +1PRF is not changed. –2PRF is enhanced because 
–1PRF exposes a “hungry” Met codon in the A site, which favors the slippage. In the absence 
of Leu- and Trp-tRNA, the –1PRF efficiency increases to 45%, as expected; –2PRF is 
unchanged; and again a small amount of the +1-frame product is formed (Fig. 16). Without 
addition of Leu-, Trp-, and Met-tRNAs, the products of all three alternative frames are found. 
These data suggest that –2 and +1PRF can occur when one or more of the aa-tRNAs are 
lacking; however, when all aa-tRNAs are available the –1PRF pathway is prevalent. 
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3.1.4 Kinetics of FFR and FLR –1 frameshifting pathway 
To understand the two different –1 frameshifting regimes, we monitored translation and 
–1PRF efficiency on wt mRNA using the codon-walk approach (Caliskan et al., 2014) in the 
absence and presence of different amounts of Leu-tRNALeu(UUA). The codon-walk method 
allows us to determine the exact place and timing of frameshifting by comparing rates of 
incorporation of individual aa into the growing peptide under the assumption that recoding 
affects the rate of translation. Time courses of aa incorporations are evaluated using 
numerical integration and the rates are derived according to the developed kinetic models. 
To verify and substantiate our kinetic analysis provided below, we estimated the rate 
constants of Arg and Gly incorporation in independent experiments using model mRNAs 
without or with mutated frameshifting elements (Fig. 17A,B). The rate of Arg incorporation 
was checked in the context of MFR and MLR peptides to account for both frameshifting 
regimes. The rate of Gly incorporation was monitored at U4C HIV mRNA at 1-fold excess 
of TC(Leu-UUA) because the translation here mostly results in the 0-frame peptide 
MQANFLG. 
 
Figure 17. Supporting kinetic experiments.  
(A) Time courses of MFR (purple squares) and MLR (blue squares) formation on model fM-F-
R(AGG)-Stop and fM-L-R(AGG)-Stop mRNAs, respectively. Phe-tRNAPhe, Leu-tRNALeu(UUA) and 
Arg-tRNAArg were used at 1.6 µM (10-fold over 70S), 0.16 µM (1-fold over 70S) and 1.6 µM  
(10-fold over 70S) concentrations, respectively. Single-exponential fits are shown as continues lines. 
The rates of MFR and MLR formation are 0.22 ± 0.01 s-1 and 0.27 ± 0.03 s-1, respectively. The upper 
panel shows the sequence of the model mRNA and the respective aa. 
(B) Time courses of MQANFL (blue downward triangles) and MQANFLG (green diamonds) 
formation on U4C mRNA at 1-fold excess of TC(Leu-UUA). Gly-tRNAGly was used at 1.5 µM  
(7.5-fold over 70S). The upper panel shows aa incorporated into 0-frame peptide. 
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(C) Time course of MQANF-tRNAPhe drop-off from ribosomes upon translation of frameshifting wt 
mRNA. The upper panel shows the aa incorporated into –1-frame FFR and 0-frame peptide. 
For the –1PRF model in the absence of Leu-tRNALeu(UUA), we introduced the steps that 
result in the formation of MQANF and the –1-frame products MQANFF and MQANFFR 
(Fig. 18A,B). In addition, we introduced two reaction branches that account for the 
incomplete conversion of the 70S IC into products as follows. Because a fraction of ICs 
(about 20%) does not enter translation, we introduced a step that accounts for this 
unproductive population (M → Mn, non-reactive). We also noticed that MQANF-tRNA
Phe 
in the absence of the A-site ligand tends to slowly dissociate from the ribosome over time 
(Fig. 17C); to account for this loss of peptidyl-tRNA, we introduced the respective drop-off 
reaction. Global fitting of the time courses using numerical integration yielded a unique 
solution for all rate constants (Fig. 18B; Table 25). The step leading to the incorporation of 
the second Phe is slow, ~0.01 s-1, compared to all translation steps, which are at least 10 
times faster. MQANFF peptides do not accumulate and are converted to the –1-frame 
peptide, MQANFFR. Thus, the incorporation of the second Phe residue is the rate-limiting 
step of frameshifting, which commits the ribosome to the –1-frame translation.  
In the presence of Leu-tRNALeu(UUA), the ribosome synthesizes the 0-frame MQANF 
peptide and then either continues translation with Leu incorporation in the 0-frame or shifts 
into the –1-frame before Leu-tRNALeu(UUA) can bind. If Leu is incorporated, the 0-frame 
MQANFL product can partition between the 0-frame MQANFLG and the –1-frame 
MQANFLR. Global fitting of the time courses gives well-defined rate constants for most of 
the steps (Fig. 18C-E). The rate-limiting step for the –1-frame FFR pathway has a rate 
constant of ~ 0.03 s-1, similar to that for the isolated FFR pathway. The efficiency of the FFR 
pathway depends on the ratio of the rates of –1-slippage and Leu-tRNALeu(UUA) binding. 
While the rate of slippage is constant, the rate of Leu-tRNALeu(UUA) binding increases with 
concentration. This explains why the addition of excess Leu-tRNALeu(UUA) inhibits the FFR 
route. At high concentrations of Leu-tRNALeu(UUA), the probability to bind Leu-tRNALeu(UUA) 
to the A site is higher than to slip into the –1-frame. At this condition, the FFR pathway is 
suppressed and only the FLR pathway remains operational. After Leu incorporation, the  
–1PRF efficiency of the FLR route is defined at the translocation step, because the 
partitioning between 0- and –1-frames takes place before decoding by Gly- and Arg-tRNAs 
(Fig. 18E). The ratio of the rate constants of Gly and Arg incorporation (0.53 s-1 and  




Figure 18. Kinetic mechanism of –1PRF.  
(A) Time courses of translation in the absence of tRNALeu(UUA). Peptides are MQAN (grey circles), 
MQANF (purple tringles), MQANFF (orange hexagons), and MQANFFR (red squares). Global fits 
are shown as continuous lines. The top panel shows aa in 0-frame and FFR –1-frame and respective 
codons on the mRNA. 
(B) Kinetic model of the FFR pathway in the absence of tRNALeu(UUA). Rates of all steps are calculated 
by global fitting. 
(C & D) Time courses of translation in the presence of limiting concentrations of tRNALeu(UUA)  
(C, 0.3-fold per ribosome) and near-saturating concentrations of tRNALeu(UUA) (D, 1-fold per 
ribosome). Peptides are MQAN (grey circles), MQANF (purple triangles), MQANFL (blue 
downward triangles), MQANFLG (green diamonds), and MQANFFR/MQANFLR (red squares). 
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Global fits are shown as continuous lines. The top panel shows aa in 0-frame and –1-frame and 
respective codons on the mRNA. 
(E) Kinetic model of the FFR/FFL pathways. Rates of all steps are calculated by global fitting.  
0- and –1-frames are indicated by dotted arrows. *Incorporation of Leu-tRNALeu(UUA) is a bimolecular 
reaction and its rate depends on the concentration of tRNALeu(UUA). The two rates correspond to  
0.3- and 1.0-fold excess of tRNALeu(UUA) over ribosomes, respectively. 





















* The two rate constants correspond to 0.3- and 1.0-fold excess of tRNALeu(UUA) over ribosomes, respectively. 
a The rate constant is from Fig. 17A. 
b The rate constant is from Fig. 17B. 
3.1.5 –1PRF in HIV-1 studied with native human aa-tRNA 
Our finding that Leu-tRNALeu isoacceptor reading the UUA codon affects the 
mechanism and efficiency of –1PRF prompted us to validate the key results with eukaryotic 
translation components. First, we analyzed the relative abundance of human Leu-
tRNALeu(UUA) in total tRNA from different human cell types using qRT-PCR (Fig. 19).  
Step Product Rate constant, s-1 
–Leu-tRNALeu(UUA) 
k1 M → Mn 0.13 ± 0.07 
k2 MQAN 0.34 ± 0.17 
k3 MQANF 0-frame 0.21 ± 0.06 
k4 MQANF drop-off 0.007 ± 0.01 
k5 MQANFF 0.01 ± 0.009 
k6a MQANFFR –1-frame 0.22 ± 0.01 
+Leu-tRNALeu(UUA) 
k1 M drop-off 0.13 ± 0.07 
k2 MQAN 0.34 ± 0.17 
k3 MQANF 0.24 ± 0.10 
k4 MQANF drop-off 0.02 ± 0.01 
k5 MQANFF 0.03 ± 0.01 
k6a MQANFFR –1-frame 0.22 ± 0.01 
k7 MQANFL 0.33 ± 0.06 / 0.9 ± 0.2* 
k8b MQANFLG 0-frame 0.53 ± 0.22 
k9 MQANFLR –1-frame 0.04 ± 0.02 
Arg-tRNAArg incorporation in 0-framea 
 MFR 0.22 ± 0.01 s-1 
 MLR 0.27 ± 0.03 s-1 
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HIV-1 mainly infects CD4+ T-lymphocytes and macrophages (Freed, 2001). We determined 
the ratio of Leu- tRNALeu(UUA) to Leu-tRNALeu(CUG) reading the most abundant Leu codon 
CUG. Leu-tRNALeu(UUA) is 7-17-fold less abundant than Leu-tRNALeu(CUG) in cell lines 
derived from T-lymphocytes, and about 20-fold in HeLa cells, whereas in other types of 
human cells the ratio is about 1:3 (Fig. 19). As a control, we quantified the relative 
abundance of Val-tRNAVal isoacceptors reading a rare GUA codon and an abundant GUG 
codon, respectively. The tRNAVal(GUA) isoacceptor reading the rare codon is about 7-8 times 
less abundant than common tRNAVal(GUG), except for the 293T epithelial cells, where the 
amount of tRNAVal(GUA) is even lower (Fig. 19). Because the relative abundance of 
tRNALeu(UUA) in HeLa cells is similar to that in cells used as a model for the HIV infection, 
we used total human tRNA purified from HeLa cells for the in vitro translation experiments 
described below. 
 
Figure 19. Relative abundance of tRNA isoacceptors in different cell types. Plotted is the ratio of 
tRNALeu(CUG) to tRNALeu(UUA) (red bars) and tRNAVal(GUG) to tRNAVal(GUA) (blue bars), that read 
frequent and rare codons, respectively, in human cell lines. Error bars represent s.e.m of three 
biological replicates with three technical replicates each. Experimental design of qRT-PCR was 
according to (Wan Makhtar et al., 2017). Human cell lines are indicated below the graph. Sup-T1, 
Jurkat and PM1 are derived from human T-lymphocytes; 174xCEM is B-T-lymphocyte fusion; HeLa 
are derived from cervical epithelial carcinoma; 293T is a kidney epithelial cell line. 
To check if HeLa aa-tRNA is active in translation with bacterial translation machinery, 
we first tested the TC formation between bacterial elongation factor EF-Tu and the tRNA in 
the presence of GTP. To find the optimal translation conditions, we titrated EF-Tu over the 
tRNA in a wide range of concentrations (0-300 µM EF-Tu over 1.4 µM aa-tRNA). We then 
employed electrophoretic mobility shift assay using native gel-electrophoresis to distinguish 
between EF-Tu-bound and free aa-tRNA and to quantify TC formation. About 60% of 
human aa-tRNA is found in the TC with EF-Tu at 1:7 molar ratio of the two (Fig. 20A); 
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these conditions were used in subsequent experiments. This observation suggests that human 
aa-tRNA could be efficiently used in the heterologous E. coli in vitro translation system. 
 
Figure 20. Characterization of the heterologous in vitro translation system.  
(A) Top panel. Formation of TC between E. coli EF-Tu and human native aa-tRNA (1.4 µM) 
monitored at varying concentrations of EF-Tu by electrophoretic mobility shift assay. The amount 
of the formed TC was calculated as a ratio between the EF-Tu-bound (TC) and free aa-tRNA 
multiplied by 100%. 
(B) Translation of γB-crystallin (γBC) in a heterologous system with human aa-tRNA using mRNAs 
with harmonized (E. coli) and native (B. taurus) codon usage. The full-length γB-crystallin is marked 
with an arrow.  
(C) Time courses of synthesis of full-length γB-crystallin on the native mRNA from B. taurus (grey 
circles) and 0-frame peptide on long wt HIV-1 mRNA (red squares). The fraction of 0-frame was 
calculated as a ratio between 0-frame product and all products of translation.  
The conformity of the human aa-tRNA to the codon usage of mammalian mRNA was 
validated by translation of an mRNA coding for bovine Bos taurus (B. taurus) B-crystallin. 
The codon usage of B-crystallin matches the tRNA abundance of its eukaryotic host, but 
not of E. coli. With native human aa-tRNA, B-crystallin mRNA is translated efficiently 
(Fig. 20B). Introducing synonymous mutations in the mRNA to match the codon usage in 
E. coli, which is different from that in the mammalian host (Buhr et al., 2016), reduces the 
yield of the full-length product (Fig. 20B). Thus, E. coli heterologous system with human 
native tRNA is suitable for efficient translation of mammalian mRNAs in vitro. 
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Next, we used this system to study –1PRF on long wt HIV mRNA, which was optimized 
for peptide separation and their visualization with Tris-Tricine PAGE. The long wt mRNA 
encompasses the region from the nearest native (elongator) AUG codon of the gag mRNA 
upstream of the SS1, the SS1 with its downstream SL1 and the second putative frameshifting 
site, pSS2, with a 32-nt downstream sequence, which is predicted to form a SL (pSL2)  
(Fig. 21A). To distinguish between 0- and –1-frame translation products, we introduced a 
stop codon UAG in the 0-frame to obtain a peptide 52 aa in length; –1PRF results in a  
120-aa peptide product (Fig. 21B). To identify potential –2-PRF products, we mutated all 
native stop codons in the –2-frame downstream of the pSS2 in the original wt mRNA 
(mRNA denoted as no-stop). Translation of no-stop mRNA leaves the product lengths in the 
0- and –1-frames unchanged, but additionally yields a 120-aa –2-frame product. Despite 
their identical length, the –1-frame and –2-frame products have different electrophoretic 







Figure 21. Translation and frameshifting with native human aa-tRNAs.  
(A) The mRNA used for translation experiments. SS1 and pSS2 are highlighted light green, SL1 and 
the potential SL element downstream of the pSS2 (pSL2) are shown. Sizes of 0-, –1- and –2-frame 
peptides formed upon translation of the mRNA are indicated. 
(B) Time course of 0-frame and –1-frame translation on long wt mRNA with native human tRNA. 
Times of translation and frame markers are shown above the gel. Frames are indicated with arrows. 
(C) Time courses of 0, –1, and –2-frame peptides synthesized on no-stop mRNA with native human 
tRNA.  
The rate of translation of long wt HIV mRNA is similar to that of B-crystallin mRNA 
and constitutes about 0.5-0.7 aa/s (Fig. 20C), however, translation of HIV mRNA proceeds 
via multiple intermediates (Fig. 21B,C). Their identity was identified by comparing marker 
peptides of defined length with the peptides formed during translation (Fig. 22A,B). 
Interestingly, many peptide products corresponding to stalling sites could be most likely 
attributed to the rare codons in the Gag-Pol sequence (Table 26). We note that the codon 
usage of HIV late-expressing genes including gag and pol is grossly different from that of 
its human host, which could explain observed translation pauses (Berkhout et al., 2002; Li 
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et al., 2012; van Weringh et al., 2011). In addition, codons identified at stalling positions are 
A- and U-ending, which are overrepresented in the HIV genome, but underrepresented in 
highly expressed human genes.  
 
Figure 22. Characterization of translation intermediates on HIV long wt mRNA. 
(A) The mRNA constructs used to synthesize the marker peptides shown on the HIV wt mRNA. SL1 
and pSL2 are highlighted in light and dark grey, respectively. End positions of shortened mRNAs 
used to generate marker peptides are marked with lines. Numbers in red indicate the length of 
peptides (in aa) starting from the start codon AUG. 
(B) Translation intermediates formed during translation of long wt mRNA translation with native 
human tRNA. Marker peptide lengths (in aa) and translation times (15 s – 30 min) of the wt mRNA 






Table 26. Correspondence between stalling sites and low-abundant codons 
Amino acid position 
(from AUG) 
Frame Codon Amino acid Fraction per codon per 
amino acid 
12 0 and –1 UUA Leu 0.08 
19 –1 CUA Leu 0.07 
27 0 CUU Leu 0.13 
41 –1 CUU Leu 0.13 
45 0 GUA Val 0.12 
45 –1 GGU Gly 0.16 
 
The –1PRF efficiency in the heterologous translation system was determined to be 6-
7% (Fig. 23A), consistent with earlier in vivo reports (Cassan et al., 1994; Grentzmann et 
al., 1998b; Mathew et al., 2015; Plant and Dinman, 2006). Formation of 0-frame and  
–1-frame products starts after a 30-s delay which may be caused by an early translational 
pausing event (appearing as a prominent peptide band between 7 s to 30 s of translation  
(Fig. 21B & 23A). In contrast, the –2-frame product appears after a much longer delay of 
120 s (Fig. 21C & 23A). At this time, the synthesis of the 0-frame product is already 
completed on most ribosomes, suggesting that the –2PRF may arise on a fraction of 
ribosomes that undergo long translation pausing. Addition of exogenous (bacterial) Leu-
tRNALeu(UUA) decreases the –1PRF efficiency to 4% (Fig. 23B). A similarly reduced 
frameshifting efficiency is observed when the UUA codon is mutated to UUC, which does 
not interrupt the slippery run of six Us, but changes the identity of the tRNA reading the 
second slippery codon to the abundant tRNAPhe (Fig. 23C). Thus, reassigning the second 
codon of the SS1 to an abundant tRNA has the same effect as adding excess of tRNALeu(UUA) 
to the native sequence. Shortening the SS1 to four U residues decreased PRF to 2%, which 
is consistent with earlier reports. Disrupting SS1 preventing any slippages diminishes the 




Figure 23. Frameshifting efficiency and its modulation on SS1 of gag-pol overlap measured in  
E. coli heterologous translation system with native human tRNA. 
(A) Time courses of –1PRF on wt mRNA (closed circles) as well as –1PRF (open circles) and –2PRF 
(closed triangles) on mRNA where all stop codons in –2-frame were mutated to sense codons  
(no-stop).  
(B) Concentration dependence of –1PRF efficiency on exogenous tRNALeu(UUA) from E. coli 
measured on wt mRNA. Bottom panel: Titration of E. coli TC(Leu-UUA) on wt mRNA. Excesses 
of TC(Leu-UUA) are shown above the gel. 
(C) Effect of mutations in SS1 on –1PRF. The background of the measurements is ±1%. The s.e.m 
was calculated from 3-5 independent experiments. 
3.1.6 The putative second slippery sequence 
To test the effect of pSS2 that arises in virus isolates resistant to anti-HIV treatment, we 
introduced mutations that should make pSS2 more or less slippery (Fig. 24A-C). As long as 
the SS1 sequence is unchanged, mutations in pSS2 have little effect on overall –1PRF, but 
change the –2PRF efficiency, which, in turn, leads to slight variations in –1 frameshifting. 
The –2PRF efficiency is higher when both SS1 and pSS2 are slippery, suggesting that  
–2PRF results from dual –1-slippages on both sites rather than from –2-slippage on pSS2 
alone. Replacing the rare CUU codon in pSS2 with the abundant CUG reduces –2PRF 
indicating that the second slippage is due to “hungry” frameshifting on pSS2. When the  
U-string in SS1 is disrupted, the frameshifting efficiency is higher in the construct where 
pSS2 is slippery compared to the native sequence. The presumed secondary structure of the 
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mRNA downstream of pSS2 (Fig. 24A) has no effect. Disruption of both SS decreases 
frameshifting to background levels. Thus, pSS2 supports a low-level frameshifting event 
that can rescue HIV-1 when SS1 is mutated, but also causes –2PRF, which in the native 
sequence leads to premature termination of translation. 
 
Figure 24. Interplay between SS1 and pSS2.  
(A) Scheme of the wt mRNA used for translation experiments with indicated SS1, pSS2, SL1 and 
pSL2 frameshifting elements. Small letters on the sides of pSL2 correspond to mutations introduced 
to disturb its structure. The pSL2 structure was predicted by mFold software. 
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(B) Examples of translation reactions with HIV-1 mRNA variants containing mutations in SS1, pSS2 
and pSL2. Sequences of SS1 and pSS2 variants are indicated above and below the gel, respectively. 
Mutated nts are in small bold letters. –pSL2 indicates mutated pSL2. * represent mRNAs with 
removed stop codons in –2-frame. 
(C) Modulation of –1 and –2 frameshifting efficiency by interplay between SS1 and SS2. SS1 
sequences are shown above the bars, pSS2 sequences are indicated below the graph. –1PRF is 
determined with wt mRNA (black bars) or with no-stop mRNA (grey bars); –2PRF is measured with 
no-stop mRNA (white bars); the absence of pSL2 is indicated by textured pattern. Two-tailed two-
sample equal variance t-test was performed between marked samples. n.s. means not significant, ** 
indicates p ≤ 0.01, *** is ≤ 0.001. 
3.1.7 Frameshifting efficiency in HIV-1 measured with human 80S ribosomes 
To further verify our results obtained with eukaryotic/bacterial heterologous translation 
system, we studied –1PRF in HIV-1 using mammalian in vitro reconstituted homologous 
system. As compared to cellular lysates (e.g., rabbit reticulocyte lysate), this system has the 
advantage of providing a fully controlled environment due to the high purity of individual 
components and translation speed similar to in vivo rates. In eukaryotic mRNAs a start codon 
AUG was introduced 8 nt prior to the SS1 and the codon following AUG was mutated from 
CAG (Ala) to GUA (Val) to maintain a Kozak sequence required for efficient translation 
initiation. wt mRNA contained native SS1, SL1, pSS2 and pSL2 elements. Ribosomal 
subunits (40S and 60S), initiation factors (eIF1A, eIF1, eIF2, eIF3, eIF4A, eIF4B, eIF5, and 
eIF5B) and Met-tRNAi were used to form the 80S ICs with HIV mRNAs of interest. 
Translation was performed with total human tRNA aminoacylated with Val, Ala, Asn, Phe, 
Gly and Arg aa in the presence or absence of Leu, providing natural distribution of all tRNA 
isoacceptors. Translation of wt mRNA results in 0-frame peptide Met-Val-Ala-Asn-Phe-
Leu-Gly (MVANFLG) and –1-frame peptides Met-Val-Ala-Asn-Phe-Phe-Arg 
(MVANFFR) and Met-Val-Ala-Asn-Phe-Leu-Arg (MVANFLR). To determine the 
translation efficiency and identify the elution positions of the synthesized peptides from  
RP-HPLC, 0-frame and –1-frame control mRNAs were made. The –1-frame control 
contained a frameshifted nucleotide sequence cloned in-frame and slippery sites were 
mutated in both mRNAs to prevent slippages. 
Translation of the –1-frame control mRNA yields a significant amount of frameshifting 
products MVANFLR/FFR, whereas the 0-frame control mRNA shows no Arg incorporation, 
as expected (Fig. 25A). High efficiency of translation and the lack of misincorporation 
products suggest that the experimental set-up could be used to study –1PRF on the HIV-1 
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mRNA. The –1PRF efficiency in this fully reconstituted eukaryotic translation system is 
about 20-25% in the presence of native amounts of tRNALeu(UUA) (Fig. 25A,B). 
 
Figure 25. Translation of the eukaryotic gag-pol wt mRNA using a fully reconstituted homologous 
mammalian in vitro translation system.  
(A) Top panel: Sequence of gag-pol mRNA optimized for translation by eukaryotic translational 
machinery. Peptides produced in 0- and –1-frames are indicated above the sequence. Left panel: 
HPLC profile of –1 frameshifting peptides synthesized with wt (red circles), –1-frame control (black 
circles) and 0-frame control (open circles) mRNAs. Peptides were monitored using [3H]Arg. Right 
panel: –1PRF efficiency measured with wt, –1-frame and 0-frame control mRNAs. Color code is as 
in the left panel. –1PRF efficiency was calculated using [3H]Arg on the frameshifting peptide 
MVANFLR or FFR and [14C]Leu indicative of general translation efficiency. The experiment was 
performed by Dr. Akanksha Goyal. 
(B) –1PRF efficiency measured with HIV-1 gag-pol mRNA in the presence (+ tRNALeu) and in the 
absence (– tRNALeu) of total Leu-tRNALeu containing all isoacceptors in native ratios. The –1-frame 
peptide was identified based on [3H]Arg incorporation. 
As discussed above (see 3.1.2), Leu-tRNALeu(UUA) limitation leads to a significant 
increase in –1PRF efficiency in the bacterial system. To validate this finding using 
mammalian components, we prepared human aa-tRNA excluding Leu from the 
aminoacylation mix. When leucine was omitted from the aminoacylation mixture, the –1PRF 
efficiency increased from about 20% to more than 40% (Fig. 25B). Because we translate 
only the first 7 aa, Leu depletion does not interfere with the translation efficiency. This data 
suggest that the abundance of tRNALeu(UUA) acts as the main modulator of the frameshifting 
efficiency in HIV-1 regardless of the experimental system.  
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3.2 Investigation of the role of the mRNA secondary structure and a potential 
enhancer sequence in –1PRF in HIV-1 
3.2.1 Studying potential enhancer sequence in the gag-pol gene of HIV-1 using the 
E. coli in vitro translation system 
As described in the Introduction, the HIV-1 gag-pol frameshifting site contains the SL1 
following the SS1. The structure of SL1 is extensively studied, however, its significance for 
–1PRF in HIV-1 remains unclear (Bidou et al., 1997; Brunelle et al., 1999; Cassan et al., 
1994; Dulude et al., 2002; Garcia-Miranda et al., 2016; Kang, 1998; Kim et al., 2001). To 
determine the role of the mRNA secondary structure, we employed the E. coli in vitro 
reconstituted translation system and a variety of mRNA constructs with mutations or 
deletions in the SL1 region. Unless stated otherwise, we used a 1:1 molar ratio between 
tRNALeu(UUA) and 70S because at this ratio the partitioning between the FLR and the FFR 
routes is similar to that obtained in vivo (see 3.1).  
Removal of nts forming the lower stem (mRNA 38, the number indicates the nt length 
of the mRNA sequence after SS1) or both upper and lower stems (mRNA 23) has no 
significant effect on the –1PRF efficiency in HIV-1 in our system (Fig. 26A). This is 
consistent with the previous reports suggesting that the lower stem indeed plays only a 
marginal role in stimulating frameshifting (Dulude et al., 2002; Garcia-Miranda et al., 2016; 
Gaudin et al., 2005; Marcheschi et al., 2011; Mazauric et al., 2009). However, truncating the 
mRNA further down to 8 nt did not alter frameshifting efficiency either, suggesting that also 
the upper stem is not needed. On the other hand, truncating the sequence downstream of the 
SS1 to 5 nt decreases frameshifting efficiency significantly from 30% (wt) to about 10% 
(Fig. 26A), suggesting that the SS1 alone is not sufficient for frameshifting. Rather, the 
residues 5-8 nt after the SS1 appear to act as an enhancer akine to the enhancer playing a 
role in +1PRF. To identify the exact nts critical for frameshifting in HIV-1, we mutated 
positions 4 to 12 after the SS1 without changing the length of the wt mRNA (short for 
HPLC). Replacement of positions 1-3 from GGG to any other nts except for GGU are known 
to decrease the frameshifting efficiency in vivo in human cells (Mathew et al., 2015) and 
were not tested in our experiments. In addition, keeping the GGG codon unchanged allowed 
us to rely on the same radioactive labels to distinguish 0-frame and –1-frame peptides 
regardless of the downstream sequence. First, we sequentially mutated single nts at the 
positions 4 to 12 after the SS1 (Fig. 26B). Substitutions of nt 4 to 7 have the biggest effect 
on –1PRF decreasing its efficiency to 15-20%, especially when mutated to the 
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complementary nt (Fig. 26B). On the contrary, replacements of nt 8 to 12 either have no 
effect or even slightly increase the frameshifting efficiency, potentially by stabilizing base 
pairing in parts of the SL1 (Fig. 26B). To study synergetic effect of nt following the SS1 on 
–1PRF efficiency, we created mRNA variants in which nts 4-8 or 4-12 were simultaneously 
mutated (see Fig. 26C, mRNA sequence, mutated nt are indicated as lower-case letters). In 
cucuaCUGG mRNA, nts 4-8 (AAGAU) were mutated to cucua while 9-12 nt (CUGG) 
remained unchanged (Fig. 26C). –1PRF efficiency with this mRNA is about 17% as 
compared to wt, in agreement with the effects of single mutations at these positions (compare 
Fig. 26B & C). Although nt 8-12 alone did not seem to contribute to –1PRF efficiency, we 
tested the cumulative effect of positions 4-12. We designed cucuagUaa and ccucaaUaa 
mRNAs, in which 4-9 (cucuag or ccucaa, respectively) and 11-12 (aa) nt were mutated in 
different manner; U10 was left unchanged (Fig. 26C). Regardless of exact mutations, 
changes of nt in positions 4-12 lower frameshifting to less than 10% suggesting cooperative 
effect of positions 4-7 and 9-12. Finally, truncating SL1 to 23 nt combined with 4-12 nt 
mutations does not change –1PRF efficiency as compared to mutations alone, and it remains 
at about 10% (ccucaaUaa 23 nt mRNA). All of the presented data suggest that –1PRF in 
HIV-1 could be indeed stimulated by an enhancer sequence spanning the first 4-12 nt 
following the SS1 and probably encompassing the GGG intercodon. However, any 
introduced mutations changing the secondary structure may result in SL1 remodelling, 
which also could affect the frameshift efficiency. To exclude this possibility, we swapped 
the nt sequence corresponding to the potential enhancer with its complementary sequence 
(see Fig. 26A, inverted lower stem mRNA), which allowed us to change the nt identity after 
the SS1 without disturbing the SL1. Frameshifting efficiency on the inverted lower stem 
mRNA is comparable to that on mRNAs with mutated enhancer (about 15%) confirming the 






Figure 26. Effect of variations in the potential enhancer sequence following the SS1 in the gag-pol 
frameshifting site of HIV-1. 
(A) Left panel: gag-pol frameshifting motif. SS1 is highlighted in light green, SL1 is in grey. 
Positions of mRNA truncations are marked with lines. Red numbers on the sides correspond to nt 
positions starting from the G following the SS1. Right panel: –1PRF efficiency measured with wt 
(black) and mRNAs truncated at 38 (magenta), 23 (blue), 20 (green), 17 (orange), 14 (grey),  
11 (purple), 8 (yellow) and 5 (red) nts after the SS1. 
(B) Upper panel: sequence of HIV-1 wt mRNA from start codon AUG to the end of potential 
enhancer (12 nt after the SS1). Aa incorporated into 0- and –1-frames are shown above the sequence. 
Red numbers correspond to nts positions starting from the G following the SS1. Lower panel: –1PRF 
efficiency determined on mRNAs with single-nucleotide substitutions in positions 4-12 after the SS1. 
Positions and identity of nts in wt mRNA are shown below. Substituted nts are color-coded: C is in 
blue, G is in green, U is in magenta and A is in grey. Wt mRNA is depicted in black. 
(C) Effect of the potential enhancer sequence on FLR and FFR routes of –1PRF in HIV-1. Upper 
panel: same as in (B), but with indicated nt substitutions in cucuagUaa (green) and ccucaaUaa 
(orange) mRNAs. Lower panel: frameshifting efficiency on wt (black), mRNA truncated at position 
36 nt (magenta), 23 nt (blue), cucuaCUGG (light green), cucuagUaa (green), ccucaaUaa (orange), 
ccucaaUaa 23 nt (yellow) and inverted lower stem (grey) mRNAs determined at at 0-fold (diagonal 
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pattern), 1-fold (respective colours) and 4-fold (horizontal pattern) excesses of tRNALeu(UUA). Small 
letters in mRNA names refer to mutated nts following GGG codon after SS1 (either 4-8 or 4-12 nt); 
capital letters refer to unchanged nts, e.g., cucuaCUGG means that 4-8 nt were mutated to cucaa 
while 9-12 nt CUGG remained as in wt sequence. 
All the experiments described above were carried out at equimolar concentrations of 
tRNALeu(UUA) and 70S allowing for both routes of frameshifting to take place. We then 
explored which frameshifting regime is stimulated by the enhancer. To do so, we translated 
wt and cucuagUaa (mutated 4-12 nt) mRNAs in the absence of tRNALeu(UUA) allowing only 
the FFR route to take place. Interestingly, the –1PRF efficiency on both mRNAs is about 
40-45% suggesting that the FFR route is independent of the enhancer (Fig. 26C). To supress 
the FFR and to maximize the FLR route, we increased the excess of tRNALeu(UUA) to 4-fold. 
The increase of tRNALeu(UUA) abundance significantly lowers the frameshifting efficiency, 
as shown with wt mRNA (30% at 1-fold vs 10% at 4-fold Leu-tRNALeu(UUA) excess;  
Fig. 15A & 26C). –1PRF measured on mRNAs with either mutated or inverted lower stem 
is <5% (Fig. 26C). This notion suggests that the enhancer affects primarily the FLR route. 
This is in agreement with the published data that show that translocation-dependent 
frameshifting is modulated by downstream regulatory mRNA sequences, typically a SL or a 
pseudoknot (Caliskan et al., 2014; Chen et al., 2014). Intriguingly, increase in the 
tRNALeu(UUA) concentration has no effect on frameshifting with truncated mRNAs (38 nt and 
23 nt) (Fig. 26C), which could either suggest that the FFR route is still operational or 
represent an artefact resulting from the different behaviour of the shortened mRNAs in the 
ribosomal mRNA tunnel or the peptidyl-tRNA drop-off at different steps of translation. 
Hence, 1-12 nt after the SS1 constitute the potential enhancer sequences in HIV-1, which 
modulates the efficiency of the FLR frameshifting route. In the future, the role of this 
potential enhancer sequence for –1PRF in HIV-1 will be further investigated using in vitro 
reconstituted mammalian translation system and human cell culture with dual-luciferase 





3.3 Characterization of frameshifting motif and frameshifting efficiency in 6K 
mRNA of Semliki Forest virus 
3.3.1 Determination of mRNA secondary structure in SFV 
HIV-1 and phylogenetically distant alphaviruses including SFV and MIDV share the 
same SS sequence of U1 UUU4 UUA7, but have different downstream stimulatory secondary 
structure elements in the mRNA. The secondary structures of HIV-1 and MIDV were 
experimentally determined and shown to be a bulged SL and a pseudoknot, respectively. On 
the contrary, the secondary structure predictions suggested that the downstream element in 
SFV is an extended SL, but this finding was not tested experimentally (Chung et al., 2010). 
Our goal was to solve the mRNA secondary structure in the SFV frameshifting mRNA using 
chemical probing (Moore, 1975; Peattie and Gilbert, 1980; Stern et al., 1988; Weeks, 2010). 
This approach allows us to determine which regions of the mRNA are single- or double-
stranded based on the nucleotide accessibility for chemical modifications. For chemical 
probing, we designed two model SFV mRNAs: wt and test. Both mRNAs contain a native 
SFV frameshifting site bearing the SS and the predicted SL, but the test mRNA was 
optimized for translation with E. coli ribosomes by introducing a SD sequence 8 nt upstream 
of the start codon AUG and an AUG 8 nt upstream of the SS. In addition, in the test mRNA 
we mutated the internal methionine AUG codon (59-61 nt downstream of the SS) into AUC 
to prevent translation initiation at this position. Chemical probing was performed with both 
free mRNAs and with the test mRNA in an IC. We used DMS, CMCT and KE to probe the 
mRNA secondary structure. These reagents add chemical adducts to various nts if they are 
located in the single-stranded RNA region and are thus accessible for modifications. RNA 
double-stranded regions are protected from chemical modifications due to base pairing to 
the complementary strand. DMS modifies nts via methylation of N1 adenosine and N3 of 
cytosine, CMCT reacts primarily with N3 of uridine and to a lesser extent with N1 of guanine 
and KE alters the N1 of guanine (Ziehler and Engelke, 2001). Upon RNA modification, RT 
reaction is performed with the fluorescence labeled primer binding to the 3’ end of the SFV 
mRNA sequence and synthesizing its cDNA copy. The presence of the modified base 
hinders the progression of the RT resulting in the production of shortened DNA fragments, 
which could be then visualized on the sequencing PAGE.  
To determine the structure of the SFV mRNA, our probing data was compared with the 
structure predicted by the bioinformatics analysis (Chung et al., 2010). Nucleotides between 
the SS and position 65 in the potential SL are well-resolved (Fig. 27A-C). One way to resolve 
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the downstream sequence would be to anneal a synthetic DNA oligo to the 3’ end of the 
mRNA, which would harbor a primer-binding site instead (Fig. 27A,C). Unlike RNA 
extensions, this DNA fragment should not interfere with the original mRNA secondary 
structure. As predicted by bioinformatics analysis (Chung et al., 2010), SFV SL contains a 
long lower stem encompassing nt 16-26 after the SS, as seen from the lack of chemical 
modifications of this region (Fig. 27B,C). Interestingly, C27 is not modified suggesting that 
it also belongs to the upper stem, although the bioinformatical analysis predicted it to be a 
part of the loop separating the lower and the upper stems. Notably, this loop is also seen in 
our analysis, because 28-29 nt are accessible to DMS modification. The upper stem was 
predicted to span nt 30-35, however, we see that adjacent nt 36-39 are also protected from 
modifications and might thus belong to the upper stem, although their base pairing partners 
are unclear (Fig. 27B,C). Both stems are GC-rich. The upper stem is closed by a large bulge 
spanning nt 40-49. Nucleotides 49-52 were predicted to form a small stem, which is not seen 
in our data. According to the bioinformatics analysis, C54 is base paired with G61, whereas 
we show that although C54 is non-modified, G61 is modified. In addition, when G61 is 
mutated to C61 in the test mRNA, the latter nt is protected. This data leaves the questions 
about the existence of the C54-G61 pair and other possible interactions of C54 open. Finally, 
we confirm the presence of the unstructured loop AGUAAU on top of the upper stem  
(Fig. 27B,C). Hence, despite the discussed differences, the determined structure of SFV SL 
largely resembles the one previously predicted by bioinformatic analysis (Chung et al., 
2010). As expected, SS is found in the single-stranded region of the SFV mRNA. 
Modifications introduced to the test mRNA do not change the overall structure of the SL in 
SFV, however, seem to influence base-pairing patterns of several nts, e.g., C14, G24 and 
A53 (Fig. 27B,C). The presence of the 70S (IC) also does not affect the mRNA structure, 







Figure 27. Determination of the mRNA secondary structure in SFV 6K frameshifting site using 
chemical probing.  
(A) Sequence of the SFV test mRNA with introduced SD-sequence (SD) and start codon AUG. SD 
and SS are underlined; mutated nt as compared to wt are in small red letters; numbers indicate nt 
positions starting from the SS. The position of the 70S in the IC is marked with an arrow.  
(B) Example of a sequencing gel showing the positions of RT stops due to chemical modifications 
of the RNA. mRNAs and chemical probing reagents are indicated above the gel; – stands for 
untreated control. C, U, A, G are sequencing lanes prepared with wt mRNA without prior 
modifications, where RT was stopped by addition of ddNTPs. Numbered nts to the left refer to the 
nts in the SFV frameshifting site starting from the slippery sequence.  
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(C) mRNA secondary structure of SFV based on bioinformatics prediction and probing results. 
Slippery site (SS) and stem-loop (SL) elements are indicated and underlined. Modified nts are 
marked with circles: red for the wt mRNA, blue for the test mRNA and green for test mRNA in the 
IC. Sequences in boxes indicate nt forming lower and upper stems of the SL. Primer-binding site for 
RT is marked with an arrow; triangle on the 5’ of the primer indicates its fluorescence label 
Atto647N. 
3.3.2 Characterization of –1 frameshifting on SFV frameshifting motif 
We next determined the –1PRF efficiency on the SFV frameshifting site. We utilised 
our in vitro reconstituted bacterial translation system, as described for HIV-1. SFV model 
mRNAs were optimized for translation with E. coli components by introducing a SD 
sequence and a start codon AUG. In addition, the second codon after AUG, CUU (Leu), was 
mutated to AAG (Lys) to improve translation efficiency with E. coli purified tRNAs  
(Fig. 28A). The short SS/SL mRNA contains both native frameshifting elements, whereas 
short SS/– has a wt SS but no SL (cut 18 nt after the SS). In mRNAs CGAU and GACU nts 
3-6 and 7-10 downstream of the SS, respectively, are mutated to the complementary nts 






Figure 28. Characterisation of the FFS and FLS –1 frameshifting regimes with the SFV mRNA. 
(A) Sequence of short SFV model mRNA. 0-frame and –1-frame peptides as well as CGAU (red) 
and GACU (blue) mutations in the mRNA are indicated.  
(B) Effect of Phe-tRNAPhe on FFS peptide formation in the absence of Leu-tRNALeu(UUA) measured 
on short SS/SL mRNA. Translation was carried out using TC(MSKF). MSKSF peptides are shown 
as purple triangles, MSKSFFS peptides as orange hexagons. 
(C) Concentration dependence of –1PRF in SFV on the TC with Leu-tRNALeu(UUA) monitored at 
SS/SL (closed circles) and SS/– (opened circles). 
(D) Effect of Val-tRNAVal (green circles) and Ser-tRNASer (grey circles) concentration on –1PRF 
efficiency in SFV. Translation was carried out using equimolar concentrations of Leu-tRNALeu(UUA) 
and ribosomes on SS/SL mRNA. 
(E) Influence of nt mutations downstream of the SS on –1PRF efficiency in SFV. Translation was 
performed using 0-fold, 0.3-fold and 1-fold of Leu-tRNALeu(UUA) over the 70S on SS/SL (black), 
CGAU (grey) and GACU (white) mRNAs. 
Translation of SFV mRNAs results in 0-frame peptides fMet-Ser-Lys-Ser-Phe 
(MSKSF), fMet-Ser-Lys-Ser-Phe-Leu (MSKSFL) and fMet-Ser-Lys-Ser-Phe-Leu-Val 
(MSKSFLV) (Fig. 28A). By analogy to HIV-1, –1PRF on the SFV mRNA is expected to 
yield two products: fMet-Ser-Lys-Ser-Phe-Phe-Ser (MSKSFFS) and fMet-Ser-Lys-Ser-Phe-
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Leu-Ser (MSKSFLS) (Fig. 28A). To facilitate the identification of –1-frame products, we 
monitored incorporation of Ala and Thr into MSKSFFSAT/MSKSFLSAT peptides on short 
SS/SL and SS/– mRNA, and Arg into MSKSFFSRS/MSKSFLSRS or 
MSKSFFSAR/MSKSFLSAR peptides on the CGAU and the GACU mRNA constructs, 
respectively. Translation products were separated by RP-HPLC using the same gradient as 
for HIV-1 peptides. 0-frame products were identified based on [14C]Val while –1-peptides 
were distinguished using [14C]Ala and [14C]Thr or [14C]Arg for CGAU and GACU mRNAs. 
The –1 frameshifting efficiency was calculated as a ratio between –1-frame peptides and the 
sum of –1-frame and all 0-frame products, multiplied by 100%. 
Because HIV-1 and SFV share the same SS sequence, we hypothesized that –1PRF in 
SFV also results in two peptides, FFS and FLS, depending on the presence of the Leu-
tRNALeu(UUA) isoacceptor (Fig. 28A). The FFS product is formed efficiently in the absence 
of Leu-tRNALeu(UUA) and its amount depends on the concentration of Phe-tRNAPhe  
(Fig. 28B). When titrating with Leu-tRNALeu(UUA), we observed a dramatic decrease in  
–1PRF efficiency from about 70% in the absence of tRNALeu(UUA) to about 18% in the 
presence of saturating amounts of tRNALeu(UUA) (Fig. 28C). This indicates that – similarly to 
HIV-1 – the FFS route is operational when tRNALeu(UUA) is absent or in limited supply, 
whereas under saturating translation conditions the FLS route becomes prevalent. FFS 
peptides are likely to result from the single P-site MSKSF-tRNAPhe slippage when Leu-
tRNALeu(UUA) is absent in the A site. To better understand the FLS regime, we tested the 
competition between 0-frame Val-tRNAVal and –1-frame Ser-tRNASer for binding at the 
codon following the SS, GUG. Titration of these tRNAs in the presence of equimolar 
amounts of tRNALeu(UUA) (1:1 molar ratio to 70S) does not change the frameshifting 
efficiency appreciably (Fig. 28D). These results suggest that similarly to HIV-1, FLS 
products result from dual slippage of the SS tRNAs Phe and Leu(UUA) in the late stage of 
translocation before the GUG codon is presented in the A site. 
Next, we studied the effect of the SL on both frameshifting regimes in SFV. Removal 
of the SL decreases –1PRF in the absence of tRNALeu(UUA) from about 70% (SS/SL) to about 
50% (Fig. 28C). This finding is surprising because single-tRNA slippage is typically 
independent of downstream stimulators and is triggered by a translational pause. The effect 
of the SL is also seen at low or equimolar amounts of tRNALeu(UUA) (1:1 molar ratio to 70S) 
where –1PRF on SS/– mRNA is about 25% as compared to about 40% on SS/SL mRNA. 
However, when tRNALeu(UUA) is present in large excesses, the –1-frameshifting efficiency 
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on both mRNA constructs, with and without the SL, is the same (about 20%), i.e. the SL 
does not seem to play a role in –1-frameshifting. 
As discussed in the Introduction, mutations in the first 18-20 nt downstream of the SS 
in SFV were shown to be detrimental for the frameshifting efficiency in vivo in human cells 
(Chung et al., 2010). These nts might act as either a downstream enhancer or a recognition 
motif for a microRNA or a protein, which stimulate –1 slippage by binding to this region. 
To test the functional significance of this sequence, we measured the –1PRF efficiency on 
the short CGAU and the GACU mRNA at different amounts of tRNALeu(UUA) (Fig. 28A,E). 
Because we use an in vitro reconstituted translation system with highly purified components, 
we could exclude the effect of small interfering RNAs or exogenous proteins. In the absence 
of tRNALeu(UUA) mutating the CGAU sequence 3-6 nt downstream of the SS decreases the  
–1PRF efficiency from about 70% to about 48%, whereas changing the GACU sequence  
7-10 nt nts downstream does not have an appreciable effect (Fig. 28E). When tRNALeu(UUA) 
is present at 0.3 molar ratio to the 70S, no effect on frameshifting is seen while at 1:1 molar 
ratio a 10% decrease in the frameshifting efficiency is observed with both mRNAs. This data 
suggest that mutating nts adjacent to the SS in SFV has a very moderate effect on –1PRF 
efficiency in vitro in the bacterial translation system and might argue for the presence of 
trans-acting factors in vivo in human cells. 
3.3.3 –1PRF in SFV measured with total human tRNA 
By analogy to HIV-1, we verified our key findings on SFV frameshifting in translation 
experiments with human total tRNA prepared from HeLa cell extracts and long SFV mRNAs 
optimized for Tris-Tricine PAGE. We prepared model mRNAs with stop codon UAG 51 nt 
downstream of AUG in 0-frame to distinguish between 0-frame (17 aa) and –1-frame  
(32 aa) peptides. Unlike in short mRNAs described above, the second codon of the SS, CUC, 
remained unchanged (Fig. 29A). To check the translation efficiency and confirm the 
positions of peptides on a gel, we used 0-frame (0 mRNA) and –1-frame (–1 mRNA) control 
mRNAs. In both mRNAs the SS was disrupted to prevent the slippage and in the –1 mRNA 




Figure 29. –1PRF in SFV determined with human total tRNA. 
(A) Outline of the SFV frameshifting motif. Slippery site and stem-loop (SL) are indicated. Small 
nts on the sides of the SL correspond to mutations introduced into SS/– (purple), SS/– mut1 (red), 
SS/– mut2 (red and green combined). 
(B) Examples of translation reactions with SFV mRNAs visualized with Tris-Tricine SDS-PAGE. 
mRNAs and frame markers are indicated. –1-frame and 0-frame products are marked with arrows. 
(C) –1PRF efficiency determined from the protein band intensities in the gel with different SFV 
mRNA constructs.  
(D) Comparison between –1 frameshifting efficiency measured with short (such as used for the 
peptide analysis by HPLC) and long mRNAs using individually purified tRNAs from E. coli. 
Translation was performed at 1:1 molar ratio of tRNALeu(UUA) to 70S. SS/SL and SS/– are in black 
and white, respectively. 
Translation with long SS/SL mRNA containing both native frameshifting signals results 
in a frameshifting efficiency of about 40%, which is consistent with the results obtained with 
E. coli tRNAs (Fig. 29). We note that the –1PRF efficiency reported in vivo in human cells 
is lower, about 15% (Chung et al., 2010). Mutations disturbing (SS/– mut1 and mut2 
mRNAs) and removing (SS/–) the SL element have a dramatic effect on frameshifting, 
lowering its efficiency by 4-fold to about 10% (Fig. 29B,C). On the contrary, with purified 
E. coli tRNAs, the SL showed only a moderate effect on frameshifting, which is reduced less 
than 2-fold when the SL is removed (Fig. 29D). To understand the effect of the SL, we first 
tested the translation efficiency of SS/– mRNA to exclude a potential effect of mutations. 
The high translational efficiency of –1-frame control of SS/– mRNA suggests that 
introduced mutations do not impair synthesis of –1-peptide (Fig. 29B,C; –1 SS/– mRNA). 
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Next, we translated short SS/SL and SS/– mRNAs that we utilize to determine the 
frameshifting efficiency by HPLC and the respective long mRNAs using bacterial individual 
tRNAs. The –1PRF efficiency on long SS/SL mRNA remains unchanged (about 40%), 
however, –1-slippage on the long SS/– mRNA increases to about 25% (Fig. 29D), as was 
reported for short SFV mRNAs. This data suggests that the effect of the SL could be 
connected to the tRNA abundance and rates of translation. Because of the pronounced effect 
of the SL observed with human tRNA, we then translated the long analogues of CGAU and 
the GACU mRNAs under the same conditions. However, mutations of nts downstream of 
the SS do not influence –1PRF in vitro regardless of the translation conditions (Fig. 29B,C). 
Finally, mutating the second codon of the SS UUA into highly abundant UUC decreases  
–1PRF in SFV to less than 5% (Fig. 29B,C). All together this data might indicate that –1PRF 
in SFV requires a very low concentration of Leu-tRNALeu(UUA), which would allow the 






3.4 Thermodynamic control of –1 programmed ribosomal frameshifting in dnaX 
Bock, L., Caliskan, N., Korniy, N., Peske, F., Rodnina, M.V. & Grubmüller, H. (2019). 
Thermodynamic control of –1 programmed ribosomal frameshifting (submitted to  
Nat Commun). 
As described in the Introduction, –1PRF in E. coli dnaX gene is one of the best studied 
examples of backward slippage with a particularly high frameshifting efficiency of 50%-
80% (Caliskan et al., 2017; Chen et al., 2013; Tsuchihashi and Brown, 1992). The 
frameshifting motif consists of the SS A1 AAA4 AAG7, a SL element and additionally a SD-
like sequence upstream of the SS (Tsuchihashi and Brown, 1992). Typically, mutations of 
the SS nts alter frameshifting efficiency, however, many mutations which should abolish 
frameshifting because they interrupt the SS lead to surprisingly high –1PRF efficiencies. For 
example, A1G and A4G mutations, which should disfavour re-pairing in the –1-frame, 
decrease the frameshifting efficiency to 20% and 46%, respectively, instead of abolishing it 
completely, which would be expected based on their position (Tsuchihashi and Brown, 
1992).  
To understand what defines the shiftiness of frameshifting motifs and thereby the 
efficiency of –1PRF, we designed a set of dnaX mRNA constructs containing the native SD-
like sequence and the SL, but with 64 different variants of the SS. All variants can be 
classified into four groups depending on the aa identity of the SS codons in the 0-frame: Lys-
Lys (wt), Phe-Phe, Lys-Phe and Phe-Lys (Fig. 30A). In addition, mutations were introduced 
in the first, fourth and seventh positions of the SS (Fig. 30A). To measure frameshifting on 
these mRNAs, we utilized the in vitro reconstituted translation system from E. coli and 
separated the 0- and –1-frame peptides by RP-HPLC as described before (Caliskan et al., 
2017). The –1PRF efficiency for each mRNA construct was calculated as a ratio between  





Figure 30. Variations of the E. coli dnaX SS and measured –1PRF efficiencies. Figure and figure 
legend are courtesy of Dr. Lars Bock. 
(A) All possible mutations of the SS coding for the following tRNA pairs: Lys-Lys, Phe-Phe, Lys-
Phe, and Phe-Lys. For each tRNA pair (upper row), the mRNA sequence (lower row) is shown for 
the 0-frame (left) and the –1-frame (right) together with mutations (pink) that do not change the 
codon identity in the 0-frame. The resulting codon-anticodon interactions at the two SS codons are 
highlighted by different colors, with Watson-Crick (WC) interaction in light green, G–S and A–S 
pairs where S denotes the modified nt mnm5s2U in yellow and dark green, respectively, the U–G 
wobble pair in brown, and A–A and U–U mismatch in different shades of red.  
Table 27. –1PRF efficiencies for the indicated dnaX slippery sequence variants 
Slippery site –1PRF efficiency ± SD, % 
Lys-Lys 
A AAA AAG 80 ± 1 
c AAA AAG 19 ± 1. 
u AAA AAG 14 ± 1 
g AAA AAG 29 ± 1 
A AAg AAG 43 ± 3 
c AAg AAG 8 ± 1 
u AAg AAG 6 ± 1 
g AAg AAG 9 ± 2 
A AAA AAa 48 ± 4 
c AAA AAa 9 ± 0.6 
u AAA AAa 6 ± 1 
g AAA AAa 13 ± 2 
A AAg AAa 20 ± 2 
c AAg AAa 3 ± 0.5 
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u AAg AAa 4 ± 0.4 
g AAg AAa 6 ± 1 
Phe-Phe 
U UUU UUU 45 ± 4 
a UUU UUU 29 ± 1 
c UUU UUU 21 ± 2 
g UUU UUU 26 ± 4 
U UUc UUU 4 ± 1 
a UUc UUU 4 ± 1 
c UUc UUU 2 ± 1 
g UUc UUU 4 ± 1 
U UUU UUc 22 ± 0.6 
a UUU UUc 8 ± 3 
c UUU UUc 6 ± 1 
g UUU UUc 12 ± 2 
U UUc UUc 3 ± 0.4 
a UUc UUc 2 ± 0.4 
c UUc UUc 2 ± 0.5 
g UUc UUc 2 ± 0.4 
Lys-Phe 
A AAA UUU 23 ± 5 
c AAA UUU 5 ± 1 
u AAA UUU 5 ± 1 
g AAA UUU 10 ± 1 
A AAg UUU 20 ± 5 
c AAg UUU 5 ± 1 
u AAg UUU 3 ± 1 
g AAg UUU 6 ± 0.4 
A AAA UUc 6 ± 1 
c AAA UUc 3 ± 0.6 
u AAA UUc 2 ± 0.5 
g AAA UUc 4 ± 2 
A AAg UUc 6 ± 2 
c AAg UUc 4 ± 1 
u AAg UUc 1 ± 0.5 
g AAg UUc 6 ± 1 
Phe-Lys 
U UUU AAG 21 ±2 
a UUU AAG 5 ± 2 
101 
 
c UUU AAG 5 ± 3 
g UUU AAG 5 ± 1 
U UUc AAG 5 ± 0.5 
a UUc AAG 7 ± 2 
c UUc AAG 4 ± 2 
g UUc AAG 4 ± 1 
U UUU AAa 7 ± 1 
a UUU AAa 4 ± 2 
c UUU AAa 4 ± 2 
g UUU AAa 5 ± 2 
U UUc AAa 4 ± 2 
a UUc AAa 3 ± 2 
c UUc AAa 4 ± 2 
g UUc AAa 4 ± 0.8 
Wt sequence of the SS is in bold, mutated nts are in small letters. 
–1PRF on the wt SS A1 AAA4 AAG7 is about 80%, whereas A1G and A4G mutations 
lower frameshifting to about 29% and 43%, respectively (Fig. 30B; Table 27), confirming 
previously published data (Caliskan et al., 2017; Chen et al., 2013; Tsuchihashi and Brown, 
1992). Several SS variants support efficient frameshifting, whereas others diminish 
frameshifting considerably (Fig. 30B; Table 27). Notably, the frameshifting efficiency was 
high not only with sequences where –1PRF results in canonical WC base pairs in the 1st and 
2nd codon positions, but also with variants bearing mismatches in any position. Examples of 
such mismatches include C/U/G AAA AAA (19%, 14% and 29%, respectively), A AAG 
AAA/G (20% and 43%, respectively), A/C/G UUU UUU (about 25%), A AAG UUU (20%) 
or U UUU AAG (21%) sequences. Moreover, in some cases –1-frame tRNAs have 1st 
position mismatches on both slippery codons, such as with G/C AAG AAG or G AAG UUC 
sequences, and yet the frameshifting efficiency is not diminished completely but remains at 
6-9%. In addition, SS variants with identical codons in 0- and –1-frames, such as A AAA 
AAA or U UUU UUU, result in about 50% –1PRF despite being “super-slippery”. These 
findings suggest that –1PRF relies on some characteristics of the complexes other than a 
simple complementarity. We note that the rate of translocation on the SS of dnaX is very 
low due to the presence of the mRNA secondary structure element (Caliskan et al., 2017), 
which leaves plenty of time for thermodynamic re-equilibration of tRNA binding in the two 
alternative frames.  
Upon obtaining –1PRF efficiencies on all dnaX mRNA variants, we asked the questions 
whether the frameshifting efficiencies can be explained by the free-energy differences of 
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tRNA interactions in 0- and –1-frames, and – in the simplest model –whether these 
differences result from the free energies of the codon-anticodon base pairing. To answer this 
question, Dr. Lars Bock developed the free-energy model of –1PRF in dnaX (not presented 
here), which was then applied to our experimental data. We obtained the free energies of the 
base pairs in the 0 and –1 frame and show that the frameshifting efficiency of a given 
sequence can be reproduced and even predicted from the free energies of tRNA-mRNA base 





4.1 Frameshifting on the gag-pol mRNA of HIV-1 
4.1.1 Routes to frameshifting on gag-pol HIV-1 mRNA  
In this study, we investigated the mechanism and modulation of –1PRF on gag-pol 
mRNA of HIV-1 using three in vitro reconstituted translation systems: homologous 
translation with E. coli components, heterologous bacterial system with native human tRNA 
and homologous mammalian translation system. The –1PRF efficiency differs depending on 
the type of a model system, a phenomenon which was noted before and attributed to different 
translation and degradation rates in vivo and in vitro and to differences between in vitro 
assays (Dinman et al., 1997; Kollmus et al., 1994; Parkin et al., 1992; Reil et al., 1993). 
Presumably, the presence of the bulk aa-tRNA also plays a role in defining the frameshifting 
efficiency (compare Figs. 15A & 23A). However, regardless of the system used, we show 
that –1PRF on HIV-1 mRNA operates in two regimes, one that is caused by a limitation of 
Leu-tRNALeu(UUA) resulting in the FFR –1-frame product, and another where ribosomes slip 
during tRNAPhe–tRNALeu(UUA) translocation over the SS codons yielding the FLR –1-frame 
product. The switch between the two regimes is modulated by the availability of Leu-
tRNALeu(UUA), which we demonstrate with E. coli, mammalian or hybrid translation systems, 
thereby minimizing the likelihood of potential translation system-dependent experimental 
artefacts and underscoring the notion that this frameshifting mechanism is universally 
conserved. We show that Leu-tRNALeu(UUA) is rare in cell lines derived from human immune 
cells, which represent the natural reservoir for HIV-1 infection. This finding is supported by 
earlier in vivo experiments indicating that limitation of Leu in the culture medium leads to 
increased –1PRF in E. coli (Yelverton et al., 1994). The switch to “hungry” frameshifting is 
often caused by unfavorable conditions, e.g. aa starvation, as was described for “hungry”  
–1 frameshifting on E. coli dnaX mRNA (Caliskan et al., 2017; Gallant and Lindsley, 1993; 
Gallant and Lindsley, 1992, 1998). In contrast, HIV-1 can use both pathways constitutively 
due to the inherently low concentration of the key tRNALeu(UUA) isoacceptor in human cells. 
Furthermore, we find that the ribosome on the HIV SS can slip into the –1-, –2-, or  
+1-frames when some aa-tRNAs are lacking, but when all aa-tRNAs are supplied, the  
–1-product remains predominant. Translation of the E. coli dnaX mRNA can also lead to 
slippages into the –2-, +2-, or –4-frames when aa-tRNAs are in limiting supply (Caliskan et 
al., 2017; Yan et al., 2015). In the native gag-pol sequence, ribosomes shifting into the  
+1- or –2-frame will soon encounter one of the multiple downstream stop codons, which 
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lead to premature termination. Pre-termination prevents the formation of non-functional 
peptides, especially under conditions of aa-tRNA limitation. –1 frameshifting on many non-
programmed tetra- and heptanucleotide slippery sites results in the production of truncated 
and non-functional peptides, because translation is typically terminated 5-10 codons after 
the frame is changed (Ketteler, 2012). However, in case of HIV-1, alternative slippages 
could still influence the ratio between Gag and Gag-Pol proteins and thus influence the 
overall –1PRF efficiency. Premature termination upon frameshifting can also result in the 
production of functional proteins. One example is E. coli gene copA encoding a copper ion 
transporter (Meydan et al., 2017). Here –1PRF causes pre-termination and formation of a 
truncated peptide CopA(Z), which turned out to be a copper chaperone protecting cells from 
excessive copper concentrations in the environment (Meydan et al., 2017). On the other 
hand, premature termination upon –1PRF in human CCR5 mRNA leads to mRNA 
degradation by the nonsense-mediated decay pathway, thus, regulating mRNA stability and 
gene expression (Belew et al., 2014). 
4.1.2 The role of the tRNA pool 
As the ratio of the Gag and Gag-Pol products is crucial for virus propagation (Biswas et 
al., 2004; Karacostas et al., 1993; Park and Morrow, 1991; Shehu-Xhilaga et al., 2001),  
HIV-1 must have evolved to achieve the desired –1PRF efficiency at the limited 
concentrations of tRNALeu(UUA) prevalent in human cells. The UUA codon is rare in the 
human genome, as are all other A-ending codons. The respective cognate tRNALeu(UUA) is 
significantly underrepresented in the tRNA pool as compared to tRNALeu(CUG) reading the 
most abundant Leu codon CUG (Fig. 19 and (Wan Makhtar et al., 2017)). While in 
eukaryotes the tRNA expression is tissue-specific, the relative expression of tRNA 
isoacceptors in some tissues shows statistically significant correlation to the codon usage of 
tissue-specific genes (Dittmar et al., 2006). The low relative abundance of tRNALeu(UUA)  in 
the lymphocyte-derived cell types may be a result of adaptation to the codon usage in these 
cells. On the other hand, the rare UUA codon accounts for 45% of all Leu codons in late-
expressing HIV-1 genes including gag and pol (Berkhout et al., 2002; Sharp et al., 1988; van 
Weringh et al., 2011). Thus the HIV-1 ORF may act as a sponge for tRNALeu(UUA). The ratio 
between FLR and FFR routes is about 70% to 30%, as reported with mammalian ribosomes 
(Jacks et al., 1988b) and 80% to 20%, as measured with E. coli 70S (Cardno et al., 2015; 
Liao et al., 2011; Yelverton et al., 1994). If –1PRF occurred after Leu incorporation only, 
the low abundance and variations in the concentration of tRNALeu(UUA) could severely affect 
–1PRF efficiency and thus impair virus propagation. Our data explain how HIV-1 might 
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overcome this problem. When the concentration of tRNALeu(UUA) decreases, the ribosome 
switches to the FFR route leading to robust –1PRF at low tRNALeu(UUA) concentrations. In 
contrast, increasing the tRNALeu(UUA) concentration above the 1:1 ratio to the ribosome leads 
to a significant reduction in the –1PRF efficiency.  
Our results suggest that tRNALeu(UUA) enrichment in virus-infected human cells could 
become a new approach in antiviral therapy. Based on codon usage differences between 
retroviruses and the human host, multiple tRNA species were predicted, which are critical 
for retroviral protein synthesis but dispensable for human translation laying the foundation 
for the hypothetical tRNA Inhibition Therapy (TRIT) (Frias et al., 2013). Inactivation of 
these tRNAs should drastically reduce the elongation rate of viral protein synthesis leaving 
the host translation unaffected. One of the best targets of TRIT, which could be exploited in 
HIV-1 and other retroviruses (HIV-2, HTLV-1 and 2), is tRNALeu with the anticodon UAG 
reading the CUA codon of the mRNA (Frias et al., 2013). While TRIT remains hypothetical, 
a similar approach to exploit the codon usage disparity was already utilized to inhibit 
synthesis of HIV-1 proteins by translating the schlafen gene (SLFN11) (Li et al., 2012). 
Because SLFN11 mRNA has a codon usage similar to that of the late genes of HIV-1, its 
translation acts as a tRNA sponge and thus makes the cellular tRNA pool suboptimal for the 
translation of HIV-1 mRNAs (Li et al., 2012). 
Given the low level of tRNALeu(UUA) in human T-lymphocytes, the question remains how 
HIV-1 can satisfy its high demand for this tRNA to achieve an efficient translation of its late 
genes gag and pol. It is known that HIV-1 can package some cellular tRNAs, among them 
tRNALys, tRNAIle and to a lesser extent tRNALeu(UUA), during virion assembly (Pavon-
Eternod et al., 2010). Because tRNA packaging happens passively governed by the 
concentration gradient, these tRNAs must be present in the cell at significant concentrations. 
There are multiple indirect indications that HIV-1 itself can affect the tRNA pools by yet 
unknown mechanisms (van Weringh et al., 2011) and that HIV infection can change the 
cellular localization of individual aa-tRNA synthetases from the multi-aa-tRNA synthetase 
complex (Duchon et al., 2017), which may affect aminoacylation efficiencies. Other viruses 
whose genomes have a codon usage different from their host indeed alter the free tRNA 
pools by changing polysome-associated tRNA levels (vaccinia and influenza A) or by tRNA 
misacylation (influenza A and adenovirus) (Netzer et al., 2009; Pavon-Eternod et al., 2013), 
but the exact mechanism of HIV-1 action remains unknown.  
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4.1.3 The second slippery site 
Anti-HIV therapy with protease inhibitors leads to accumulation of mutations in the 
HIV-1 protease that impair the recognition of its specific cleavage sites. Secondary 
mutations also arise at the pSS2, which harbors the p1/p6 cleavage site of Gag polyprotein 
(Bally et al., 2000; Banke et al., 2009; de Oliveira et al., 2003; Larrouy et al., 2011; Pettit et 
al., 2002) that allow polyprotein maturation by the mutated protease. The C5U mutation in 
pSS2 substitutes Leu with Phe, which enhances van der Waals interactions between the 
substrate and the mutant protease, thereby increasing the protease activity by about 10-fold 
(Ozen et al., 2014). The same mutation produces a U1 UUU4 UUU7 pSS2, which can also 
support –1PRF, but the role of pSS2 depends on the sequence of SS1. With native SS1, the 
joint activity of SS1 and pSS2 is not different from SS1 alone. However, when SS1 is 
mutated to a non-shifty sequence, the C5U mutation in the pSS2 supports a level of –1PRF 
that may be sufficient for virus propagation. The finding that pSS2 can alleviate the 
detrimental effects of SS1 mutations is consistent with previous in vitro and in vivo reports 
(Brierley and Dos Ramos, 2006; Doyon et al., 1998; Garcia-Miranda et al., 2016; Girnary et 
al., 2007; Knops et al., 2012). Interestingly, during antiviral therapy, drug-resistant herpes 
simplex viruses also develop an unusual SS which supports both –1 and +1PRF at levels 
sufficient for virus replication and pathogenicity despite the treatment (Griffiths, 2011; Pan 
and Coen, 2012). Similarly, the C5U mutation in the pSS2 of gag-pol HIV-1 mRNA does 
not only modulate the frameshifting efficiency, but also improves the activity of the mutant 
proteases that emerge upon protease inhibitor treatment. This suggests a mechanism for 
HIV-1 rescue to maintain its life cycle despite the damage caused by the therapy. Thus, HIV-
1 can constitutively use different frameshifting regimes and might have contingency 
mechanisms to ensure a low but crucial level of frameshifting required for its proliferation. 
4.1.4 The contribution of an mRNA enhancer sequence  
Several reports suggest a crucial contribution of SL1 for frameshifting in HIV-1 (Bidou 
et al., 1997; Cassan et al., 1994; Garcia-Miranda et al., 2016; Kollmus et al., 1994; Parkin et 
al., 1992). However, most constructs used to study the effect of the SL1 are truncated either 
immediately after the SS1 or after the next codon GGG leaving open the question about the 
role of nt 3’ adjacent to SS1. The efficiency of –1PRF measured on such a short construct is 
indeed severely decreased as compared to the full-length SL1 (see Fig. 26A, black and red 
bars). However, by doing sequential mutation analysis, we show that this effect is 
independent of SL1 and can be attributed to specific nucleotide sequence within the HIV-1 
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mRNA, which we call an enhancer. We identified that this enhancer is located within the 
first 4-12 nt after SS1 and that 4-7 nt are the most critical to maintain the –1PRF efficiency. 
We also hypothesize that the enhancer sequence includes the GGG codon after the SS1, 
because it was previously shown to be critical for –1PRF in HIV-1 in vivo in human cells 
(Mathew et al., 2015). As described in the Introduction (see 1.2.1.4), enhancer sequences act 
as modulators of both +1 and –1PRF, and their presumed mechanism of action is via specific 
interactions with certain parts of the rRNA which lead to ribosome pausing and thereby 
promote frameshifting, similar to the mRNA secondary structures (Guarraia et al., 2007). 
Structural studies and profiling data indicated that the translating ribosome covers about  
28 nt of the mRNA sequence (about 13 nt starting from the P-site codon) (Ingolia et al., 
2009; Qu et al., 2011), suggesting that the nts within the enhancer in HIV-1 might indeed 
interact with the ribosome and thus stimulate –1PRF. We also note that despite the high 
mutation rate of HIV-1, the first 12 nt after the SS1 show a high degree of conservation 
among different viral subtypes with the first 5 nt being invariable (Fig. 31, nt 8-19 (Baril et 
al., 2003a)), further supporting the importance of the enhancer sequence.  
 
Figure 31. Comparison of frameshifting sites encompassing the SS1 (nt 1-7), the SL1 (nt 8-52) and 
the pSS2 (nt 46-52) derived from different HIV-1 subtypes of group M (subtypes A, B, C, D, E, F, 
J, K(a) and K(b)). T is in red, A is in green, G is in yellow and C is in blue. Nts corresponding to the 
potential enhancer sequence are found at positions 8-19 (1-12 nt after SS1). DNA sequences of 
different viral subtypes were taken from (Baril et al., 2003a). Sequence logo was generated by 
https://weblogo.berkeley.edu.  
We also show that only the FLR route is modulated by the presence of the downstream 
enhancer while the FFR pathway is independent of cis-acting stimulators and relies only on 
the availability of Leu-tRNALeu(UUA). These results are in a good agreement with dnaX 
studies indicating that only frameshifting during translocation requires the SL while the 




Interestingly, two alphaviruses, SFV and MIDV, which share the same SS sequence with 
HIV-1, also seem to comprise potential enhancers (Chung et al., 2010; Firth et al., 2008). 
MIDV is predicted to have a pseudoknot 6 nt downstream of its SS (Fig. 32). Mutations and 
deletions within the pseudoknot decrease the frameshifting efficiency by about 50% while 
changes in the 6-nt spacer are detrimental for frameshifting lowering it to background level 
(Chung et al., 2010). This observation suggests that the spacer itself might act as an enhancer 
with the pseudoknot having only a modulatory function. SFV will be discussed in the next 
section. 
 
Figure 32. Frameshifting motif of MIDV (Chung et al., 2010). The slippery site is highlighted light 
green. 
 
4.2 Frameshifting on 6K mRNA of SFV 
Because HIV-1 and alphaviruses share the same SS, we hypothesized that the 
mechanism of –1PRF might be also conserved. Here we show that –1PRF in 6K mRNA of 
SFV indeed follows the same frameshifting pathways as in HIV-1. The FLS route (analogue 
of FLR in HIV-1) takes place under saturating translation conditions and represents typical 
dual-slippage –1PRF during the late stage of translocation. In turn, the FFS peptide (which 
is analogous to FFR in HIV-1) is a product of a single P-site tRNA slippage in the presence 
of an empty A site due to the limited supply of aa-tRNAs. Thus mounting evidence suggests 
that the two frameshifting regimes – one at the late steps of translocation and another when 
the ribosome is waiting for a rare aa-tRNA to enter the A site – account for the majority of 
the reported –1PRF examples. Also, similarly to HIV-1, Leu-tRNALeu(UUA) acts as the main 
modulator of –1PRF in SFV and defines the ratio between FLS and FFS proteins.  
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Frameshifting motifs of most alphaviruses harbour mRNA secondary structures, either 
SL or pseudoknots. SFV was predicted to comprise a SL, which was not experimentally 
verified (Chung et al., 2010). Here, using a chemical probing approach, we identify the 
presence of an extended SL 6 nt after the SS. The SL spans over 79 nt and consists of two 
stems separated by unstructured bulges and loops (see Fig. 27). It is very similar in size and 
composition to the SL of the Sindbis virus (SINV), and the frameshifting efficiencies 
measured with SINV and SFV are also in the same range (10% and 15%, respectively) 
(Chung et al., 2010). However, the contribution of the SL to –1PRF in SFV remains unclear. 
Chung and co-authors suggest that the secondary structure is dispensable and only the first 
18-20 nt after the SS are critical for frameshifting. Unexpectedly, we show that the SL has a 
strong modulatory effect on frameshifting when the amount of Leu-tRNALeu(UUA) is limiting 
(≤1 molecule per ribosome). However, under saturating conditions with Leu-tRNALeu(UUA) 
the contribution of the SL is negligible. This observation holds true in both homologous and 
heterologous (with HeLa tRNA) in vitro translation systems, however, in the presence of 
HeLa tRNA the effect of the SL is more dramatic (compare Figs. 29C & D). This finding 
could be explained by the difference in translation rates between the two systems: slower 
translation could leads to a pause during which the ribosome slips into the –1-frame, making 
the SL dispensable. Interestingly, the replacements of the UUA codon to UUC in the SS1 of 
HIV-1 decreases the –1PRF efficiency by about 30% (see Fig. 23C), whereas in SFV it 
abolishes frameshifting (see Fig. 29). This observation suggests that the rare Leu codon UUA 
and thus the tRNALeu(UUA) limitation might be of critical importance for –1PRF and that 
“hungry” FFS route might be dominant in SFV. Previously, the frameshifting efficiency in 
SFV was measured in 293T cells (Chung et al., 2010), in which the abundance of 
tRNALeu(UUA) is high, i.e. its concentration is only 3-fold lower that of tRNALeu(CUG) (see  
Fig. 19). However, the natural reservoirs for SFV infection are neuronal cells (neurons and 
oligodendrocytes) and spinocerebral liquid (Fragkoudis et al., 2009), in which the level of 
tRNALeu(UUA) remains to be determined. Thus, the published in vivo data on the effect of the 
SL on –1PRF in SFV could be biased due to the choice of the cell line, where the high 
abundance of tRNALeu(UUA) suppresses the FFS route. One other example of “hungry” 
frameshifting stimulated by an mRNA secondary structure was described for the bacterial 
SS U1 UUC4 AUA7. Placing the SL from the MMTV gag-pol frameshifting site after this SS 
greatly increases the –1PRF efficiency, but only under starvation conditions when 
tRNAIle(AUA) is in a limited supply (Atkinson et al., 1997). 
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As described before, the first 18-20 nt after the SS in SFV were shown to be critical for  
–1PRF in SFV measured in human cells (Chung et al., 2010). Our mutation analysis 
performed in vitro shows that this sequence on its own does not play a significant role in 
frameshifting and does not function as a cis-acting enhancer like in HIV-1. Chung and  
co-authors hypothesized that either a protein or a miRNA could bind within the 18-20 nt 
downstream of the SS, thereby promoting frameshifting. This suggestion remains to be 
tested and the exact contribution of the 18-20 nt sequence following the SS in SFV is to be 
determined in the future. 
 
4.3 Conclusions 
In the present work, we compare frameshifting mechanisms in HIV-1 and in several 
other viruses and show that the mechanism of viral frameshifting is similar on prokaryotic 
(bacteria) and eukaryotic (mammals) ribosomes, highlighting the evolutionary significance 
of this process and suggesting that it relies on highly conserved components of the translation 
machinery. We indicate that most of the described cases of –1PRF follow two alternative 
frameshifting routes, dual-slippage during translocation under saturating translation 
conditions and single-slippage caused by aa-tRNA limitation and prolonged translation 
pause. We find that the availability of specific tRNAs could determine –1PRF efficiency and 
define the frameshifting pathways. We also provide evidence that the basal level of –1PRF 
could be stimulated by the SS alone, however, either an mRNA secondary structure or a 
specific enhancer sequence downstream of the SS is required to provide an additional layer 
of frameshifting modulation. This research expands our knowledge of frameshifting in 
human-pathogenic viruses and contributes to the understanding of virus-host interactions at 





1. Ablashi, D.V., Berneman, Z.N., Kramarsky, B., Whitman, J., Jr., Asano, Y., and 
Pearson, G.R. (1995). Human herpesvirus-7 (HHV-7): current status. Clin Diagn 
Virol 4, 1-13. 
2. Adio, S., Sharma, H., Senyushkina, T., Karki, P., Maracci, C., Wohlgemuth, I., 
Holtkamp, W., Peske, F., and Rodnina, M.V. (2018). Dynamics of ribosomes and 
release factors during translation termination in E. coli. eLife 7. 
3. Agirrezabala, X., Samatova, E., Klimova, M., Zamora, M., Gil-Carton, D.,  
Rodnina, M.V., and Valle, M. (2017). Ribosome rearrangements at the onset of 
translational bypassing. Sci Adv 3, e1700147. 
4. Ahn, D.G., Lee, W., Choi, J.K., Kim, S.J., Plant, E.P., Almazan, F., Taylor, D.R., 
Enjuanes, L., and Oh, J.W. (2011). Interference of ribosomal frameshifting by 
antisense peptide nucleic acids suppresses SARS coronavirus replication. Antiviral 
Res 91, 1-10. 
5. Atkins, J., and Gesteland, R.F. (2010). Recoding: expansion of decoding rules 
enriches gene expression (Springer). 
6. Atkins, J.F., Loughran, G., Bhatt, P.R., Firth, A.E., and Baranov, P.V. (2016). 
Ribosomal frameshifting and transcriptional slippage: From genetic steganography 
and cryptography to adventitious use. Nucleic Acids Res 44, 7007-7078. 
7. Atkinson, J., Dodge, M., and Gallant, J. (1997). Secondary structures and starvation-
induced frameshifting. Mol Microbiol 26, 747-753. 
8. Bally, F., Martinez, R., Peters, S., Sudre, P., and Telenti, A. (2000). Polymorphism 
of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and 
implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 16, 
1209-1213. 
9. Banke, S., Lillemark, M.R., Gerstoft, J., Obel, N., and Jorgensen, L.B. (2009). 
Positive selection pressure introduces secondary mutations at Gag cleavage sites in 
human immunodeficiency virus type 1 harboring major protease resistance 
mutations. J Virol 83, 8916-8924. 
10. Baranov, P.V., Gesteland, R.F., and Atkins, J.F. (2002). Recoding: translational 
bifurcations in gene expression. Gene 286, 187-201. 
11. Baril, M., Dulude, D., Gendron, K., Lemay, G., and Brakier-Gingras, L. (2003a). 
Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the 
112 
 
human immunodeficiency virus type 1 group M. RNA (New York, NY) 9, 1246-
1253. 
12. Baril, M., Dulude, D., Steinberg, S.V., and Brakier-Gingras, L. (2003b). The 
frameshift stimulatory signal of human immunodeficiency virus type 1 group O is a 
pseudoknot. J Mol Biol 331, 571-583. 
13. Barry, J.K., and Miller, W.A. (2002). A -1 ribosomal frameshift element that requires 
base pairing across four kilobases suggests a mechanism of regulating ribosome and 
replicase traffic on a viral RNA. Proc Natl Acad Sci U S A 99, 11133-11138. 
14. Bednarova, A., Hanna, M., Durham, I., VanCleave, T., England, A., Chaudhuri, A., 
and Krishnan, N. (2017). Lost in translation: defects in transfer RNA modifications 
and neurological disorders. Front Mol Neurosci 10, 135. 
15. Belardinelli, R., Sharma, H., Caliskan, N., Cunha, C.E., Peske, F., Wintermeyer, W., 
and Rodnina, M.V. (2016). Choreography of molecular movements during ribosome 
progression along mRNA. Nat Struct Mol Biol 23, 342-348. 
16. Belcourt, M.F., and Farabaugh, P.J. (1990). Ribosomal frameshifting in the yeast 
retrotransposon Ty: tRNAs induce slippage on a 7 nucleotide minimal site. Cell 62, 
339-352. 
17. Belew, A.T., Meskauskas, A., Musalgaonkar, S., Advani, V.M., Sulima, S.O., 
Kasprzak, W.K., Shapiro, B.A., and Dinman, J.D. (2014). Ribosomal frameshifting 
in the CCR5 mRNA is regulated by miRNAs and the NMD pathway. Nature 512, 
265-269. 
18. Berkhout, B., Grigoriev, A., Bakker, M., and Lukashov, V.V. (2002). Codon and 
amino acid usage in retroviral genomes is consistent with virus-specific nucleotide 
pressure. AIDS Res Hum Retroviruses 18, 133-141. 
19. Bidou, L., Stahl, G., Grima, B., Liu, H., Cassan, M., and Rousset, J.P. (1997). In vivo 
HIV-1 frameshifting efficiency is directly related to the stability of the stem-loop 
stimulatory signal. RNA (New York, NY) 3, 1153-1158. 
20. Bieri, P., Greber, B.J., and Ban, N. (2018). High-resolution structures of 
mitochondrial ribosomes and their functional implications. Curr Opin Struct Biol 49, 
44-53. 
21. Biswas, P., Jiang, X., Pacchia, A., Dougherty, J., and Peltz, S. (2004). The human 
immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence 
determinant and an important target for antiviral therapy. J Virol 78, 2082-2089. 
22. Bjork, G.R. (1995). Genetic dissection of synthesis and function of modified 
nucleosides in bacterial transfer RNA. Prog Nucleic Acid Res Mol Biol 50, 263-338. 
113 
 
23. Blinkowa, A.L., and Walker, J.R. (1990). Programmed ribosomal frameshifting 
generates the Escherichia coli DNA polymerase III gamma subunit from within the 
tau subunit reading frame. Nucleic Acids Res 18, 1725-1729. 
24. Bohnsack, M.T., and Sloan, K.E. (2018). The mitochondrial epitranscriptome: the 
roles of RNA modifications in mitochondrial translation and human disease. Cell 
Mol Life Sci 75, 241-260. 
25. Brakier-Gingras, L., Charbonneau, J., and Butcher, S.E. (2012). Targeting 
frameshifting in the human immunodeficiency virus. Expert Opin Ther Targets 16, 
249-258. 
26. Breitschopf, K., Achsel, T., Busch, K., and Gross, H.J. (1995). Identity elements of 
human tRNA(Leu): structural requirements for converting human tRNA(Ser) into a 
leucine acceptor in vitro. Nucleic Acids Res 23, 3633-3637. 
27. Brierley, I. (1995). Ribosomal frameshifting viral RNAs. J Gen Virol 76 ( Pt 8), 
1885-1892. 
28. Brierley, I., and Dos Ramos, F.J. (2006). Programmed ribosomal frameshifting in 
HIV-1 and the SARS-CoV. Virus Res 119, 29-42. 
29. Brunelle, M., Payant, C., Lemay, G., and Brakier-Gingras, L. (1999). Expression of 
the human immunodeficiency virus frameshift signal in a bacterial cell-free system: 
influence of an interaction between the ribosome and a stem-loop structure 
downstream from the slippery site. Nucleic Acids Res 27, 4783-4874. 
30. Buhr, F., Jha, S., Thommen, M., Mittelstaet, J., Kutz, F., Schwalbe, H.,  
Rodnina, M.V., and Komar, A.A. (2016). Synonymous codons direct cotranslational 
folding toward different protein conformations. Mol Cell 61, 341-351. 
31. Bulmer, M. (1987). Coevolution of codon usage and transfer RNA abundance. 
Nature 325, 728-730. 
32. Caliskan, N., Katunin, V.I., Belardinelli, R., Peske, F., and Rodnina, M.V. (2014). 
Programmed -1 frameshifting by kinetic partitioning during impeded translocation. 
Cell 157, 1619-1631. 
33. Caliskan, N., Peske, F., and Rodnina, M.V. (2015). Changed in translation: mRNA 
recoding by -1 programmed ribosomal frameshifting. Trends Biochem Sci 40, 265-
274. 
34. Caliskan, N., Wohlgemuth, I., Korniy, N., Pearson, M., Peske, F., and Rodnina, M.V. 
(2017). Conditional switch between frameshifting regimes upon translation of dnaX 
mRNA. Mol Cell 66, 558-567 e554. 
114 
 
35. Cardno, T.S., Shimaki, Y., Sleebs, B.E., Lackovic, K., Parisot, J.P., Moss, R.M., 
Crowe-McAuliffe, C., Mathew, S.F., Edgar, C.D., Kleffmann, T., et al. (2015).  
HIV-1 and human PEG10 frameshift elements are functionally distinct and 
distinguished by novel small molecule modulators. PLoS One 10, e0139036. 
36. Cassan, M., Delaunay, N., Vaquero, C., and Rousset, J.P. (1994). Translational 
frameshifting at the gag-pol junction of human immunodeficiency virus type 1 is not 
increased in infected T-lymphoid cells. J Virol 68, 1501-1508. 
37. Chang, S.Y., Sutthent, R., Auewarakul, P., Apichartpiyakul, C., Essex, M., and  
Lee, T.H. (1999). Differential stability of the mRNA secondary structures in the 
frameshift site of various HIV type 1 viruses. AIDS Res Hum Retroviruses 15, 1591-
1596. 
38. Chen, C., Zhang, H., Broitman, S.L., Reiche, M., Farrell, I., Cooperman, B.S., and 
Goldman, Y.E. (2013). Dynamics of translation by single ribosomes through mRNA 
secondary structures. Nat Struct Mol Biol 20, 582-588. 
39. Chen, J., Coakley, A., O'Connor, M., Petrov, A., O'Leary, S.E., Atkins, J.F., and 
Puglisi, J.D. (2015). Coupling of mRNA structure rearrangement to ribosome 
movement during bypassing of non-coding regions. Cell 163, 1267-1280. 
40. Chen, J., Petrov, A., Johansson, M., Tsai, A., O'Leary, S.E., and Puglisi, J.D. (2014). 
Dynamic pathways of -1 translational frameshifting. Nature 512, 328-332. 
41. Chung, B.Y., Firth, A.E., and Atkins, J.F. (2010). Frameshifting in alphaviruses: a 
diversity of 3' stimulatory structures. J Mol Biol 397, 448-456. 
42. Clare, J.J., Belcourt, M., and Farabaugh, P.J. (1988). Efficient translational 
frameshifting occurs within a conserved sequence of the overlap between the two 
genes of a yeast Ty1 transposon. Proc Natl Acad Sci U S A 85, 6816-6820. 
43. Clark, M.B., Janicke, M., Gottesbuhren, U., Kleffmann, T., Legge, M., Poole, E.S., 
and Tate, W.P. (2007). Mammalian gene PEG10 expresses two reading frames by 
high efficiency -1 frameshifting in embryonic-associated tissues. J Biol Chem 282, 
37359-37369. 
44. Cobucci-Ponzano, B., Conte, F., Benelli, D., Londei, P., Flagiello, A., Monti, M., 
Pucci, P., Rossi, M., and Moracci, M. (2006). The gene of an archaeal alpha-L-
fucosidase is expressed by translational frameshifting. Nucleic Acids Res 34, 4258-
4268. 
45. Cobucci-Ponzano, B., Rossi, M., and Moracci, M. (2012). Translational recoding in 
archaea. Extremophiles : life under extreme conditions 16, 793-803. 
115 
 
46. Craigen, W.J., and Caskey, C.T. (1986). Expression of peptide chain release factor 2 
requires high-efficiency frameshift. Nature 322, 273-275. 
47. Cullen, B.R. (1991). Regulation of HIV-1 gene expression. Faseb J 5, 2361-2368. 
48. Cunha, C.E., Belardinelli, R., Peske, F., Holtkamp, W., Wintermeyer, W., and 
Rodnina, M.V. (2013). Dual use of GTP hydrolysis by elongation factor G on the 
ribosome. Translation 1, e24315. 
49. Curran, J.F., and Yarus, M. (1988). Use of tRNA suppressors to probe regulation of 
Escherichia coli release factor 2. J Mol Biol 203, 75-83. 
50. Danilevskaya, O., Slot, F., Pavlova, M., and Pardue, M.L. (1994). Structure of the 
Drosophila HeT-A transposon: a retrotransposon-like element forming telomeres. 
Chromosoma 103, 215-224. 
51. de Oliveira, T., Engelbrecht, S., Janse van Rensburg, E., Gordon, M., Bishop, K.,  
zur Megede, J., Barnett, S.W., and Cassol, S. (2003). Variability at human 
immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of 
viral fitness? J Virol 77, 9422-9430. 
52. Dever, T.E., and Green, R. (2012). The elongation, termination, and recycling phases 
of translation in eukaryotes. Cold Spring Harb Perspect Biol 4, a013706. 
53. Dinman, J. (2012). Mechanisms and implications of programmed translational 
frameshifting. Wiley interdisciplinary reviews RNA 3, 661-673. 
54. Dinman, J.D. (2006). Programmed ribosomal frameshifting goes beyond viruses: 
organisms from all three kingdoms use frameshifting to regulate gene expression, 
perhaps signaling a paradigm shift. Microbe Wash DC 1, 521-527. 
55. Dinman, J.D., Richter, S., Plant, E.P., Taylor, R.C., Hammell, A.B., and Rana, T.M. 
(2002). The frameshift signal of HIV-1 involves a potential intramolecular triplex 
RNA structure. Proc Natl Acad Sci U S A 99, 5331-5336. 
56. Dinman, J.D., Ruiz-Echevarria, M.J., Czaplinski, K., and Peltz, S.W. (1997). 
Peptidyl-transferase inhibitors have antiviral properties by altering programmed  
-1 ribosomal frameshifting efficiencies: development of model systems. Proc Natl 
Acad Sci U S A 94, 6606-6611. 
57. Dittmar, K.A., Goodenbour, J.M., and Pan, T. (2006). Tissue-specific differences in 
human transfer RNA expression. PLoS Genet 2, e221. 
58. Doerfel, L.K., Wohlgemuth, I., Kothe, C., Peske, F., Urlaub, H., and Rodnina, M.V. 
(2013). EF-P is essential for rapid synthesis of proteins containing consecutive 
proline residues. Science 339, 85-88. 
116 
 
59. Dong, H., Nilsson, L., and Kurland, C.G. (1996). Co-variation of tRNA abundance 
and codon usage in Escherichia coli at different growth rates. J Mol Biol 260, 649-
663. 
60. Donly, B.C., Edgar, C.D., Williams, J.M., and Tate, W.P. (1990). Tightly controlled 
expression systems for the production and purification of Escherichia coli release 
factor 1. Biochem Int 20, 437-443. 
61. Doyon, L., Payant, C., Brakier-Gingras, L., and Lamarre, D. (1998). Novel Gag-Pol 
frameshift site in human immunodeficiency virus type 1 variants resistant to protease 
inhibitors. J Virol 72, 6146-6150. 
62. Drummond, D.A., and Wilke, C.O. (2009). The evolutionary consequences of 
erroneous protein synthesis. Nat Rev Genet 10, 715-724. 
63. Duchon, A.A., St Gelais, C., Titkemeier, N., Hatterschide, J., Wu, L., and Musier-
Forsyth, K. (2017). HIV-1 exploits a dynamic multi-aminoacyl-tRNA synthetase 
complex to enhance viral replication. J Virol 91. 
64. Dulude, D., Baril, M., and Brakier-Gingras, L. (2002). Characterization of the 
frameshift stimulatory signal controlling a programmed -1 ribosomal frameshift in 
the human immunodeficiency virus type 1. Nucleic Acids Res 30, 5094-5102. 
65. Endoh, T., and Sugimoto, N. (2013). Unusual -1 ribosomal frameshift caused by 
stable RNA G-quadruplex in open reading frame. Anal Chem 85, 11435-11439. 
66. Engelberg-Kulka, H., and Schoulaker-Schwarz, R. (1988). Stop is not the end: 
physiological implications of translational readthrough. J Theor Biol 131, 477-485. 
67. Fang, Y., Treffers, E.E., Li, Y., Tas, A., Sun, Z., van der Meer, Y., de Ru, A.H.,  
van Veelen, P.A., Atkins, J.F., Snijder, E.J., et al. (2012). Efficient −2 frameshifting 
by mammalian ribosomes to synthesize an additional arterivirus protein. Proc Natl 
Acad Sci U S A 109, E2920–E2928. 
68. Farabaugh, P.J. (1996). Programmed translational frameshifting. Microbiol Rev 60, 
103-134. 
69. Farabaugh, P.J. (1997). Programmed alternative reading of teh genetic code. In 
(Austin, Texas, USA, Heidelberg, Germany: RG Landes Company, Springer-
Verlag), pp. 69-101. 
70. Farabaugh, P.J. (2000). Translational frameshifting: implications for the mechanism 
of translational frame maintenance. Prog Nucleic Acid Res Mol Biol 64, 131-170. 
71. Farabaugh, P.J., Zhao, H., and Vimaladithan, A. (1993). A novel programed 
frameshift expresses the POL3 gene of retrotransposon Ty3 of yeast: frameshifting 
without tRNA slippage. Cell 74, 93-103. 
117 
 
72. Fayet, O., and Prère, M.-F. (2010). Programmed ribosomal −1 frameshifting as a 
tradition: the bacterial transposable elements of the IS3 family. In Recoding: 
Expansion of Decoding Rules Enriches Gene Expression, J.F. Atkins, and R.F. 
Gesteland, eds. (Springer New York), pp. 259-280. 
73. Fersht, A.R. (1977). Editing mechanisms in protein synthesis. Rejection of valine by 
the isoleucyl-tRNA synthetase. Biochemistry 16, 1025-1030. 
74. Firth, A.E., Chung, B.Y., Fleeton, M.N., and Atkins, J.F. (2008). Discovery of 
frameshifting in Alphavirus 6K resolves a 20-year enigma. Virol J 5, 108. 
75. Fischer, N., Neumann, P., Bock, L.V., Maracci, C., Wang, Z., Paleskava, A., 
Konevega, A.L., Schroder, G.F., Grubmuller, H., Ficner, R., et al. (2016). The 
pathway to GTPase activation of elongation factor SelB on the ribosome. Nature 540, 
80-85. 
76. Florin, T., Maracci, C., Graf, M., Karki, P., Klepacki, D., Berninghausen, O., 
Beckmann, R., Vazquez-Laslop, N., Wilson, D.N., Rodnina, M.V., et al. (2017). An 
antimicrobial peptide that inhibits translation by trapping release factors on the 
ribosome. Nat Struct Mol Biol 24, 752-757. 
77. Fragkoudis, R., Tamberg, N., Siu, R., Kiiver, K., Kohl, A., Merits, A., and 
Fazakerley, J.K. (2009). Neurons and oligodendrocytes in the mouse brain differ in 
their ability to replicate Semliki Forest virus. J Neurovirol 15, 57-70. 
78. Freed, E.O. (2001). HIV-1 replication. Somat Cell Mol Genet 26, 13-33. 
79. Frias, D., Monteiro-Cunha, J.P., Mota-Miranda, A.C., Fonseca, V.S., de Oliveira, T., 
Galvao-Castro, B., and Alcantara, L.C. (2013). Human retrovirus codon usage from 
tRNA point of view: therapeutic insights. Bioinform Biol Insights 7, 335-345. 
80. Gallant, J., and Lindsley, D. (1993). Ribosome frameshifting at hungry codons: 
sequence rules, directional specificity and possible relationship to mobile element 
behaviour. Biochem Soc Trans 21, 817-821. 
81. Gallant, J.A., and Lindsley, D. (1992). Leftward ribosome frameshifting at a hungry 
codon. J Mol Biol 223, 31-40. 
82. Gallant, J.A., and Lindsley, D. (1998). Ribosomes can slide over and beyond 
"hungry" codons, resuming protein chain elongation many nucleotides downstream. 
Proc Natl Acad Sci U S A 95, 13771-13776. 
83. Garcia-Miranda, P., Becker, J.T., Benner, B.E., Blume, A., Sherer, N.M., and 
Butcher, S.E. (2016). Stability of HIV frameshift site RNA correlates with frameshift 
efficiency and decreased virus infectivity. J Virol 90, 6906-6917. 
118 
 
84. Garofalo, R., Wohlgemuth, I., Pearson, M., Lenz, C., Urlaub, H., and Rodnina, M.V. 
(2019). Broad range of missense error frequencies in cellular proteins. Nucleic Acids 
Res. 
85. Gaudin, C., Mazauric, M.H., Traikia, M., Guittet, E., Yoshizawa, S., and Fourmy, D. 
(2005). Structure of the RNA signal essential for translational frameshifting in HIV-
1. J Mol Biol 349, 1024-1035. 
86. Geslain, R., and Pan, T. (2010). Functional analysis of human tRNA isodecoders.  
J Mol Biol 396, 821-831. 
87. Gesteland, R., and Atkins, J. (1996). Recoding: dynamic reprogramming of 
translation. Annu Rev Biochem 65, 741-809. 
88. Gesteland, R.F., Weiss, R.B., and Atkins, J.F. (1992). Recoding: reprogrammed 
genetic decoding. Science 257, 1640-1641. 
89. Girnary, R., King, L., Robinson, L., Elston, R., and Brierley, I. (2007). Structure-
function analysis of the ribosomal frameshifting signal of two human 
immunodeficiency virus type 1 isolates with increased resistance to viral protease 
inhibitors. J Gen Virol 88, 226-235. 
90. Goodenbour, J.M., and Pan, T. (2006). Diversity of tRNA genes in eukaryotes. 
Nucleic Acids Res 34, 6137-6146. 
91. Grentzmann, G., Ingram, J., Kelly, P., Gesteland, R., and Atkins, J. (1998). A dual-
luciferase reporter system for studying recoding signals. RNA (New York, NY) 4, 
479-565. 
92. Griffiths, A. (2011). Slipping and sliding: frameshift mutations in herpes simplex 
virus thymidine kinase and drug-resistance. Drug Resist Updat 14, 251-259. 
93. Groisman, I., and Engelberg-Kulka, H. (1995). Translational bypassing: a new 
reading alternative of the genetic code. Biochem Cell Biol 73, 1055-1059. 
94. Guarraia, C., Norris, L., Raman, A., and Farabaugh, P.J. (2007). Saturation 
mutagenesis of a +1 programmed frameshift-inducing mRNA sequence derived from 
a yeast retrotransposon. RNA (New York, NY) 13, 1940-1947. 
95. Hardin, A., Villalta, C.F., Doan, M., Jabri, M., Chockalingham, V., White, S.J., and 
Fowler, R.G. (2007). A molecular characterization of spontaneous frameshift 
mutagenesis within the trpA gene of Escherichia coli. DNA repair 6, 177-189. 
96. Hartmuth, K., Raker, V.A., Huber, J., Branlant, C., and Luhrmann, R. (1999). An 
unusual chemical reactivity of Sm site adenosines strongly correlates with proper 
assembly of core U snRNP particles. J Mol Biol 285, 133-147. 
119 
 
97. Hellen, C.U.T. (2018). Translation termination and ribosome recycling in 
eukaryotes. Cold Spring Harb Perspect Biol 10. 
98. Hjerten, S. (1962). "Molecular sieve" chromatography on polyacrylamide gels, 
prepared according to a simplified method. Arch Biochem Biophys Suppl 1, 147-
151. 
99. Holtkamp, W., Cunha, C.E., Peske, F., Konevega, A.L., Wintermeyer, W., and 
Rodnina, M.V. (2014a). GTP hydrolysis by EF-G synchronizes tRNA movement on 
small and large ribosomal subunits. EMBO J 2;33(9), 1073-1085. 
100. Holtkamp, W., Wintermeyer, W., and Rodnina, M.V. (2014b). Synchronous tRNA 
movements during translocation on the ribosome are orchestrated by elongation 
factor G and GTP hydrolysis. BioEssays : news and reviews in molecular, cellular 
and developmental biology 36, 908-918. 
101. Honda, A., Nakamura, T., and Nishimura, S. (1995). RNA signals for translation 
frameshift: influence of stem size and slippery sequence. Biochem Biophys Res 
Commun 213, 575-582. 
102. Horsfield, J., Wilson, D., Mannering, S., Adamski, F., and Tate, W. (1995). 
Prokaryotic ribosomes recode the HIV-1 gag-pol-1 frameshift sequence by an E/P 
site post-translocation simultaneous slippage mechanism. Nucl Acids Res 23, 1487-
1494. 
103. Hung, M., Patel, P., Davis, S., and Green, S.R. (1998). Importance of ribosomal 
frameshifting for human immunodeficiency virus type 1 particle assembly and 
replication. J Virol 72, 4819-4824. 
104. Ingolia, N.T., Ghaemmaghami, S., Newman, J.R., and Weissman, J.S. (2009). 
Genome-wide analysis in vivo of translation with nucleotide resolution using 
ribosome profiling. Science 324, 218-223. 
105. Jacks, T., Madhani, H., Masiarz, F., and Varmus, H. (1988a). Signals for ribosomal 
frameshifting in the Rous sarcoma virus gag-pol region. Cell 55, 447-505. 
106. Jacks, T., Power, M.D., Masiarz, F.R., Luciw, P.A., Barr, P.J., and Varmus, H.E. 
(1988b). Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. 
Nature 331, 280-283. 
107. Jackson, R.J., Hellen, C.U., and Pestova, T.V. (2010). The mechanism of eukaryotic 




108. Jackson, R.J., Hellen, C.U., and Pestova, T.V. (2012). Termination and post-
termination events in eukaryotic translation. Adv Protein Chem Struct Biol 86, 45-
93. 
109. Jagger, B.W., Wise, H.M., Kash, J.C., Walters, K.A., Wills, N.M., Xiao, Y.L., 
Dunfee, R.L., Schwartzman, L.M., Ozinsky, A., Bell, G.L., et al. (2012). An 
overlapping protein-coding region in influenza A virus segment 3 modulates the host 
response. Science 337, 199-204. 
110. Jang, S.K., Pestova, T.V., Hellen, C.U., Witherell, G.W., and Wimmer, E. (1990). 
Cap-independent translation of picornavirus RNAs: structure and function of the 
internal ribosomal entry site. Enzyme 44, 292-309. 
111. Johnson, K.A. (2009). Fitting enzyme kinetic data with KinTek Global Kinetic 
Explorer. Methods Enzymol 467, 601-626. 
112. Kang, H. (1998). Direct structural evidence for formation of a stem-loop structure 
involved in ribosomal frameshifting in human immunodeficiency virus type 1. 
Biochim Biophys Acta 1397, 73-78. 
113. Karacostas, V., Wolffe, E.J., Nagashima, K., Gonda, M.A., and Moss, B. (1993). 
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation 
of HIV-1 protease and inhibition of assembly and budding of virus-like particles. 
Virology 193, 661-671. 
114. Kendra, J.A., de la Fuente, C., Brahms, A., Woodson, C., Bell, T.M., Chen, B., 
Khan, Y.A., Jacobs, J.L., Kehn-Hall, K., and Dinman, J.D. (2017). Ablation of 
programmed -1 ribosomal frameshifting in Venezuelan Equine Encephalitis virus 
results in attenuated neuropathogenicity. J Virol 91. 
115. Ketteler, R. (2012). On programmed ribosomal frameshifting: the alternative 
proteomes. Front Genet 3, 242. 
116. Kim, H.K., Liu, F., Fei, J., Bustamante, C., Gonzalez, R.L., Jr., and Tinoco, I., Jr. 
(2014). A frameshifting stimulatory stem loop destabilizes the hybrid state and 
impedes ribosomal translocation. Proc Natl Acad Sci U S A 111, 5538-5543. 
117. Kim, Y.G., Maas, S., and Rich, A. (2001). Comparative mutational analysis of cis-
acting RNA signals for translational frameshifting in HIV-1 and HTLV-2. Nucleic 
Acids Res 29, 1125-1131. 
118. Knops, E., Brakier-Gingras, L., Schulter, E., Pfister, H., Kaiser, R., and  
Verheyen, J. (2012). Mutational patterns in the frameshift-regulating site of HIV-1 
selected by protease inhibitors. Med Microbiol Immunol 201, 213-218. 
121 
 
119. Kobayashi, Y., Zhuang, J., Peltz, S., and Dougherty, J. (2010). Identification of a 
cellular factor that modulates HIV-1 programmed ribosomal frameshifting. J Biol 
Chem 285, 19776-19784. 
120. Kollmus, H., Honigman, A., Panet, A., and Hauser, H. (1994). The sequences of 
and distance between two cis-acting signals determine the efficiency of ribosomal 
frameshifting in human immunodeficiency virus type 1 and human T-cell leukemia 
virus type II in vivo. J Virol 68, 6087-6091. 
121. Kothe, U., Paleskava, A., Konevega, A.L., and Rodnina, M.V. (2006). Single-step 
purification of specific tRNAs by hydrophobic tagging. Anal Biochem 356, 148-150. 
122. Kozak, M. (1987). An analysis of 5'-noncoding sequences from 699 vertebrate 
messenger RNAs. Nucleic Acids Res 15, 8125-8148. 
123. Kuhlenkoetter, S., Wintermeyer, W., and Rodnina, M.V. (2011). Different 
substrate-dependent transition states in the active site of the ribosome. Nature 476, 
351-354. 
124. Kurland, C. (1979). Reading frame errors on ribosomes. Nonsense Mutations and 
tRNA Suppressors Academic Press, New York, NY, 97-108. 
125. Larrouy, L., Lambert-Niclot, S., Charpentier, C., Fourati, S., Visseaux, B.,  
Soulie, C., Wirden, M., Katlama, C., Yeni, P., Brun-Vezinet, F., et al. (2011). 
Positive impact of HIV-1 gag cleavage site mutations on the virological response to 
darunavir boosted with ritonavir. Antimicrob Agents Chemother 55, 1754-1757. 
126. Larsen, B., Wills, N., Gesteland, R., and Atkins, J. (1994). rRNA-mRNA base 
pairing stimulates a programmed -1 ribosomal frameshift. J Bacteriol 176, 6842-
6851. 
127. Leger, M., Dulude, D., Steinberg, S.V., and Brakier-Gingras, L. (2007). The three 
transfer RNAs occupying the A, P and E sites on the ribosome are involved in viral 
programmed -1 ribosomal frameshift. Nucleic Acids Res 35, 5581-5592. 
128. Li, M., Kao, E., Gao, X., Sandig, H., Limmer, K., Pavon-Eternod, M., Jones, T.E., 
Landry, S., Pan, T., Weitzman, M.D., et al. (2012). Codon-usage-based inhibition of 
HIV protein synthesis by human schlafen 11. Nature 491, 125-128. 
129. Li, Y., Treffers, E.E., Napthine, S., Tas, A., Zhu, L., Sun, Z., Bell, S., Mark, B.L., 
van Veelen, P.A., van Hemert, M.J., et al. (2014). Transactivation of programmed 




130. Liao, P.Y., Choi, Y.S., Dinman, J.D., and Lee, K.H. (2011). The many paths to 
frameshifting: kinetic modelling and analysis of the effects of different elongation 
steps on programmed -1 ribosomal frameshifting. Nucleic Acids Res 39, 300-312. 
131. Lin, Z., Gilbert, R.J., and Brierley, I. (2012). Spacer-length dependence of 
programmed -1 or -2 ribosomal frameshifting on a U6A heptamer supports a role for 
messenger RNA (mRNA) tension in frameshifting. Nucleic Acids Res 40, 8674-
8689. 
132. Lorenz, C., Lunse, C.E., and Morl, M. (2017). tRNA modifications: impact on 
structure and thermal adaptation. Biomolecules 7. 
133. Loughran, G., Chou, M.Y., Ivanov, I.P., Jungreis, I., Kellis, M., Kiran, A.M., 
Baranov, P.V., and Atkins, J.F. (2014). Evidence of efficient stop codon readthrough 
in four mammalian genes. Nucleic Acids Res 42, 8928-8938. 
134. Loveland, A.B., Demo, G., Grigorieff, N., and Korostelev, A.A. (2017). Ensemble 
cryo-EM elucidates the mechanism of translation fidelity. Nature 546, 113-117. 
135. Low, J.T., Garcia-Miranda, P., Mouzakis, K.D., Gorelick, R.J., Butcher, S.E., and 
Weeks, K.M. (2014). Structure and dynamics of the HIV-1 frameshift element RNA. 
Biochemistry 53, 4282-4291. 
136. Lusso, P., Cocchi, F., Balotta, C., Markham, P.D., Louie, A., Farci, P., Pal, R., 
Gallo, R.C., and Reitz, M.S., Jr. (1995). Growth of macrophage-tropic and primary 
human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell 
clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-
1. J Virol 69, 3712-3720. 
137. Luthi, K., Moser, M., Ryser, J., and Weber, H. (1990). Evidence for a role of 
translational frameshifting in the expression of transposition activity of the bacterial 
insertion element IS1. Gene 88, 15-20. 
138. Maag, D., Fekete, C.A., Gryczynski, Z., and Lorsch, J.R. (2005). A conformational 
change in the eukaryotic translation preinitiation complex and release of eIF1 signal 
recognition of the start codon. Mol Cell 17, 265-275. 
139. Maartens, G., Celum, C., and Lewin, S.R. (2014). HIV infection: epidemiology, 
pathogenesis, treatment, and prevention. Lancet (London, England) 384, 258-271. 
140. Machnicka, M.A., Olchowik, A., Grosjean, H., and Bujnicki, J.M. (2014). 
Distribution and frequencies of post-transcriptional modifications in tRNAs. RNA 
Biol 11, 1619-1629. 
141. Mahlab, S., Tuller, T., and Linial, M. (2012). Conservation of the relative tRNA 
composition in healthy and cancerous tissues. RNA (New York, NY) 18, 640-652. 
123 
 
142. Maldonado, R., and Herr, A.J. (1998). Efficiency of T4 gene 60 translational 
bypassing. J Bacteriol 180, 1822-1830. 
143. Manktelow, E., Shigemoto, K., and Brierley, I. (2005). Characterization of the 
frameshift signal of Edr, a mammalian example of programmed -1 ribosomal 
frameshifting. Nucleic Acids Res 33, 1553-1563. 
144. Marcheschi, R.J., Staple, D.W., and Butcher, S.E. (2007). Programmed ribosomal 
frameshifting in SIV is induced by a highly structured RNA stem-loop. J Mol Biol 
373, 652-663. 
145. Marcheschi, R.J., Tonelli, M., Kumar, A., and Butcher, S.E. (2011). Structure of 
the HIV-1 frameshift site RNA bound to a small molecule inhibitor of viral 
replication. ACS Chem Biol 6, 857-864. 
146. Mathew, S.F., Crowe-McAuliffe, C., Graves, R., Cardno, T.S., McKinney, C., 
Poole, E.S., and Tate, W.P. (2015). The highly conserved codon following the 
slippery sequence supports -1 frameshift efficiency at the HIV-1 frameshift site. 
PLoS One 10, e0122176. 
147. Matsufuji, S., Matsufuji, T., Miyazaki, Y., Murakami, Y., Atkins, J.F.,  
Gesteland, R.F., and Hayashi, S. (1995). Autoregulatory frameshifting in decoding 
mammalian ornithine decarboxylase antizyme. Cell 80, 51-60. 
148. Mazauric, M.-H., Seol, Y., Yoshizawa, S., Visscher, K., and Fourmy, D. (2009). 
Interaction of the HIV-1 frameshift signal with the ribosome. Nucleic Acids Res 37, 
7654-7718. 
149. Mejlhede, N., Atkins, J.F., and Neuhard, J. (1999). Ribosomal -1 frameshifting 
during decoding of Bacillus subtilis cdd occurs at the sequence CGA AAG.  
J Bacteriol 181, 2930-2937. 
150. Melian, E.B., Hinzman, E., Nagasaki, T., Firth, A.E., Wills, N.M., Nouwens, A.S., 
Blitvich, B.J., Leung, J., Funk, A., Atkins, J.F., et al. (2010). NS1' of flaviviruses in 
the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and 
plays a role in viral neuroinvasiveness. J Virol 84, 1641-1647. 
151. Melnikov, S., Ben-Shem, A., Garreau de Loubresse, N., Jenner, L., Yusupova, G., 
and Yusupov, M. (2012). One core, two shells: bacterial and eukaryotic ribosomes. 
Nat Struct Mol Biol 19, 560-567. 
152. Meydan, S., Klepacki, D., Karthikeyan, S., Margus, T., Thomas, P., Jones, J.E., 
Khan, Y., Briggs, J., Dinman, J.D., Vazquez-Laslop, N., et al. (2017). Programmed 
ribosomal frameshifting generates a copper transporter and a copper chaperone from 
the same gene. Mol Cell 65, 207-219. 
124 
 
153. Milligan, J.F., Groebe, D.R., Witherell, G.W., and Uhlenbeck, O.C. (1987). 
Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA 
templates. Nucleic Acids Res 15, 8783-8798. 
154. Milon, P., and Rodnina, M.V. (2012). Kinetic control of translation initiation in 
bacteria. Crit Rev Biochem Mol Biol 47, 334-348. 
155. Moazed, D., and Noller, H.F. (1987). Interaction of antibiotics with functional sites 
in 16S ribosomal RNA. Nature 327, 389-394. 
156. Moore, G. (1975). Chemical modification of ribosomes with dimethyl sulfate: a 
probe to the structural organization of ribosomal proteins and RNA. Can J Biochem 
53, 328-337. 
157. Mouzakis, K.D., Lang, A.L., Vander Meulen, K.A., Easterday, P.D., and  
Butcher, S.E. (2013). HIV-1 frameshift efficiency is primarily determined by the 
stability of base pairs positioned at the mRNA entrance channel of the ribosome. 
Nucleic Acids Res 41, 1901-1913. 
158. Mullis, K.B. (1990). Target amplification for DNA analysis by the polymerase 
chain reaction. Ann Biol Clin (Paris) 48, 579-582. 
159. Munroe, D., and Jacobson, A. (1990). mRNA poly(A) tail, a 3' enhancer of 
translational initiation. Mol Cell Biol 10, 3441-3455. 
160. Namy, O., Moran, S.J., Stuart, D.I., Gilbert, R.J., and Brierley, I. (2006). A 
mechanical explanation of RNA pseudoknot function in programmed ribosomal 
frameshifting. Nature 441, 244-247. 
161. Napthine, S., Ling, R., Finch, L.K., Jones, J.D., Bell, S., Brierley, I., and Firth, A.E. 
(2017). Protein-directed ribosomal frameshifting temporally regulates gene 
expression. Nat Commun 8, 15582. 
162. Netzer, N., Goodenbour, J.M., David, A., Dittmar, K.A., Jones, R.B.,  
Schneider, J.R., Boone, D., Eves, E.M., Rosner, M.R., Gibbs, J.S., et al. (2009). 
Innate immune and chemically triggered oxidative stress modifies translational 
fidelity. Nature 462, 522-526. 
163. Novoa, E.M., Pavon-Eternod, M., Pan, T., and Ribas de Pouplana, L. (2012). A role 
for tRNA modifications in genome structure and codon usage. Cell 149, 202-213. 
164. Ofori, L.O., Hilimire, T.A., Bennett, R.P., Brown, N.W., Jr., Smith, H.C., and 
Miller, B.L. (2014). High-affinity recognition of HIV-1 frameshift-stimulating RNA 




165. Olubajo, B., and Taylor, E.W. (2005). A -1 frameshift in the HIV-1 env gene is 
enhanced by arginine deficiency via a hungry codon mechanism. Mutat Res 579, 
125-132. 
166. Ozen, A., Lin, K.H., Kurt Yilmaz, N., and Schiffer, C.A. (2014). Structural basis 
and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. 
Proc Natl Acad Sci U S A 111, 15993-15998. 
167. Pan, D., and Coen, D.M. (2012). Net -1 frameshifting on a noncanonical sequence 
in a herpes simplex virus drug-resistant mutant is stimulated by nonstop mRNA. Proc 
Natl Acad Sci U S A 109, 14852-14857. 
168. Pan, T. (2018). Modifications and functional genomics of human transfer RNA. 
Cell Res 28, 395-404. 
169. Park, J., and Morrow, C.D. (1991). Overexpression of the gag-pol precursor from 
human immunodeficiency virus type 1 proviral genomes results in efficient 
proteolytic processing in the absence of virion production. J Virol 65, 5111-5117. 
170. Parkin, N.T., Chamorro, M., and Varmus, H.E. (1992). Human immunodeficiency 
virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary 
structure: demonstration by expression in vivo. J Virol 66, 5147-5151. 
171. Passmore, L.A., Schmeing, T.M., Maag, D., Applefield, D.J., Acker, M.G.,  
Algire, M.A., Lorsch, J.R., and Ramakrishnan, V. (2007). The eukaryotic translation 
initiation factors eIF1 and eIF1A induce an open conformation of the 40S ribosome. 
Mol Cell 26, 41-50. 
172. Pavon-Eternod, M., David, A., Dittmar, K., Berglund, P., Pan, T., Bennink, J.R., 
and Yewdell, J.W. (2013). Vaccinia and influenza A viruses select rather than adjust 
tRNAs to optimize translation. Nucleic Acids Res 41, 1914-1921. 
173. Pavon-Eternod, M., Wei, M., Pan, T., and Kleiman, L. (2010). Profiling non-lysyl 
tRNAs in HIV-1. RNA (New York, NY) 16, 267-273. 
174. Peattie, D.A., and Gilbert, W. (1980). Chemical probes for higher-order structure 
in RNA. Proc Natl Acad Sci U S A 77, 4679-4682. 
175. Peske, F., Kuhlenkoetter, S., Rodnina, M.V., and Wintermeyer, W. (2014). Timing 
of GTP binding and hydrolysis by translation termination factor RF3. Nucleic Acids 
Res 42, 1812-1820. 
176. Peske, F., Rodnina, M.V., and Wintermeyer, W. (2005). Sequence of steps in 
ribosome recycling as defined by kinetic analysis. Mol Cell 18, 403-412. 
177. Pestova, T.V., and Hellen, C.U. (2003). Coupled folding during translation 
initiation. Cell 115, 650-652. 
126 
 
178. Pettit, S.C., Henderson, G.J., Schiffer, C.A., and Swanstrom, R. (2002). 
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag 
processing sites can inhibit or enhance the rate of cleavage by the viral protease. J 
Virol 76, 10226-10233. 
179. Pisarev, A.V., Unbehaun, A., Hellen, C.U., and Pestova, T.V. (2007). Assembly 
and analysis of eukaryotic translation initiation complexes. Methods Enzymol 430, 
147-177. 
180. Plant, E.P. (2012 ). Ribosomal frameshift signals in viral genomes. In Viral 
Genomes - Molecular Structure, Diversity, Gene Expression Mechanisms and Host-
Virus Interactions, P.M. Garcia, ed. (InTech). 
181. Plant, E.P., and Dinman, J.D. (2006). Comparative study of the effects of 
heptameric slippery site composition on -1 frameshifting among different eukaryotic 
systems. RNA (New York, NY) 12, 666-673. 
182. Qiao, Q., Yan, Y., Guo, J., Du, S., Zhang, J., Jia, R., Ren, H., Qiao, Y., and Li, Q. 
(2017). A review on architecture of the gag-pol ribosomal frameshifting RNA in 
human immunodeficiency virus: a variability survey of virus genotypes. J Biomol 
Struct Dyn 35, 1629-1653. 
183. Qu, X., Wen, J.D., Lancaster, L., Noller, H.F., Bustamante, C., and Tinoco, I., Jr. 
(2011). The ribosome uses two active mechanisms to unwind messenger RNA during 
translation. Nature 475, 118-121. 
184. Ramsey, J., and Mukhopadhyay, S. (2017). Disentangling the frames, the state of 
research on the Alphavirus 6K and TF proteins. Viruses 9. 
185. Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., 
Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., et al. (1985). Complete 
nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284. 
186. Reil, H., Kollmus, H., Weidle, U.H., and Hauser, H. (1993). A heptanucleotide 
sequence mediates ribosomal frameshifting in mammalian cells. J Virol 67, 5579-
5584. 
187. Rodnina, M.V. (2012). Quality control of mRNA decoding on the bacterial 
ribosome. Adv Protein Chem Struct Biol 86, 95-128. 
188. Rodnina, M.V. (2016). The ribosome in action: tuning of translational efficiency 
and protein folding. Protein Sci 25, 1390-1406. 




190. Rodnina, M.V., Beringer, M., and Wintermeyer, W. (2006). Mechanism of peptide 
bond formation on the ribosome. Q Rev Biophys 39, 203-225. 
191. Rodnina, M.V., Fischer, N., Maracci, C., and Stark, H. (2017). Ribosome dynamics 
during decoding. Philos Trans R Soc Lond B Biol Sci 372. 
192. Rodnina, M.V., Fricke, R., Kuhn, L., and Wintermeyer, W. (1995). Codon-
dependent conformational change of elongation factor Tu preceding GTP hydrolysis 
on the ribosome. Embo J 14, 2613-2619. 
193. Rodnina, M.V., Savelsbergh, A., Katunin, V.I., and Wintermeyer, W. (1997). 
Hydrolysis of GTP by elongation factor G drives tRNA movement on the ribosome. 
Nature 385, 37-41. 
194. Rodnina, M.V., Semenkov, Y.P., and Wintermeyer, W. (1994). Purification of 
fMet-tRNA(fMet) by fast protein liquid chromatography. Anal Biochem 219, 380-
381. 
195. Rodnina, M.V., Stark, H., Savelsbergh, A., Wieden, H.J., Mohr, D.,  
Matassova, N.B., Peske, F., Daviter, T., Gualerzi, C.O., and Wintermeyer, W. 
(2000). GTPases mechanisms and functions of translation factors on the ribosome. 
Biol Chem 381, 377-387. 
196. Rodnina, M.V., and Wintermeyer, W. (1995). GTP consumption of elongation 
factor Tu during translation of heteropolymeric mRNAs. Proc Natl Acad Sci U S A 
92, 1945-1949. 
197. Rodnina, M.V., and Wintermeyer, W. (2001a). Fidelity of aminoacyl-tRNA 
selection on the ribosome: kinetic and structural mechanisms. Annu Rev Biochem 
70, 415-435. 
198. Rodnina, M.V., and Wintermeyer, W. (2001b). Ribosome fidelity: tRNA 
discrimination, proofreading and induced fit. Trends Biochem Sci 26, 124-130. 
199. Rodnina, M.V., and Wintermeyer, W. (2009). Recent mechanistic insights into 
eukaryotic ribosomes. Curr Opin Cell Biol 21, 435-443. 
200. Saini, S., Bhalla, P., Gautam, H., Baveja, U.K., Pasha, S.T., and Dewan, R. (2012). 
Resistance-associated mutations in HIV-1 among patients failing first-line 
antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic) 11, 203-209. 
201. Salter, R.D., Howell, D.N., and Cresswell, P. (1985). Genes regulating HLA class 
I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21, 235-246. 
202. Samatova, E., Konevega, A.L., Wills, N.M., Atkins, J.F., and Rodnina, M.V. 
(2014). High-efficiency translational bypassing of non-coding nucleotides specified 
by mRNA structure and nascent peptide. Nat Commun 5, 4459. 
128 
 
203. Sanchez-Pescador, R., Power, M.D., Barr, P.J., Steimer, K.S., Stempien, M.M., 
Brown-Shimer, S.L., Gee, W.W., Renard, A., Randolph, A., Levy, J.A., et al. (1985). 
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). 
Science 227, 484-492. 
204. Savelsbergh, A., Katunin, V.I., Mohr, D., Peske, F., Rodnina, M.V., and 
Wintermeyer, W. (2003). An elongation factor G-induced ribosome rearrangement 
precedes tRNA-mRNA translocation. Mol Cell 11, 1517-1523. 
205. Schagger, H., and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 
to 100 kDa. Anal Biochem 166, 368-379. 
206. Scolnick, E., Tompkins, R., Caskey, T., and Nirenberg, M. (1968). Release factors 
differing in specificity for terminator codons. Proc Natl Acad Sci U S A 61, 768-774. 
207. Sharma, H., Adio, S., Senyushkina, T., Belardinelli, R., Peske, F., and  
Rodnina, M.V. (2016). Kinetics of spontaneous and EF-G-accelerated rotation of 
ribosomal subunits. Cell Rep 16, 2187-2196. 
208. Sharp, P.M., Cowe, E., Higgins, D.G., Shields, D.C., Wolfe, K.H., and Wright, F. 
(1988). Codon usage patterns in Escherichia coli, Bacillus subtilis, Saccharomyces 
cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo 
sapiens; a review of the considerable within-species diversity. Nucleic Acids Res 16, 
8207-8211. 
209. Shatsky, I.N., Terenin, I.M., Smirnova, V.V., and Andreev, D.E. (2018). Cap-
independent translation: what's in a name? Trends Biochem Sci 43(11), 882-895. 
210. Shehu-Xhilaga, M., Crowe, S.M., and Mak, J. (2001). Maintenance of the Gag/Gag-
Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization 
and viral infectivity. J Virol 75, 1834-1841. 
211. Snyder, J.E., Kulcsar, K.A., Schultz, K.L., Riley, C.P., Neary, J.T., Marr, S.,  
Jose, J., Griffin, D.E., and Kuhn, R.J. (2013). Functional characterization of the 
alphavirus TF protein. J Virol 87, 8511-8523. 
212. Soll, D. (1990). The accuracy of aminoacylation--ensuring the fidelity of the 
genetic code. Experientia 46, 1089-1096. 
213. Staple, D.W., and Butcher, S.E. (2003). Solution structure of the HIV-1 frameshift 
inducing stem-loop RNA. Nucleic Acids Res 31, 4326-4331. 
214. Staple, D.W., and Butcher, S.E. (2005). Solution structure and thermodynamic 
investigation of the HIV-1 frameshift inducing element. J Mol Biol 349, 1011-1023. 
129 
 
215. Steitz, J.A., and Jakes, K. (1975). How ribosomes select initiator regions in mRNA: 
base pair formation between the 3' terminus of 16S rRNA and the mRNA during 
initiation of protein synthesis in Escherichia coli. Proc Natl Acad Sci U S A 72, 4734-
4738. 
216. Stern, S., Moazed, D., and Noller, H.F. (1988). Structural analysis of RNA using 
chemical and enzymatic probing monitored by primer extension. Methods Enzymol 
164, 481-489. 
217. Tabor, S., and Richardson, C.C. (1985). A bacteriophage T7 RNA 
polymerase/promoter system for controlled exclusive expression of specific genes. 
Proc Natl Acad Sci U S A 82, 1074-1078. 
218. Taliaferro, D., and Farabaugh, P.J. (2007). An mRNA sequence derived from the 
yeast EST3 gene stimulates programmed +1 translational frameshifting. RNA (New 
York, NY) 13, 606-613. 
219. Telenti, A., Martinez, R., Munoz, M., Bleiber, G., Greub, G., Sanglard, D., and 
Peters, S. (2002). Analysis of natural variants of the human immunodeficiency virus 
type 1 gag-pol frameshift stem-loop structure. J Virol 76, 7868-7873. 
220. Torres, A.G., Batlle, E., and Ribas de Pouplana, L. (2014). Role of tRNA 
modifications in human diseases. Trends Mol Med 20, 306-314. 
221. Tsuchihashi, Z., and Brown, P.O. (1992). Sequence requirements for efficient 
translational frameshifting in the Escherichia coli dnaX gene and the role of an 
unstable interaction between tRNA(Lys) and an AAG lysine codon. Genes Dev 6, 
511-519. 
222. Tsuchihashi, Z., and Kornberg, A. (1990). Translational frameshifting generates the 
gamma subunit of DNA polymerase III holoenzyme. Proc Natl Acad Sci U S A 87, 
2516-2520. 
223. Turner, B.G., and Summers, M.F. (1999). Structural biology of HIV. J Mol Biol 
285, 1-32. 
224. Urbonavicius, J., Qian, Q., Durand, J.M., Hagervall, T.G., and Bjork, G.R. (2001). 
Improvement of reading frame maintenance is a common function for several tRNA 
modifications. Embo J 20, 4863-4873. 
225. van Tol, H., Stange, N., Gross, H.J., and Beier, H. (1987). A human and a plant 
intron-containing tRNATyr gene are both transcribed in a HeLa cell extract but 
spliced along different pathways. Embo J 6, 35-41. 
130 
 
226. van Weringh, A., Ragonnet-Cronin, M., Pranckeviciene, E., Pavon-Eternod, M., 
Kleiman, L., and Xia, X. (2011). HIV-1 modulates the tRNA pool to improve 
translation efficiency. Mol Biol Evol 28, 1827-1834. 
227. Vimaladithan, A., and Farabaugh, P.J. (1994). Special peptidyl-tRNA molecules 
can promote translational frameshifting without slippage. Mol Cell Biol 14, 8107-
8116. 
228. Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S., and Alizon, M. (1985). 
Nucleotide sequence of the AIDS virus, LAV. Cell 40, 9-17. 
229. Wan Makhtar, W.R., Browne, G., Karountzos, A., Stevens, C., Alghamdi, Y., 
Bottrill, A.R., Mistry, S., Smith, E., Bushel, M., Pringle, J.H., et al. (2017). Short 
stretches of rare codons regulate translation of the transcription factor ZEB2 in 
cancer cells. Oncogene 36, 6640-6648. 
230. Wang, X., Xuan, Y., Han, Y., Ding, X., Ye, K., Yang, F., Gao, P., Goff, S.P., and 
Gao, G. (2019). Regulation of HIV-1 Gag-Pol expression by Shiftless, an inhibitor 
of programmed -1 ribosomal frameshifting. Cell 176, 625-635.e614. 
231. Weeks, K.M. (2010). Advances in RNA structure analysis by chemical probing. 
Curr Opin Struct Biol 20, 295-304. 
232. Weiss, A., Wiskocil, R.L., and Stobo, J.D. (1984). The role of T3 surface molecules 
in the activation of human T cells: a two-stimulus requirement for IL 2 production 
reflects events occurring at a pre-translational level. J Immunol 133, 123-128. 
233. Weiss, R.B., Dunn, D.M., Atkins, J.F., and Gesteland, R.F. (1987). Slippery runs, 
shifty stops, backward steps, and forward hops: -2, -1, +1, +2, +5, and +6 ribosomal 
frameshifting. Cold Spring Harb Symp Quant Biol 52, 687-693. 
234. Weiss, R.B., Dunn, D.M., Shuh, M., Atkins, J.F., and Gesteland, R.F. (1989). E. 
coli ribosomes re-phase on retroviral frameshift signals at rates ranging from 2 to 50 
percent. New Biol 1, 159-169. 
235. Wickner, R.B. (1989). Yeast virology. Faseb J 3, 2257-2265. 
236. Wills, N.M., Moore, B., Hammer, A., Gesteland, R.F., and Atkins, J.F. (2006). A 
functional -1 ribosomal frameshift signal in the human paraneoplastic Ma3 gene. J 
Biol Chem 281, 7082-7088. 
237. Wilson, W., Braddock, M., Adams, S.E., Rathjen, P.D., Kingsman, S.M., and 
Kingsman, A.J. (1988). HIV expression strategies: ribosomal frameshifting is 




238. Xu, J., Hendrix, R.W., and Duda, R.L. (2004). Conserved translational frameshift 
in dsDNA bacteriophage tail assembly genes. Mol Cell 16, 11-21. 
239. Yan, S., Wen, J.D., Bustamante, C., and Tinoco, I., Jr. (2015). Ribosome excursions 
during mRNA translocation mediate broad branching of frameshift pathways. Cell 
160, 870-881. 
240. Yelverton, E., Lindsley, D., Yamauchi, P., and Gallant, J.A. (1994). The function 
of a ribosomal frameshifting signal from human immunodeficiency virus-1 in 
Escherichia coli. Mol Microbiol 11, 303-313. 
241. Yu, C.H., Teulade-Fichou, M.P., and Olsthoorn, R.C. (2014). Stimulation of 
ribosomal frameshifting by RNA G-quadruplex structures. Nucleic Acids Res 42, 
1887-1892. 
242. Zaher, H.S., and Green, R. (2009). Quality control by the ribosome following 
peptide bond formation. Nature 457, 161-166. 
243. Ziehler, W.A., and Engelke, D.R. (2001). Probing RNA structure with chemical 






Most of all, I would like to express my sincere gratitude to my supervisor Prof. Marina 
V. Rodnina who I know for almost nine years. In the beginning of my Bachelor in 2010 I 
applied for a summer internship in her department, and this short research stay has reinforced 
my passion for science and layed a foundation for my future Master and PhD studies in 
Göttingen. Marina has been an amazing mentor and I truly thank her for all the scientific 
expertise that she had passed on me but also for the constant personal support, understanding, 
guidance and advice. I also thank Dr. Ekaterina Samatova and Dr. Frank Peske for their daily 
help with experimental design, insightful discussions, constructive criticism and cosy talks 
with a cup of coffee. Special thanks goes to Ekaterina for being a wonderful friend and 
keeping me motivated throughout my PhD. I thank all of my colleagues and friends from 
Rodnina lab who created a wonderful working atmosphere. A big thanks to Betty, the best 
labmate ever, who had answers to all of my questions and I could rely on her in all situations. 
I would like to thank my TAC members, Prof. Holger Stark and Prof. Stefan Pöhlmann, 
for contributing to the success of my graduate school. I also thank all of my collaborators, 
Prof. Stefan Pöhlmann and Dr. Markus Hoffmann from German Primate Center,  
Dr. Akanksha Goyal from Rodnina lab, Dr. Lars Bock from Grübmüller lab and  
Dr. Maria M. Anokhina from Lührmann lab, for sharing their knowledge and expertise and 
making my scientific advances possible. I thank the coordination office of Molecular 
Biology MSc/PhD program, Dr. Steffen Burkhardt and Kerstin Grüniger, for making my 
integration in Germany very smooth and helping with all kinds of professional, 
organizational and personal questions and issues. I would also like to thank my funding 
agency, Boehringer Ingelheim Fonds, for allowing me to attend many conferences and 
meetings and all the personal support that I have received as a fellow. 
Finally, I would like to thank my family and friends for their everlasting love, care and 
support; without them, my PhD journey would not have been so successful and enjoyable. 
 
